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ABSTRACT
PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE RECEPTOR:
MULTIPLE SIGNALING PATHWAYS INVOLVED IN ENERGY HOMEOSTASIS
Brian Maunze, B.S
Marquette University, 2022
Pituitary adenylate cyclase activating polypeptide (PACAP) exerts pleiotropic
effects on ventromedial nuclei (VMN) of the hypothalamus and its control of feeding and
energy expenditure through the Type I PAC1 receptor (PAC1R). However, the
endogenous role of PAC1R’s in the VMN and the downstream signaling responsible for
PACAP’s effects are unknown.
To determine the endogenous role of PAC1Rs and signaling that may explain
PACAP’s pleiotropic effects, we knocked down VMN PAC1Rs and pharmacologically
inhibited PKA, PKC and PAC1R trafficking. Knocking down PAC1Rs increased meal
sizes, reduced total number of meals, and induced body weight gain. Inhibition of either
PKA or PKC alone in awake male Sprague Dawley rats, attenuated PACAP’s anorectic
effects during the dark phase. However, PKA or PKC inhibition resulted in a potentiation
of PACAP’s hypophagic effects during the light phase. Additionally, PKA or PKC
inhibition augmented PACAP’s thermogenic effects during the light phase, whereas only
PKA inhibition augmented PACAP’s locomotor effects given that PKC inhibition had no
effect. PACAP administration in the VMN induces PAC1R surface trafficking into the
cytosol which was blocked by endocytosis inhibitors. Subsequently, inhibition of PAC1R
trafficking into the cytosol attenuated PACAP-induced hypophagia.
PACAP signaling replicates the effects of leptin administration in the VMN and
appears to enable leptin regulation of energy homeostasis. However, the manner in
which PACAP influences leptin signaling is unknown. We used co-immunoprecipitation
to show that VMN PAC1 and leptin receptors are found in the same cell, and they form
an immunocomplex. Inhibiting downstream effectors of PACAP signaling, such as PKA
and PKC, enhanced or prevented leptin signaling respectively.
The current findings revealed that endogenous PACAP signaling in the VMN has
a potent regulatory influence over both energy intake in the form of feeding, and energy
output via thermogenesis and locomotor activity. Moreover, PACAP actions in the VMN
share a nearly identical sequelae to leptin administration in the same brain region
suggesting that these two neuropeptides could functionally intersect. These experiments
explored VMN PAC1Rs dependence on PKA, PKC, and receptor trafficking to mediate
PACAP’s pleiotropic effects on feeding and metabolism as well as potential intersecting
points with leptin receptor signaling.
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CHAPTER I

INTRODUCTION
General introduction
Obesity is a major world public health issue resulting from homeostatic
imbalances between energy intake and energy expenditure that can lead to
serious and chronic health complications such as heart disease and diabetes
(King, 2006; Wilding, 2002; Williams et al., 2001). According to the World Health
Organization an estimated 1.5 billion individuals are considered overweight and
approximately half a million adults are obese worldwide. The lack of effective
treatments or thorough understanding of the mechanisms that lead to obesity
contributes to the negative health impact. Efforts made to alleviate complications
associated with dysregulated energy homeostasis and obesity will greatly
improve quality of life in affected individuals and those caring for them. Various
attempts to target neuropeptide systems have shown promise to mitigate obesity,
however, none have succeeded, as reviewed in (Boughton & Murphy, 2012).
Energy balance is largely regulated by the central nervous system which
coordinates information to and from the entire body (J K Elmquist, Elias, & Saper,
1999). Although there is a wide variation in daily food consumption and energy
expenditure, most individuals maintain a stable body weight (Leibel, 2008).
Evolutionarily, a complex system has evolved to maintain energy homeostasis,
primarily centered within the hypothalamus (Figure 1.1) (Andermann & Lowell,
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2017; Hetherington & Ranson, 1942; King, 2006), which is a small region at the
base of the brain comprised of a collection of highly organized small nuclei that
regulate distinct homeostatic functions such as thermoregulation, thirst, hunger,
stress, and reproductive needs (King, 2006; Waterson & Horvath, 2015; Wilding,
2002). What is lacking, however, is a comprehensive understanding of how these
various neuropeptides regulate the complex network between key hypothalamic
nuclei. One of the most enigmatic and often-overlooked cell groups in
hypothalamic regulation of energy balance are the hypothalamic ventromedial
nuclei (Choi, Horsley, Aguila, & Dallman, 1996; Hetherington & Ranson, 1942;
King, 2006) (Figure 1.2).

Figure 1.1. Central control of energy balance. The hypothalamus integrates central and
peripheral signals to maintain energy balance. Created with BioRender.com
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Hypothalamic ventromedial nuclei regulation of feeding

Figure 1.2. Hypothalamic nuclei control energy balance. Energy balance is
maintained by several hypothalamic nuclei including the hypothalamic
ventromedial nuclei. Created with BioRender.com

The ventromedial hypothalamic nuclei (VMN) constitute a group of cells
found at the base of the hypothalamus and that early on were shown to
demonstrate that disruption by bilateral lesions produced hyperphagia and
obesity in several different species, including humans (Choi et al., 1996;
Hetherington & Ranson, 1942; King, 2006). By contrast, electrical stimulation of
the VMN reduces food intake in hungry rats (Beltt & Keesey, 1975). Lesions of
the VMN produce an obesity that is distinct from other medial hypothalamic
obesities, in that it is characterized not only by increased food intake and body
weight but also increased circulating corticosterone and insulin concentrations
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during the light phase and decreased metabolism (Choi, Wong, Yamat, &
Dallman, 1998). In nocturnal animals such as the rat, food intake and activity
levels peak during the dark phase of their circadian rhythm. This led to VMN
being designated as the “satiety center” (Choi et al., 1996) also reviewed in
(King, 2006; Williams et al., 2001). Rodents with VMN lesions eat a significant
amount of food and gain twice as much weight as any other lesion in the
hypothalamus (Hetherington & Ranson, 1942). These early studies identifying
the VMN as an important center for energy homeostasis were confirmed by more
targeted (Choi et al., 1998) and restricted lesions involving steroidogenic factor 1
(SF1), a well-established and exclusive marker of VMN cells (Davis et al., 2004).
However, it is important to note that the VMN is not the only hypothalamic cell
group to be important for energy regulation. It should be recognized that the
VMN are a part of a highly connected network of hypothalamic and extrahypothalamic cell groups that participate in the regulation energy balance
(Hawke et al., 2009; Kalkhoff, Gossain, Matute, & Wilson, 1976; Resch et al.,
2013). Several hypothalamic nuclei receive both direct and indirect projections
from the VMN, including the arcuate, dorsomedial, paraventricular and lateral
hypothalamic nuclei (Bai et al., 1985; Elias et al., 1998; Horst & Luiten, 1986)
The sympathetic nervous system also plays a role in the development of
hypothalamic VMN obesity. Previous studies that produce VMN lesions report a
reduction in sympathetic nervous system activity and subsequently reducing the
activation of interscapular brown adipose tissue (BAT) (Sakaguchi, Bray, &
Eddlestone, 1988). Both white adipose tissue (WAT) and BAT function as a
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major means of storing energy but unlike WAT, BAT is a major source of nonshivering and diet-induced thermogenesis (Foster & Frydman, 1979; HimmsHagen, 1990). Thus, sustained decreases in sympathetic input to BAT decreases
non-shivering and diet-induced thermogenesis, and therefore, decreases overall
energy expenditure (Himms-Hagen, 1990). The VMN have been demonstrated
to have direct regulatory connections and function of sympathetic output to
targets such as BAT (Bozadjieva-Kramer et al., 2021; Foster & Frydman, 1979).
Although the VMN have been established as a key center for feeding
behavior and metabolism (Choi et al., 1998), the broader regulation of energy
homeostasis requires a more intricate neuroendocrine system involving
numerous neuropeptides that have either orexigenic or anorexigenic effects
and/or governance over energy expenditure. Within the VMN can be found many
neuropeptide and neurohormone-responsive receptors involved in feeding and
metabolism including cholecystokinin (CCK), brain derived neurotrophic factor
(BDNF) receptor Trkb, neuropeptide Y receptors, orexin receptors, melanocortin4 receptors, and the long-form leptin receptor (lepRb) just to list a few. However,
the known number of neuropeptides originating from within the VMN are still few
(Flak et al., 2020; Koizumi et al., 2020). Brain derived neurotrophic factor (BDNF)
and pituitary adenylate cyclase-activating polypeptide (PACAP) have been
shown to be abundantly expressed in the VMN, and both are necessary for
energy balance regulation (King, 2006; Resch et al., 2011; Zink et al., 2004).
Elucidating the endogenous role of PACAP and the mechanisms mediating the
actions of PACAP in the VMN will be the focus of this dissertation.
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Pituitary adenylate cyclase-activating polypeptide (PACAP)
PACAP is a 38-amino acid peptide from the vasoactive intestinal peptide
(VIP) glucagon secretin superfamily (Dickson & Finlayson, 2009; Gottschall,
Tatsuno, Miyata, Arimura, & Gottschall, 1990; LAM et al., 1990; Lu & DiCiccoBloom, 1997; Miyata et al., 1989, 1990; Ohtakis et al., 1993; Vaudry et al., 2009)
and was first isolated from ovine hypothalamic tissue. PACAP is the most
evolutionarily conserved member of the glucagon family according to sequence
length that determine the identity of amino acids (Sherwood, Krueckl, & McRory,
2000). PACAP is identified in more than 15 vertebrate species from humans to
tunicates, suggesting that PACAP is biologically important for survival (Hosoya et
al., 1992; Sherwood et al., 2000). This point is well illustrated by the fact that
congenital PACAP knockout is lethal (Mounien et al., 2009). PACAP has a
myriad of functions in several regions of the body including the nervous,
endocrine, cardiovascular and immune systems (Sherwood et al., 2000).
PACAP is encoded by the gene (ADCYAP1), and following transcription and
post-translational proteolytic processing of a larger PACAP precursor protein
generates polypeptides in varying sizes including PACAP38 (38 amino acids
long) and PACAP27 (27 amino acids long) (Miyata et al., 1989; Ohtakis et al.,
1993; Vaudry et al., 2009). PACAP38 is the predominant form of PACAP that is
expressed in the central nervous system (H. Hashimoto et al., 2000; Miyata et
al., 1990), although both peptides, PACAP27 and PACAP38, are functionally
similar (Fahrenkrug & Hannibal, 2004). On the other side of neuronal signaling,
PACAP has two receptor subtypes that it binds to with equal affinity, Type I and
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Type II, that belong to the class B family of G-protein coupled receptors (GPCRs)
(Apostolakis, Riherd, & O’Malley, 2005; Arimura, 1998; Jozwiak-Bebenista,
Dejda, & Nowak, 2007; Vaudry et al., 2009; Warfvinge & Edvinsson, 2020). The
two receptors under the Type II receptor category, VPAC1 and VPAC2, also bind
vasoactive intestinal polypeptide whereas the Type I or PAC1 receptor (PAC1R)
selectively binds PACAP. PACAP binds PAC1R with a 1000-fold higher affinity
than VIP, compared to VPAC1 and VPAC2 receptors, which bind PACAP and
VIP with similar affinity (Vaudry et al., 2009). Looking at the distribution of
PAC1R within the brain (Figure 1.3), the PAC1 receptor is abundantly expressed
in the hypothalamus and shown to be a potent pleiotropic regulator of energy
homeostasis within several nuclei (Chang et al., 2021; Hawke et al., 2009; Resch
et al., 2011, 2013; Resch, Maunze, Phillips, & Choi, 2014). It is therefore not
surprising why PACAP is tightly conserved in evolution as organisms inherently
need metabolism for survival. Acute PACAP administration in hypothalamic
ventromedial nuclei (VMN) decreases food intake with concomitant increases in
core body temperature and spontaneous locomotor activity, which results in rapid
reductions in body weight (Resch et al., 2011, 2013, 2014). In the VMN, these
hypophagic and positive metabolic affects were confirmed to be mediated
specifically by PAC1 receptors with no apparent involvement of the VPAC
receptors (Resch et al., 2011, 2013). Moreover, there are early indicators that
PACAP integrates within a broader context of energy homeostatic systems with
evidence showing PACAP administration in the VMN is accompanied by
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increases in STAT3 phosphorylation, and BDNF and SOCS3 transcription
(Hurley et al., 2020, 2016; Resch et al., 2013, 2014) all of which have been
independently shown to regulate feeding behavior and metabolism.
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Figure 1.3. In situ hybridization of PAC1R distribution
in the ventromedial hypothalamic region. 1) 1.25X
magnification of a coronal rat brain section, B)
schematic, C) 5X magnification. Resch et al., AJP
Integr Comp Physiol 301; 2011.
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Pituitary adenylate cyclase-activating polypeptide receptors
As a class B GPCR, PAC1R signals through coupling to G-alpha subunits
Gs and Gq that typically activate adenylyl cyclase (AC) and phospholipase Cb
enzymes, respectively (Marinissen & Gutkind, 2001; W. Wang, Qiao, & Li, 2018).
A recent analysis of the PAC1R C-terminus (Lyu, Germano, Joon Ki Choi, Le, &
Pisegna, 2000) revealed essential amino acid motifs that are necessary for Gs,
Gq-protein coupling, and receptor trafficking. Numerous studies have now
confirmed that PAC1Rs are coupled to both Gas/adenylyl cyclase/protein kinase
A (Gas/AC/PKA) and Gaq/phospholipase C/protein kinase C (Gaq/PLC/PKC),
while also undergoing trafficking following stimulation (Liao, Remington, May, &

Figure 1.4. Structure of the PACAP-specific PAC1
receptor showing the location of the known splice
variants within the structure. TMD=transmembrane
domain. Figure reproduced from Rudecki and Gray
(2016) Trends in Endocrinology and Metabolism 27(9):
620-632).

Li, 2021; May, Lutz, MacKenzie, et al., 2010; Rudecki & Gray, 2016). As an
added layer of signaling complexity, PAC1Rs exist in multiple isoforms that can
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generate diverse and complex signaling by coupling to multiple G-proteins that
can modulate channel function and cell responses in different tissues (Blechman,
Levkowitz, & Vaudry, 2013; Fukuchi et al., 2015; Holighaus, Mustafa, & Eiden,
2011; Lyu et al., 2000; Zhou et al., 2001). PAC1 receptor isoforms are generated
from alternative splicing of the transcript from a single gene and inclusion or
exclusion of one or two cassettes, the hip and hop cassettes (Blechman et al.,
2013; Holighaus et al., 2011; Sherwood et al., 2000). Initially, seven PAC1R
splice variants were isolated from rat brain. Figure 1.4. illustrates the various
isoforms and the location of splice variants found in the rat brain which include
PAC1null, PAC1hop1, PAC1hop2, PAC1hip, PAC1hip-hop, PAC1-short, and
PAC1-very short (Amir-Zilberstein et al., 2012; Apostolakis et al., 2005;
Blechman et al., 2013). Interestingly, except for the PAC1hip variant, all PAC1R
variants stimulate adenylyl cyclase (AC) equally through Gs (Blechman et al.,
2013; Holighaus et al., 2011; Sherwood et al., 2000). However, PLC/PKC
accumulation is stimulated to varying degrees through Gq/PLC/PKC (Blechman
et al., 2013; Hardwick et al., 2017; Sherwood et al., 2000). Recent studies show
that PAC1hop contains a consensus PKC phosphorylation (Blechman et al.,
2013; Holighaus et al., 2011; May, Buttolph, Girard, Clason, & Parsons, 2014;
Sherwood et al., 2000). These unique variants may serve a purpose such as
regulation of mRNA stability, G-protein coupling and receptor desensitization and
trafficking (Holighaus et al., 2011; May et al., 2014). For example, in HEK293,
cardiac, and dentate cells, the PAC1hop isoform is internalized following PACAP
stimulation and is necessary for induction of kinase signaling and action potential
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generation (Johnson, Parsons, May, & Hammack, 2020; May et al., 2014; May,
Lutz, MacKenzie, et al., 2010). Although G-protein coupling has been the primary
focus of PAC1R signaling, recent evidence in cardiac and dentate granule
neurons have demonstrated that PAC1R endocytosis facilitates neuronal
excitation, which further adds to the complex PACAP signaling repertoire
(Johnson et al., 2020; May, Lutz, MacKenzie, et al., 2010; May & Parsons, 2017;
Parsons & May, 2018).
Although VMN and PACAP studies have made tremendous progress in
characterizing energy homeostasis regulation, the endogenous role of PACAP,
and the intracellular signaling mechanisms that determine the comprehensive
responsivity of VMN cells to PACAP is poorly understood. Considering its clear
and marked involvement in regulating energy homeostasis, it becomes essential
to characterize down-stream consequences of PACAP ligand binding in order to
identify potential etiologies of obesity as well as exploring possible future
therapies. Examination of the activated receptor cascade may help to
differentiate the mechanisms by which PACAP can exert a diverse array of
actions on specific cellular and physiological processes that may ultimately
impact disease states such as obesity. For example different PAC1R isoforms
have been shown to influence sleep (Hannibal, Georg, & Fahrenkrug, 2016),
stress (Amir-Zilberstein et al., 2012), locomotion (Vaudry et al., 2009), and posttraumatic stress disorder (PTSD) (Ressler et al., 2011). This raises the question,
how does PAC1R signaling regulate disparate aspects of feeding and
metabolism in the VMN? Unique characteristics of class B family of G-protein
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coupled receptors may explain PACAP’s pleiotropic effects in the VMN by
enabling PAC1R-dependent regulation of feeding and metabolism through Gprotein coupling and PAC1R trafficking.

G-protein coupled receptor signaling and termination

GPCRs are seven transmembrane spanning proteins that form the largest
family of cell-surface receptors (Marinissen & Gutkind, 2001; Nogueras-Ortiz &
Yudowski, 2016). Classically, GPCRs are activated by extracellular ligands that
induce intracellular signaling by coupling to transducer proteins from four families
of heterotrimeric G-proteins (Eichel & Von Zastrow, 2018; Jalink & Moolenaar,
2010; W. Wang et al., 2018). It has now been demonstrated that individual
GPCRs produce complex signaling that allow for multidimensional regulation of

Figure 1.5. GPCR signaling cycle. Figure reproduced from , A Last
GASP for GPCRs?, Volume: 297, Issue: 5581, Pages: 529-531,
DOI: (10.1126/science.1075453)
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cellular function (Eichel & Von Zastrow, 2018). PAC1R stimulation has been
shown to engage Gas, Gaq, and Gai signaling (Blechman et al., 2013).
PAC1 receptor signaling is regulated in a similar manner to other GPCRs,
through desensitization and endocytosis of the receptors (May, Lutz, Mackenzie,
et al., 2010; Tompkins et al., 2018a). Canonically, GPCR desensitization and
endocytosis are regulated by serine/threonine kinases such as PKA and PKC,
and G-protein receptor kinases (GRKs) (Di Fiore & von Zastrow, 2014; Eichel &
Von Zastrow, 2018). Once phosphorylated, GPCRs are recognized by b-arrestins
and other nucleating protein complexes such as adaptor proteins that facilitate
clathrin aggregation (Delom & Fessart, 2011; DeWire, Ahn, Lefkowitz, & Shenoy,
2007; Lobingier & von Zastrow, 2019). This results in plasma membrane
invagination that is cleaved by dynamin to form endosomes, that is either
recycled to the membrane or tagged for lysosomal degradation (Cosker & Segal,
2014; Scita & Di Fiore, 2010; Sposini et al., 2017). Classically, GRKs
(Dautzenberg & Hauger, 2001; Ferguson, 2007; Hupfeld & Olefsky, 2007)
phosphorylate the C-terminal tail of GPCRs to attenuate G protein signaling,
allowing for the binding and activation of b-arrestins which mediate receptor
desensitization and internalization (Cahill et al., 2017; Di Fiore & von Zastrow,
2014). However, recent works have shown that some GPCRs engage in
sustained G-protein signaling from within internalized cellular compartments
rather than desensitizing including the PAC1 receptor (May & Parsons, 2017;
Sposini et al., 2017; Yarwood et al., 2017).
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b-arrestins facilitate dynamic and sustained GPCR signaling beyond Gprotein signaling.

Generation of second messengers by GPCRs and its termination was
thought to occur exclusively at the plasma membrane. However, this paradigm is
not consistent with recent observations that PAC1R stimulation continues to
suppress food intake and increase metabolism long after the peptide has likely
been cleared from the synapse, and membrane signaling has been terminated.
b-arrestins were classically considered as signaling terminating proteins (Cahill et
al., 2017; DeWire et al., 2007), however, these scaffolding proteins are also
critical signal transducers at the GPCRs in the membrane and downstream of
numerous GPCRs via their ability to nucleate signaling complexes containing
members of the MAPK and Src kinases (Reinecke & Caplan, n.d.; Shukla, Xiao,
& Lefkowitz, 2011; Thomsen, Jensen, Hicks, & Bunnett, 2018). Recent data
demonstrate that PAC1R forms a complex with b-arrestins (Broca et al., 2009;
Merriam et al., 2013; Shintani et al., 2018), and that the complex formed between
b-arrestins and PAC1R is critical for neuronal excitability and sustained cell
signaling (May et al., 2021; May & Parsons, 2017; Parsons & May, 2018)
Endocytosis is considered a master organizer of signal circuits with a primary
role to maintain the fidelity and resolution of signals in space and time (Scita & Di
Fiore, 2010; Sigismund et al., 2012). The integration of endocytosis is thought to
be critical for determining the net signaling output by sustaining signals that
originate from the plasma membrane and for generating unique signals that are
prohibited at the plasma membrane thus contributing to the signal diversity (Di
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Fiore & von Zastrow, 2014; Lobingier & von Zastrow, 2019; McMahon & Boucrot,
2011).
The unique small volume of endosomes is a key feature for signaling
because it supports receptor-ligand association and sustains receptor activity,
and this might help to explain peptide neurotransmission where production,
packaging and release is energy consuming (Di Fiore & von Zastrow, 2014; Scita
& Di Fiore, 2010). Endosomes are enriched with lipids and proteins such as
phosphatidylinositol-3-phosphate and lipid-raft adaptor protein, affording specific
scaffolding surfaces on which signaling complexes can nucleate (Scita & Di
Fiore, 2010; Sigismund et al., 2012). Endosomes are also unique because they
contain rapid microtubule-mediated transport of molecules which allow
transmission of signals over long distances, such as from the plasma membrane
to the nucleus, while also providing an acidic pH which is necessary for a variety
of specific signaling pathways (Di Fiore & von Zastrow, 2014; Lobingier & von
Zastrow, 2019; Sigismund et al., 2012; Sposini et al., 2017). For example, retinal
ganglion cells respond to blue light and induce PAC1R nuclear translocation (Yu,
Lin, Ouyang, Tao, & Fan, 2021), creating the possibility for direct gene
regulation.
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GPCR transactivation facilitates interconnected signaling.
GPCRs can transactivate and can be reciprocally transactivated by other
receptor types such as receptor tyrosine kinases and cytokine receptors (Moody,
Lee, & Jensen, 2020; W. Wang et al., 2018). This relationship is an important
aspect of the GPCR repertoire as it would allow GPCRs access to a broader
array of highly interconnected signaling mechanisms that influence numerous
physiological and pathological conditions (Campbell & Smrcka, 2018; Gavi,
Shumay, Wang, & Malbon, 2006). Recent studies using in vitro models have
demonstrated that PAC1Rs cause transactivation of receptor tyrosine kinases
EGFR and HER 3 to exacerbate cell proliferation in non-small cell lung cancer
(Moody et al., 2020; Moody, Ramos-Alvarez, & Jensen, 2021). Another study
demonstrated that PAC1Rs transactivate EGFR to prevent damage to corneal
endothelial cells (Moody et al., 2020). These studies demonstrate that PAC1R
transactivation-related signaling mechanisms are important for physiological and
pathological processes. More recently, in the VMN, PAC1R activation has been
shown to stimulate a number of downstream markers of the JAK2-STAT3
signaling pathway, a downstream leptin receptor signaling cascade (Hurley et al.,
2020). The crosstalk between PACAP and leptin signaling will be the subject of
chapter VIII.
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Leptin and VMN control of feeding
As mentioned earlier, the VMN contains an abundance of leptin receptors
that respond to the peripheral hormone, leptin (Dhillon et al., 2006; Joel K.
Elmquist, Bjørbæk, Ahima, Flier, & Saper, 1998; Koizumi et al., 2020). Leptin or
leptin receptor mutations lead to overeating and excessive weight gain that can
ultimately lead to morbid obesity, suggesting that intact leptin and its long-form
receptor is necessary for maintaining body weight and energy balance (J K
Elmquist et al., 1999; Wilding, 2002). The high abundance of leptin receptors in
VMN neurons suggest these cells are responsive to circulating leptin (Hawke et
al., 2009; Hurley et al., 2020). Leptin, the ob gene product, is a cytokine secreted
by adipocytes into the blood and its circulating concentrations are approximately
proportional to fat stores (J K Elmquist et al., 1999; King, 2006). Thus, leptin has
colloquially been referred to as a “lipo-stat”. Leptin delivery into the VMN likely
occurs through the blood brain barrier of the median eminence and/or
transported into the cerebrospinal fluid via the choroid, from where it then can
enter the hypothalamus (Ronghua Yang & Barouch, 2007a).
Unlike G-protein coupled receptors, the leptin receptor is a single
membrane-spanning receptor belonging to the class I cytokine receptor family
and expresses six different isoforms (a-f) (Bjørbæk et al., 2000; Mancour et al.,
2012) (Figure 1.5.). Of these isoforms, the long-form (b) is the active form and is
typically denoted as lepRb or ObRb (Banks, Davis, Bates, & Myers, 2000;
Bjørbæk et al., 2000). Like many cytokine receptors, lepRb is associated with
tyrosine kinases placing it within the category of receptor tyrosine kinase
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(Bjørbæk et al., 2000; Ghilardi & Skoda, 1997; Procaccini, Lourenco, Matarese,
& La Cava, 2009; Vaisse et al., 1996). Upon binding to the lepRb, leptin engages
the JAK-STAT pathway, which involves the activation of JAK2 (Ghilardi &
Skoda, 1997; Vaisse et al., 1996) (via phosphorylation) leading to the
phosphorylation of STAT3 (Lundin, Rondahl, Walum, & Wilcke, 2000; Procaccini
et al., 2009; Wilding, 2002). The phosphorylation of STAT3 causes its

Figure 1.6. Leptin signaling pathways In the brain, the binding
of leptin to the ObRb receptor activates janus-tyrosine kinase
2 (JAK2), which leads to the phosphorylation of two tyrosine
residues in the cytoplasmic tail of the Ob-Rb receptor,
producing the activation the signal transducer and activator of
transcription 3 (STAT3) signaling pathways. SOCS-3
negatively regulates leptin receptor signal transduction.
Figure reproduced from King et al (2018) Metab Brain Dis.
2018 Aug;33(4):1097-1110.

homodimerization, which allows it to enter the nucleus and bind to specific DNA
targets (Devos et al., 1997). The JAK-STAT pathway is tightly regulated by
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phosphatases such as suppressors of cytokine signaling 1-7 (SOCS1-7) and
protein inhibitors of activated STAT (Lundin et al., 2000; Procaccini et al., 2009;
Ronghua Yang & Barouch, 2007b).
Similar to PACAP, leptin injections into the VMN potently induces
hypophagia and hyperthermia, while also inducing pSTAT3 and SOCS3 mRNA
transcription (Hurley et al., 2020). Moreover, disruption to leptin receptor
signaling in the VMN leads to obesity (Bingham, Anderson, Reuter, Stallings, &
Parker, 2008; Choi, Sparks, Clay, & Dallman, 1999; Dhillon et al., 2006). In situ
hybridization analysis shows that leptin and PACAP receptor transcripts colocalize within the same VMN cells (Hawke et al., 2009; Hurley et al., 2020).
More importantly, blocking PAC1 receptors prevents leptin’s ability to engage its
downstream signaling and influence feeding and energy expenditure (Hawke et
al., 2009; Hurley et al., 2020). Given that PACAP and leptin signaling in the VMN
appear to have a high degree of commonality on their impact on feeding,
metabolism, and gene transcription, the possibility that both peptides alter
feeding and energy balance via a shared intracellular pathway could pose some
distinct advantages. As a collaborative pair, leptin may supply constant or tonic
activation of the system in order to prime it for activation upon the release of
PACAP, a more phasic-patterned signaling molecule. Despite the highly
speculative nature of this potential model, data collected and presented in this
thesis may provide preliminary support for such a model. Collectively, these
findings suggest that elucidating the signaling mechanisms underlying the cross
talk between PACAP and leptin signaling may be useful to understanding the
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etiologies of obesity, while providing potential therapeutic avenues to treat
obesity. In both humans and animals, an obese phenotype is often accompanied
by leptin insensitivity, which poses a barrier to therapeutic measures necessary
to achieve weight loss. The functional relationship between PACAP receptors on
leptin receptors may provide insight into an origin of leptin insensitivity or a
potential mechanism for overcoming leptin insensitivity.
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CHAPTER II
VENTROMEDIAL NUCLEI OF THE HYPOTHALAMUS & CORTICAL CELLS
EXPRESS PITUITARY ADENYLATE CYCLSE-ACTIVATING POLYPEPTIDE
RECEPTOR ISOFORMS IN THE RAT BRAIN: CONSEQUENCES FOR
SIGNALING & CONTROL OF FEEDING
Introduction
Neurons and astrocytes constitute the fundamental infrastructure for
central nervous system (CNS) signaling and function. Within these unique cell
types are gene products and their respective proteins that can define and
facilitate how cells function and communicate nuanced information processing
throughout the CNS. One gene in particular that has emerged as a critical
signaling component in neurons and astrocytes is the peptide pituitary adenylate
cyclase-activating polypeptide (PACAP) and its cognate receptors (Ciranna &
Costa, 2019; Jozwiak-Bebenista et al., 2007; Kong et al., 2016). PACAP and
PACAP receptors are abundantly expressed in numerous CNS regions
implicated in feeding, reward seeking, stress responses, and learning and
memory (Eiden, Hernández, Jiang, & Zhang, 2021; Gottschall et al., 1990; H.
Hashimoto, Ishihara, Shigemoto, Mori, & Nagata, 1993; Resch et al., 2011; Limei
Zhang, Hernandez, et al., 2021). Interestingly, examination of PACAP and
PACAP receptor distributions throughout the CNS show that the neuropeptide
and its receptors are co-expressed with glutamatergic and GABAergic markers
suggesting a putative involvement in excitatory and inhibitory neurotransmission
in the CNS (Engelund, Fahrenkrug, Harrison, & Hannibal, 2010; Fahrenkrug &

22
Hannibal, 2004; Resch et al., 2013; Limei Zhang, Hernández, et al., 2021). In
addition, PACAP signaling is important for synaptic function through
synaptogenesis and receptor/ion channel signaling regulation (Ciranna & Costa,
2019; Girard, Keller, Schutz, May, & Braas, 2004; Macdonald et al., 2005).
Disruptions in PACAP or its receptor have been implicated in a dichotomy of
nervous system disorders including post-traumatic stress disorder (Ressler et al.,
2011), depression (R. Hashimoto et al., 2010; Pinhasov et al., 2011), migraine
(Amin et al., 2014; Edvinsson, Tajti, Szalárdy, & Vécsei, 2018; Schytz et al.,
2009), and anorexia (Kocho-Schellenberg et al., 2014; Resch et al., 2011, 2013,
2014), suggesting that PACAP and its receptors are important for normal CNS
infrastructure and function. Although recent advances in molecular biology have
expanded our understanding of PACAP signaling, there is still a paucity in our
knowledge and understanding of cell-type-specific expression of PACAP and the
PAC1 receptor and how their genes may change or influence CNS
transcriptomes, and activity under physiological and pathophysiological states
The PAC1 receptor gene precursor mRNA is alternatively spliced to
generate several receptor proteins with pleiotropic properties that are relevant for
cell signaling and physiology. Although PACAP and PAC1R isoform signaling
cascades have previously been discussed and reviewed (Blechman et al., 2013;
Girard et al., 2004; Holighaus et al., 2011), none have examined the cell-typespecific PACAP and PAC1 receptor variant expression and how this may
influence signaling associated with stress, motivation and feeding behaviors.
The functional roles of these receptor variants have been proposed to influence
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ligand selectivity and/or G-proteins (Liao et al., 2019, 2021). Our lab has
previously shown PACAP influences cortical and hypothalamic regulation of
motivation, feeding, metabolism and gene transcription (Hurley, 2018; Hurley et
al., 2020; Resch et al., 2011, 2013). Tract tracing experiments show that the
cortical motive circuit and VMN are each highly connected to other brain regions
that express PACAP and PAC1R and have been shown to share functionally
consistent roles (Resch et al., 2013). It is however unknown whether PAC1Rs
and associated genes are responsive to alterations to motivational and energy
states. Additionally, the neuronal and astrocyte distributions of PAC1Rs and
genes that change in response to PACAP are unknown. Addressing cell-typespecific PAC1R isoform expression and how their unique signaling pathways
influence cell physiology and gene expression under physiological stressors may
reshape our understanding of peptide control of neurotransmission under
physiological and pathophysiological conditions
To address the cell-type-specific and physiological-dependent changes in
gene expression of PAC1 receptor isoforms, we corroborated previously
identified distributions of PACAP and PAC1R mRNA expression in select brain
regions including the hippocampus, thalamus, amygdala and VMN.
Subsequently, we matched PAC1R mRNA expression and distribution using a
PAC1R antibody and then surveyed PAC1R isoform expression in tissue and or
dissociated neurons and astrocytes from cortex, nucleus accumbens, medial
amygdala, hypothalamic paraventricular nuclei (PVN) and VMN. Next, we
assessed energy-state dependent changes in mRNA expression of PAC1Rs and
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known PACAP-responsive genes in the amygdala, VMN and nucleus
accumbens, brain regions associated with stress, feeding and motivation. Finally,
we showed that PACAP treatments in the VMN target all PAC1 receptor
isoforms, and targeted reduction of PAC1 expressing cells leads to loss of all
PAC1 receptor isoform mRNA expression.

Materials and Methods
Animals
Male Sprague-Dawley rats (Envigo, Indianapolis, IN) and transgenic
GFAP-lck-eGFP (Medical College of Wisconsin, Milwaukee, WI) knock-in rats
were individually housed in standard cages (Research Diets, New Brunswick,
NJ) in a climate-controlled room under a 12-hr light/dark cycle (lights on at
0200h). Animals were weighed daily and provided ad libitum access to standard
chow (Teklad global 18% protein diet 2018 formulation, Envigo, Indianapolis, IN)
and water. All procedures using animals were approved by the Marquette
University Institutional Animal Care and Use Committee.

GFAP-Lck-eGFP Rats
GFAP-Lck-eGFP transgenic rats were generated in collaboration with Dr.
Aron Geurts at the Medical College of Wisconsin. The Sleeping Beauty
transposon system was used to generate a GFAP-Lck-eGFP to express
membrane targeted enhanced green fluorescent protein (eGFP) under the
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regulation of the glial fibrillary acidic protein (GFAP) promoter (Katter et al.,
2013). eGFP was targeted and incorporated into the cell membrane by fusing
green fluorescent protein (GFP) with a peptide containing myristoylation and
palmitoylation domains of Lck, a Src kinase family tyrosine kinase. Together, the
use of a GFAP promoter and GFP fused to Lck resulted in GFP expression
exclusively in astrocytes membranes.

Surgery
Animals were anesthetized with 2% isoflurane using a SomnoSuite lowflow anesthesia system (Kent Scientific, Torrington, CT) and placed in a
stereotaxic apparatus (Stoelting, Wood Dale, IL). A 26-gauge stainless steel
unilateral injector (Plastics One, Roanoke, VA) was stereotaxically lowered 9.2
mm to reach the hypothalamic ventromedial nuclei (VMN) in all animals. The
stereotaxic coordinates for the VMN injection sites were: anterior/posterior, -2.5
mm from bregma; medial/lateral, ±0.6 mm from midline; dorsal/ventral, -9.2 mm
from surface of the skull based on The Rat Brain in Stereotaxic Coordinates, 6th
edition (Paxinos & Watson, 2007). The upper incisor bar was positioned -3.3 mm
below horizontal zero.

In situ Hybridization
Rat brains were sectioned coronally at 12 μm and then postfixed in 4%
paraformaldehyde, rinsed in 0.1 M PBS (pH 7.4), equilibrated in 0.1 M
triethanolamine (pH 8.0) and acetylated in triethanolamine containing 0.25%
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acetic anhydride. Standard in vitro transcription methods were used to generate
both sense and antisense riboprobes recognizing PAC1R and PACAP (Choi,
Milwaukee, WI) transcripts, which were subsequently diluted in hybridization
cocktail (Amresco, Solon, OH) with tRNA. Sections were hybridized overnight at
60 °C with either digoxigenin (DIG) or fluorescein (FITC)-labeled riboprobes.
After hybridization, slides were treated with RNase A and stringently washed in
0.3X SSC at 65 °C (PAC1R) for 30 min. Slides were incubated with an antibody
against DIG or FITC conjugated to horseradish peroxidase (HRP; Roche)
overnight at 4 °C. Riboprobe signal was amplified using the TSA-Plus
fluorophore system with either fluorescein or Cy3 (PerkinElmer; Waltham, MA).
Image capture was performed using fluorescent microscopy (Axioskop-2; Zeiss,
Thornwood, NY) and Axiovision image analysis software (Zeiss, Thornwood,
NY).

Immunohistochemistry
Brains were collected via rapid decapitation and flash frozen in OCT with a
dry ice/ethanol bath. Brains were kept at -80 °C before being cut on a cryostat
into coronal sections (12 μm thick) which were thaw-mounted onto
electrostatically clean slides. Brain sections were stored at -80 °C until
immunohistochemistry procedures. Prior to immunohistochemical staining, brain
sections were post-fixed in 4% PFA for 10 minutes on ice and rinsed in 0.1 M
PBS (pH 7.4). Brain sections were incubated in blocking buffer (0.05M KPBS, 3%
normal donkey serum, 0.1% Triton X-100) for 1h at room temperature followed
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by an overnight incubation at 4 °C in blocking buffer containing either primary
antibody against GFAP (rabbit anti-GFAP, #G9269; Signal-Aldrich; St. Louis,
MO), primary antibody against neuronal nuclear protein (NeuN) (rabbit antiNeuN, #ABN78; Millipore, Temecula, CA) or primary antibody against PAC1R
(rabbit anti-PAC1R, #; Alomone; Israel). After several rinses in 0.05M KPBS,
sections were incubated in blocking buffer containing donkey anti-rabbit
Alexafluor 594 or Alexafluor 488 conjugated secondary antibody (1:250; Life
Technologies; Grand Island, NY). Upon completion of fluorescent staining,
representative sections containing eGFP, GFAP, NeuN, PAC1R were imaged
using fluorescent microscopy (Axioskop-2, Zeiss; Thornwood, NY) and Axiovision
image analysis software (Zeiss; Thornwood, NY).

Cell Dissociation
Brain tissue dissections were collected from male GFAP-lck-eGFP or WT
Sprague Dawley rats and placed immediately into ice-cold Hanks ́ Balanced Salt
Solution (HBSS) without Ca2+ and Mg2+ (Sigma-Aldrich, St Louis, MO). Tissues
were further minced before enzymatic digestion to obtain single cell suspension
with Neural Tissue Dissociation Kit - P (Miltenyi Biotec, San Diego, CA), following
manufacturer’s protocol. 1% BSA, 1mM EDTA and 12.5 U/ml DNase DNase I
(Sigma, Cat. DN25) were added to single cell suspensions to reduce cell
clustering. Cells were incubated with 3μM Calcein Violet 450 AM Viability Dye
(eBioscience, San Diego, CA) on ice for 10min to stain live cells.

28
Fluorescence Activated Cell Sorting (FACS)
Following cell dissociation, single cells were filtered through a 70 µm filter
and subsequently washed in fluorescence-activated cell sorting (FACS) buffer
containing 2% BSA and 1 mM EDTA. FACS analysis was performed using
FACSDiva software, 6.1.3 (BD Biosciences). A primary gate based on the
physical parameters of fluorescently labeled cells (side light scatter, SSC and
forward light scatter, FSC) will be used to select for fluorescent cells to exclude
double cells, dead cells and debris. The fluorescence background level was
estimated by using cells from non-fluorescent brain tissue processed at the same
time.

Isolation of RNA and Quantitative Polymerase Chain Reaction
Total RNA was extracted from brain tissue or sorted cells by Trizol
extraction (Invitrogen; Carlsbad, CA) method. Total RNA was treated with DNase
(Life Technologies, Carlsbad, CA) to remove contaminating genomic DNA.
Subsequently, 1 µg total RNA was reverse transcribed into complementary DNA
(cDNA) using a mixture of random primers, oligodT primers and reverse
transcriptase (Reverse Transcription System, Promega; Madison, WI).

Polymerase Chain Reaction (PCR) and Gel Electrophoresis
PCR was performed with GoTaq Green Master Mix (Promega, Madison,
WI) on a thermocycler with parameters as follows. Initial denaturation (3min at
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95°C), Amplification (35 cycles of the following: 95°C for 30s, 60°C for 45s, 72°C
for 45s), and Extension (72°C for 10min). PCR products were then examined
with electrophoresis on an agarose gel (1.8%). Sequences of primers used to
amplify PAC1R isoforms and the following housekeeping genes along with a
100bp DNA Ladder (Promega, Madison, WI) used to locate target PCR products.
PAC1 Forward 5’ GGC CCC GTG GTT GGC TCT ATA ATG G 3’
PAC1 Reverse 5’ GAG AGA AGG CGA ATA CTG TG 3’
PAC1hop Reverse 5’ AGA GTA ATG GTG GAT AGT TCT GAC A 3’
PAC1hip Reverse 5’ TGG GGA CTC TCA GTC TTA AA 3’
GAPDH Forward 5’ GTT ACC AGG GCT GCC TTC TC 3’
GAPDH Reverse 5’ GGG TTT CCC GTT GAT GAC C 3’

Experiments

PACAP, PAC1R mRNA and PAC1R Protein Distribution in Rat Brain
Male Sprague-Dawley rats were euthanized by rapid decapitation
approximately 7 hours after the onset of lights on. Rat brains were frozen in OCT
and coronal sections measuring 12-14 µm in thickness were collected using a
cryostat. Rat coronal brain slices containing hippocampus, thalamus, amygdala,
and hypothalamic nuclei were selected for qualitative detection of PACAP,
PAC1R mRNA and PAC1 receptor protein using fluorescent in situ hybridization
and immunohistochemical assays respectively.
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PAC1 Receptor Isoform Expression in Rat Brain
Male Sprague-Dawley rats were euthanized at the onset of lights off and
PVN, VMN, amygdala, and nucleus accumbens tissue was collected for total
RNA extraction. One microgram of total RNA was reverse transcribed to
complementary DNA (cDNA) for PCR analyses of PAC1 receptor extracellular
domain (ECD) and intracellular loop 3 (IC3) isoform expression. Gel
electrophoresis was used to separate and visualize PAC1R isoforms amplified
from PVN, VMN, amygdala, and nucleus accumbens cDNA on a 1.5% agarose
gel. PAC1 receptor isoforms PCR products were identified using a 100 base pair
ladder.

GFAP-Lck-eGFP Rat Characterization
GFAP-Lck-eGFP rat brains were collected via rapid decapitation and flash
frozen in OCT with a dry ice/ethanol bath. Brains were cut on a cryostat into
coronal sections which were thaw-mounted onto electrostatically clean slides and
fixed in 4% paraformaldehyde. Immunohistochemistry analyses for endogenous
transgene, enhanced green fluorescent protein (eGFP), GFAP, and NeuN were
performed on slides containing striatum, VMN and amygdala sections.
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Neuron and Astrocyte-Specific PAC1R Isoform Expression
Adult VMN and embryonic day 15 (E15) striatum tissue was dissociated
and sorted by fluorescence activated cell sorting. Neuronal markers NeuN and
SCG10, and the astrocytic markers Aldh1L1 and GFAP were used to confirm
GFP negative (GFP-, neurons) and GFP positive (GPF+, astrocytes) cells. Total
RNA was extracted from neurons and astrocytes for cDNA synthesis. Nested
PAC1 receptor isoform primers were used for PCR and quantitative PCR to
identify PAC1R isoforms in dissociated neurons and astrocytes.

Energy-State and PAC1R Isoforms Expression
Male Sprague-Dawley rats were food restricted for 22 hours followed by a
2-hour access to feeding. Rats were euthanized 90 minutes following 2 hours of
feeding and brain tissue was collected from VMN, amygdala and nucleus
accumbens for total RNA extraction. One microgram total RNA was reverse
transcribed to generate tissue-specific cDNA libraries. Nested PAC1 receptor
isoform primers were used to amplify changes in PAC1R isoform mRNA
expression. Primers for PACAP, PAC1R, BDNF, SOCS3, STAT3 and xCT were
also used to quantitate changes in mRNA expression.
PACAP-Mediated Saporin annihilation of VMN Cells Expressing PAC1 Receptors
Male Sprague Dawley rats received bilateral injections of saporin (ZAP), a
ribosomal inactivating toxin alone or PACAP conjugated to saporin (PACAP-
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ZAP) in the VMN to selectively target PAC1R expressing cells. Rats were
returned to their home cages where we measured ad libitum access to food
intake and body weight for 2 weeks. Rats were euthanized by rapid decapitation
and VMN tissue was collected for total RNA extraction. RNA was reverse
transcribed into cDNA in order to use PCR to measure changes in PACAP,
PAC1R, BDNF, and xCT mRNA expression.

Data analysis
Data are presented as means ± standard errors of the mean and were
analyzed statistically by analysis of variance (with repeated measures when
appropriate). Fisher LSD, and Tukey HSD analyses were used for post-hoc
group comparisons. Group sizes were designed to detect a 0.05 significance
level with a power of 0.8 assuming a standard deviation of 10% of the mean.
Statistical analyses were performed using SigmaPlot 11 (Systat Software, Inc,
San Jose, CA). P values less than 0.05 were considered statistically significant.
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Figure 2.1. In situ hybridization photomicrographs showing PACAP mRNA distribution
in rat brain structures including the hippocampus, thalamus, amygdala, and
hypothalamus.

Results
Analysis of fluorescent in situ hybridization images show that PACAP (Fig
2.1) and PAC1R mRNA (Fig 2.2) are widely distributed in rat brain. More
specifically, we detected PACAP, PAC1R mRNA expression in the hippocampus,
thalamus, amygdala, and several hypothalamic nuclei including the VMN. In
addition to PACAP and PAC1R mRNA, we found that PAC1R protein is similarly
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distributed in the hippocampus, and hypothalamic nuclei (Fig 2.3).

Figure 2.2. PAC1 receptor mRNA distribution in rat brain structures including the
hippocampus, thalamus, amygdala, and hypothalamus
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DG

VMN

Figure 2.3. Immunohistochemical (IHC) staining of PAC1R protein in the
hippocampus and hypothalamus. IHC images highlighting gross structures
and PAC1R protein expression (green label). DG = dentate gyrus, VMN =
hypothalamic ventromedial nuclei.

Rat cortex and VMN cells express PAC1 receptor isoforms
PCR analysis for PAC1 receptors isoforms demonstrated that PAC1ECD,
PAC1null, and PAC1hop isoforms are expressed in the paraventricular nuclei of
the hypothalamus (PVN), VMN, medial amygdala (MeAmy), and nucleus
accumbens brain tissue. These brain structures are well established to modulate
feeding, stress, and motivational behaviors.
PCR digital gel shows that the N-terminal extracellular domain (ECD), and
C-terminal intracellular loop 3 (IC3) PAC1R isoforms PAC1ECD, PAC1null and
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PAC1hop are expressed in hypothalamic paraventricular nuclei (PVN), VMN,
medial amygdala (MeAmy), and nucleus accumbens (NAc) (Fig 2.4). However,
the isoforms PAC1hip or PAC1hip-hop isoforms were not detected in any of the
adult rat brain structures mentioned above. This is consistent with previous
reports showing that the major isoforms found in adult rat brain are PAC1ECD,
PAC1null and PAC1hop.

PVN
ECD IC3

VMN
ECD

IC3

MeAmy
ECD IC3

NAc
ECD IC3

500 bp
400 bp
300 bp

100 Bp
Figure 2.4 shows C-terminal intracellular loop 3 (IC3) PAC1R isoforms PAC1null and
PAC1hop are expressed in hypothalamic paraventricular nuclei (PVN), ventromedial
nuclei (VMN), medial amygdala (MeAmy), and nucleus accumbens (NAc).
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Figure 2.5. shows C-terminal intracellular loop 3 (IC3) PAC1R isoforms PAC1null and
PAC1hop are expressed in hypothalamic paraventricular nuclei (PVN), ventromedial
nuclei (VMN), and nucleus accumbens (NAc).

To determine the distribution of PAC1 receptors in rat brain cell types, we
developed a rat model with green fluorescent protein expressed in astrocytes
exclusively. We used immunohistochemistry and fluorescent microscopy to
characterize successful expression of GFP and GFAP labeling in astrocytes
alone. We found successful GFP expression in GFAP-Lck-eGFP rat astrocytes
which was confirmed by co localization with GFAP labeling. In addition, we found
that GFP expressing cells do not co-localize with NeuN, a protein exclusively
expressed in neurons.
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Figure 2.6. Astrocyte and neuron labeling in the amygdala. Transgenic GFP
immunolabeling (left top & bottom), GFAP labeling (top, middle) and NeuN
labeling (bottom, middle), transgenic GFP and GFAP co-labeling (top, right)
transgenic GFP & NeuN non co-labeling (bottom, right).

Figure 2.7. Hypothalamic ventromedial nuclei (VMN), astrocytes and neurons
labeling. Transgenic GFP immunolabeling (left top & bottom), GFAP labeling (top,
middle) and NeuN labeling (bottom, middle), transgenic GFP and GFAP colabeling (top, right) transgenic GFP & NeuN non co-labeling (bottom, right).
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Figure 2.8. Purity of FACS segregation of GFP negative (blue) and GFP positive
(green) cells (left). RT-PCR expression levels of GFAP, NeuN, SCG10 (neuron
specific growth-associated protein), and GAPDH from sorted cell populations.

To characterize PAC1 receptor isoform expression in sub-populations of
rat brain cells, we used immunohistochemistry to verify that our transgenic
GFAP-Lck-eGFP rats expressed GFP in astrocytes alone. Analysis of GFP
expression and GFAP staining was done in the hypothalamus (Fig 2.7),
amygdala (Fig 2.6), and striatum tissue (Fig 2.9). Cells in both the striatum and
hypothalamic nuclei show robust GFP expression and GFAP staining that
colocalize (Figs 2.6, 2.7, 2.9).
Next, with the help of Kong et al (Kong, 2009) we used fluorescence
activated cell sorting (FACS) to successfully isolate striatum neurons and
astrocytes from cells dissociated from GFAP-Lck-eGFP rat brain tissue. PCR
analysis of segregated astrocyte and neuron cell populations show that
astrocytes express GFAP and the neuronal cell population expressed NeuN
amplicons respectively. In addition, neurons and astrocytes in rat cortex and
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hypothalamic nuclei express both PAC1null and PAC1hop receptor isoforms.
Interestingly, only rat embryonic tissue show differential expression of PAC1
receptor isoforms in neurons vs astrocytes. At this stage of development both
neurons and astrocytes express PAC1null, PAC1hop, and PAC1hip isoforms
whereas, only neurons express the PAC1hip-hop isoform. This suggests there
may be a developmental role for PAC1hip-hop-dependent PACAP signaling that
is not present in adult rat brain.

Rat brain neurons and astrocytes differentially express PAC1R isoforms
The results show that PAC1R isoforms are developmentally and
differentially expressed in neurons vs astrocytes. Embryonic day 15 (E15)
cortical neurons express PAC1null, PAC1hop, PAC1hip, and PAC1hip-hop
isoforms, whereas astrocytes only express PAC1null, PAC1hip, and PAC1hop
and not the PAC1hip-hop isoform.

Figure 2.9. Striatum
Immuno- detection of
GFAP (left),
transgenic expression
of GFP (middle), coexpression of GFAP
and GFP signaling
(right).
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Figure 2.10. RT-PCR image showing products of mRNA extracted from dissociated rat
embryonic day 15 cortical cells. Ast = astrocytes, Mix = astrocytes + neurons, Neu = neurons.

RNA extracted from dissociated cortical neurons and astrocytes (E15)
show differential gene expression profiles. Quantitative mRNA analysis shows
PAC1R, PACAP, BDNF, xCT, and SOCS3 mRNA are enriched in neurons at the
onset of lights off, compared to astrocyte expression (Fig 2.11). BDNF is
upregulated in both neurons and astrocytes, and leptin receptor mRNA is
downregulated (Fig 2.11).
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Figure 2.11. RT-qPCR showing relative gene expression profiles of mRNA
isolated from dissociated VMN astrocytes and neurons. PAC1R, PACAP,
BDNF, xCT, and SOCS3 mRNA are enriched in neurons compared to
astrocyte expression.

Analysis of gene expression profiles show that food ingestion following a
fast induced an overall decrease in PACAP, PAC1Rs, BDNF, SOCS3, STAT3
and xCT mRNA in tissue collected from the nucleus accumbens (Fig 2.12). By
contrast, mRNA analysis from amygdala tissue revealed that feeding following a
fast stimulated an overall increase in PAC1Rs, BDNF, SOCS3, and xCT,
whereas PACAP and STAT3 decreased (Fig 2.12). In the VMN, food ingestion
following a fast resulted in increased PACAP, PAC1Rs, BDNF, and STAT3
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mRNA expression, however, SOCS3 and xCT decreased (Fig 2.12). A close
analysis of PAC1R isoforms expression revealed that food presentation following
a fast does not differentially influence VMN PAC1R isoform expression.
Interestingly, PAC1R isoforms appear differentially regulated in the amygdala
and nucleus accumbens. In the amygdala, it appears that PAC1hop isoform in
higher in expression compared to the PAC1null isoform. In the nucleus
accumbens, PAC1hop isoform decreased more that PAC1Rnull isoform.
However, whether these magnitude increases are functionally relevant remain to
be determined.

Figure 2.12. Differential gene expression in rats allowed to eat for 2 hours after
fasting for 22 hrs. PACAP, PAC1Rs, BDNF, SOCS3, STAT3 and xCT mRNA
expression from hypothalamic ventromedial nuclei (VMN), amygdala, and nucleus
accumbens tissue.
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Effect of PACAP-ZAP on VMN PAC1R Expression
Hypothalamic VMN injections of PACAP conjugated to saporin caused a
complete loss of PAC1null, and PAC1hop mRNA expression (Fig 2.13). PAC1
receptor DNA band detection following gel electrophoresis shows missing VMN
PAC1null and PAC1hop isoforms compared to PVN, and nucleus accumbens
tissue that did not receive conjugated PACAP-Saporin injections (Fig 2.13). This
indicates that the PACAP-Saporin complex was sufficient to recognize and ablate
PAC1R expressing VMN cells.

PAC1null
VMN

PVN

PAC1hip

PAC1hop
NAc

VMN

PVN

NAc

VMN

PVN

NAc

500 bp
400 bp
300 bp
200 bp

100 bp

Figure 2.13. C-terminal intracellular loop 3 (IC3) PAC1R isoforms
PAC1null and PAC1hop are expressed in hypothalamic paraventricular
nuclei (PVN), ventromedial nuclei (VMN), and nucleus accumbens
(NAc).
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Discussion

PACAP is a biologically relevant neuropeptide whose sequence has been
highly conserved throughout evolution from tunicates to mammals (Vaudry et al.,
2009). It is not surprising that PACAP and its receptor mRNA are broadly
distributed in key central nervous system cell groups. We used in situ
hybridization and immunohistochemical staining to label rat brain cell containing
PACAP, PAC1R mRNA and PAC1R protein as demonstrated in (Figs. 2.1, 2.2,
2.3). We found that PACAP, PAC1R mRNA and PAC1R protein are highly
expressed in several brain regions including the hippocampus, thalamus,
amygdala, and hypothalamus. Hypothalamic nuclei exhibited the densest PAC1R
mRNA staining as previously published by Resch et al (Resch et al., 2011,
2013). We further confirmed that the protein for PAC1R is highly expressed in
brain regions where PAC1R mRNA is expressed suggesting that the PAC1R
gene is not only transcribed but it is also translated into functional protein that
can influence key signaling events across numerous brain regions.
PACAP binding to PAC1 receptors engages multiple second messenger
signaling pathways throughout the central nervous system to regulate gene
transcription, neurotransmission, and numerous behaviors (Blechman et al.,
2013; Holighaus et al., 2011; May, Lutz, Mackenzie, et al., 2010; May & Parsons,
2017; Shintani et al., 2018; Limei Zhang, Hernandez, et al., 2021). Previous
studies have demonstrated that the PAC1R gene is highly spliced and generates
multiple isoforms that display differing sensitivity to PACAP and bias toward
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unique 2nd messenger signaling. To that end, we probed for PAC1R isoform
expression in brain regions our lab and others have previously shown to
influence feeding, stress, and motivation (He et al., 2021; Hurley et al., 2020,
2016; Loh, Herzog, & Shi, 2015; Resch et al., 2011, 2014). We found that
PAC1R isoforms PAC1ECD, PAC1null and PAC1hop were expressed in rat
hypothalamic paraventricular and ventromedial nuclei, amygdala, and the
nucleus accumbens, suggesting that PACAP signaling has another layer of
complexity that could be afforded by PAC1R isoforms. For the numerous studies
showing functional consequences of PACAP/PAC1R signaling, consideration
could and should be made towards further nuanced roles of endogenous PACAP
release parameters and the PAC1 receptor subtypes mediating physiological
outcomes.
It is now well established that both neurons and astrocytes uniquely and
coordinately regulate neurotransmission by responding to and releasing
neurotransmitter and neuropeptide factors. Recent evidence show neurons and
astrocytes both express PAC1 receptors and that both cell types can directly
respond to PACAP and influence neurotransmission (Jozwiak-Bebenista et al.,
2007; Kong et al., 2016). For example, we and others have demonstrated that
PACAP signaling influences glutamatergic signaling at the synapse (Kong et al.,
2016; Macdonald et al., 2005; Yaka, He, Phamluong, & Ron, 2003) with more
recent opportunity to closely examine neuron and astrocyte-specific gene profiles
using our newly developed GFAP-Lck-eGFP transgenic rat. This transgenic rat
model allowed us to confidently isolate astrocytes from neuronal cells as the
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GFAP-Lck-eGFP transgenic rat was designed to express a green fluorescent
protein in astrocytes exclusively. We confirmed this isolated expression using
immunohistochemistry and PCR. Photomicrographs confirmed that GFP positive
cells co-localized with GFAP, an astrocyte-specific marker, but not the neuronal
marker, NeuN or SCG10, in several brain regions including the striatum,
amygdala, and the VMN (Figs. 2.6, 2.7, 2.9). Thus, the GFAP-Lck-eGFP
transgenic rat model is an appropriate tool for dissociating gene profiles of
astrocytes from other cell types. Using dissociated astrocyte and neuron cell
populations, we found that neurons and astrocytes in rat cortex and hypothalamic
nuclei express the PAC1null and PAC1hop receptor isoforms. Although Barres et
al (Cahoy et al., 2008) had previously demonstrated PACAP and PAC1R mRNA
are present in developing and mature forebrain neurons and astrocytes, this is
the first time PAC1R isoform distributions have been shown in rodent astrocytes
and neurons. Interestingly, only rat embryonic tissue shows differential
expression of PAC1 receptor isoforms in neurons vs astrocytes. While neurons
and astrocytes express PAC1null, PAC1hop, and PAC1hip isoforms, only
embryonic neurons express the PAC1hip-hop isoform, whereas astrocytes did
not. This suggests a differential and developmental role for PAC1 receptor
isoforms that may be absent in adults. This could potentially explain specific
PACAP and PAC1R contributions to feeding and metabolism during development
that may differ from function in adult stages (Bakalar et al., 2022).
In addition to several brain regions expressing PAC1 receptor isoforms,
PAC1null and PAC1hop also have been shown to have different sensitivity to
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PACAP and shown to engage differing downstream signaling and gene
transductions, which together illustrate that PACAP signaling through PAC1Rs
cannot be generalized throughout the brain. For example, PACAP stimulation of
PAC1Rs influence NMDA receptor function to increase hippocampal and VMN
cell firing frequency but decreased firing in the striatum. These region-specific
differences may be mediated by PAC1R isoform function in either neurons and/or
astrocytes (Hurley et al., 2016; Macdonald et al., 2005; Resch et al., 2014; Yaka
et al., 2003). To date, the importance of specific receptor splice variants in
engaging combinatorial transduction pathways to regulate neurotransmission has
yet to be delineated. Another consideration to make is the PAC1R isoform
sensitivity to PACAP and resulting activation of G-protein coupling, which would
implicate another complex signaling code for PACAP-regulated
neurotransmission that differs across different cell types. Intersection with Gproteins may provide a platform to integrate other signaling systems that could
take into consideration changes in physiological state or milieu. Such complex
PAC1R-mediated effects might serve to illustrate the various regulatory
mechanisms involved in the pleiotropic actions of PACAP during behaviors that
engage stress, motivational, and energy homeostasis systems. Our laboratory
has previously shown that PACAP stimulation of PAC1 receptors in hypothalamic
VMN induced multiple effects on food intake and metabolism (Hurley et al., 2016;
Maunze et al., 2022; Resch et al., 2013). In the current study, we examined the
consequences of food deprivation and food presentation on changes in PACAP,
PAC1R isoforms, BDNF, SOCS3, STAT3 and xCT mRNA in tissue collected
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from the nucleus accumbens and VMN. Food presentation following a fast
increased in amygdala PAC1Rs, BDNF, SOCS3, and xCT whereas, PACAP and
STAT3 decreased. The profile was notably different in the VMN in animals that
fed following a fast with increased PACAP, PAC1Rs, BDNF, and STAT3 mRNA
expression, and decreases in SOCS3 and xCT. A closer analysis of PAC1R
isoforms expression revealed that food presentation following food deprivation
does not influence VMN PAC1R isoform expression. However, PAC1R isoforms
were differentially regulated in the amygdala and nucleus accumbens. The
PAC1hop isoform in the amygdala had higher expression compared to the
PAC1null isoform in contrast to the marked decrease in PAC1hom observed in
the nucleus accumbens compared to the PAC1null isoform. To further illustrate
the need to be more specific regarding PAC1 receptor related signaling, we
showed that VMN PACAP-saporin injections resulted in the loss of all PAC1R
isoforms. As a result, future therapeutic strategies employed in treating diseasestates associated with PACAP and PACAP gene products could be less
effectively deployed due to missed opportunities to recognize more selective
PACAP and PACAP receptor function in neurons and astrocytes and their
responsiveness under physiological and pathophysiological states.
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CHAPTER III
DEVELOPMENT OF PITUITARY ADENYLATE CYCLASE-ACTIVATING
POLYPEPTIDE RECEPTOR TARGETING-shRNA AND VENTROMEDIAL
NUCLEI OF THE HYPOTHALAMUS ADENO-ASSOCIATED VIRUS AND
LENTIVIRUS TRANDUCTION
Introduction
Dysregulation of energy homeostasis is associated with environmental
and genetic factors that may lead to eating disorders or obesity (Andermann &
Lowell, 2017; J K Elmquist et al., 1999; Mou et al., 2015; Timper & Brüning,
2017). In the hypothalamus, several genes including melanocortin-4 receptor
(MC4R), pro-opiomelanocortin (POMC), brain derived neurotropic factor (BDNF)
and leptin gene products have been tested for their involvement in feeding and
metabolic regulation in rodents and humans, and their dysfunction has directly
been implicated in overeating and obesity (Andermann & Lowell, 2017). Another
emerging candidate gene whose role in feeding and metabolism regulation is
pituitary adenylate cyclase-activating polypeptide (PACAP) and its cognate
receptor PAC1R (H. Hashimoto et al., 2000; Resch et al., 2014; Rudecki & Gray,
2016). PACAP and PAC1 receptors are highly expressed in the hypothalamus
with the highest expression observed in the ventromedial nuclei of the
hypothalamus (VMN) (Resch et al., 2011, 2013). Previously, our lab and others
have employed global gene knockdown and pharmacological manipulations to
elucidate putative roles for PACAP signaling in several brain regions including
the VMN control of feeding and metabolism (Bakalar et al., 2022; BozadjievaKramer et al., 2021; H. Hashimoto et al., 2000). These studies have repeatedly
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demonstrated that PACAP and PAC1R gene knockouts and pharmacological
manipulations lead to alterations in feeding and metabolism. While these
methods greatly contributed to our general knowledge about the role PACAP
signaling may play in energy homeostasis, there are limitations with the methods
that we and the field have had to acknowledge while determining the nuances of
PACAP signaling. For example, global PACAP and PAC1R gene knockouts
cause developmental lethality, modify PACAP and PAC1R DNA regulatory
element recognition by trans-acting factors, and produce cell specific PACAP and
PAC1R contributions to feeding and metabolism during development that may
differ from function in adult stages (Bakalar et al., 2022). In addition,
pharmacological antagonists used to infer necessity have been demonstrated to
act as inverse agonists thereby potentially obscuring endogenous roles of
PACAP in the VMN control of feeding and other functions (Hurley, 2018).
To address the challenges and limitations associated with global gene
knockout and pharmacological antagonism in future PACAP studies, we have
designed and tested tools to deliver short hairpin ribonucleic acid nucleotides
(shRNA) in vitro to induce RNA interference in adult rat VMN cells to knockdown
PAC1R in a confined and delineated manner. Our approach employs lentivirus
and adeno-associated viruses (AAVs) which are reliable means for delivering
gene editing tools in cell culture and brain tissue (Burger et al., 2004; de Backer,
Brans, Luijendijk, Garner, & Adan, 2010; Giering, Grimm, Storm, & Kay, 2008;
Hioki et al., 2007). Lentivirus and AAV vectors transduce non-dividing neurons to
deliver and express gene cassettes over long periods of time that allow for
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assessment of gene functions over broader ranges of time. Additional unique
feature of AAVs is that they can selectively transduce specific cell types in vitro
and in vivo using promotors or AAV DNA packaging with different serotype
capsids (Burger et al., 2004) thereby, allowing for additional controlled gene
manipulations and more selective interpretation of outcomes.
In the current studies, we designed and tested shRNA targeting PAC1
receptors in vitro using Neuro2A cells expressing PAC1 receptors. We also
tested lentivirus and adeno-associated virus serotype transduction in VMN cells.
Finally, we packaged shRNA targeting PAC1R mRNA into a lentivirus vector and
transduced VMN cells in male Sprague-Dawley rats and determined through
PCR analysis subsequent mRNA expression of PAC1R, BDNF, and suppressor
of cytokine signaling-3 (SOCS3) all of which have been shown to be responsive
to PACAP signaling. The PAC1R-targeting shRNA nucleotide sequence we
selected was sufficient to knockdown PAC1R mRNA in vitro in a dose dependent
manner and demonstrated that lentivirus and AAV serotypes AAV8, AAV9
containing this sequence successfully transduce VMN cells. Consequently,
transduction of the VMN with lentivirus- or AAV-containing PAC1R-targeting
shRNA significantly decreased PAC1R mRNA expression.
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Materials & Methods
Animals
Male Sprague-Dawley rats (Envigo, Indianapolis, IN) weighing 225-300 g
were individually housed in either standard cages or BioDAQ feeding cages
(Research Diets, New Brunswick, NJ) in a climate-controlled room under a 12-hr
light/dark cycle (lights on at 0200h). Animals were weighed daily and provided ad
libitum access to standard chow and water. All procedures using animals were
approved by the Marquette University Institutional Animal Care and Use
Committee.

Cell culture and plasmid transfection
Mouse neuroblastoma Neuro2a cells (N2a; ATCC) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) containing 10%
(vol/vol) fetal bovine serum (FBS) at 37°C and 5% CO2. Prior to plasmid
transfections, cells were seeded in 24-well plates and allowed to reach 80%
confluence overnight. Transfection of cells with control or lenti-shRNA plasmid
was performed by using Lipofectamine 2000 (Invitrogen) according to the
manufacturer's protocol.

PAC1R shRNA Plasmid Construction & virus production
Hairpin RNA designed to target PAC1R mRNA sequence
(CGGAATCCACTACACAGTATT) was cloned into a lentivirus shRNA plasmid
(Dharmacon GE (RHS3979-201740301) pLKO.1 lentiviral vector) for transfection
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in vitro. Lentivirus and adeno-associated virus (AAV) 8 and 9 particles
measuring 1x1013 titer units/mL and 15.25X1012 viral genomes (VG)/mL were
used to transduce hypothalamic ventral medial nuclei.

Immunohistochemistry
Whole brain tissue was harvested by transcardial perfusion using saline
and fixed in 4% paraformaldehyde. Coronal brain sections were cut at 30µm and
mounted on Superfrost Plus slides. Sections were washed five times with
phosphate buffered saline (PBS) and cover-slipped using Vectashield mounting
medium. Image capture was conducted on a fluorescent microscope (Axioskop2, Zeiss; Thornwood, NY) and Axiovision image analysis software (Zeiss;
Thornwood, NY).

RNA extraction and quantitative reverse transcription
Total RNA was extracted from brain tissue or sorted cells by Trizol
extraction (Invitrogen; Carlsbad, CA) method. Total RNA was treated with DNase
(Life Technologies, Carlsbad, CA) to remove contaminating genomic DNA.
Subsequently, 1µg total RNA was reverse transcribed into complementary DNA
(cDNA) using a mixture of random primers, oligodT primers and reverse
transcriptase (Reverse Transcription System, Promega; Madison, WI).
Quantitative PCR was performed using a StepOne Real-Time PCR System
(AppliedBiosystems; Carlsbad, CA), and PerfeCTa SYBR Green FastMix with
ROX (QuantaBiosciences; Gaithersberg, MD) according to the manufacturer’s
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protocol. Quantification of PAC1R, BDNF, SOCS3 mRNA expression was done
using a relative standard curve and normalized to the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primers for reach gene
were designed to span an exon-exon junction and had efficiencies of
approximately 95%. Melt curve analysis of experiments confirmed a single
product for each reaction.

Surgery
Animals were anesthetized with 2% isoflurane using a SomnoSuite lowflow anesthesia system (Kent Scientific, Torrington, CT) and placed in a
stereotaxic apparatus (Stoelting, Wood Dale, IL). A 26-gauge stainless steel
unilateral injector (Plastics One, Roanoke, VA) was stereotaxically lowered to
reach the hypothalamic ventromedial nuclei (VMN) in all animals. The stereotaxic
coordinates for the VMN injection sites were: anterior/posterior, -2.5 mm from
bregma; medial/lateral, ±0.6 mm from midline; dorsal/ventral, -9.2 mm from
surface of the skull based on The Rat Brain in Stereotaxic Coordinates, 6th
edition (Paxinos & Watson, 2007). The upper incisor bar was positioned -3.3 mm
below horizontal zero.
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Experiments

PAC1R Knockdown in Neuro2A Cells
Neuro2A cells were seeded in 24-well plates and allowed to reach ~80%
confluence overnight. Transfection experiments were prepared with n=6
wells/treatment per reaction. Neuro2A cells were transfected with either 0.5 µg,
1.0 µg, or 1.5 µg total PAC1R-shRNA plasmid DNA in lipofectamine and
incubated for 48 h. Following transfection, cells were harvested for total RNA
extraction using Trizol reagent and quantitative PCR.

AAV8, AAV9 and lentivirus GFP injections in rat VMN
0.25 µl AAV8, AAV9 and lentivirus particles containing plasmids
expressing green fluorescent protein (GFP) were unilaterally microinjected in the
VMN cells over a 30-minute period. Animals were given 2 mg/kg ketoprofen once
post-surgery and returned to their home cages where they received ad libitum
food access and water. Two weeks following virus injections, rats were
transcardially perfused with saline and fixed with 4% paraformaldehyde solution.
Rat brains were harvested and cryosectioned at 30 µm. Image capture was
conducted on a fluorescent microscope (Axioskop-2, Zeiss; Thornwood, NY) and
Axiovision image analysis software (Zeiss; Thornwood, NY).
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In vivo PAC1R knockdown in hypothalamic VMN
Lentivirus particles containing scrambled or PAC1R-targeting shRNA
plasmids with green fluorescent protein were bilaterally microinjected in VMN
cells at 0.25µl/side over a 30-minute period. Animals were given 2 mg/kg
ketoprofen once post-surgery and returned to their home cages where they
received ad libitum food access and water. Two weeks following virus injections,
rats were euthanized by rapid decapitation and VMN tissue was collected for
total RNA extraction and quantitative PCR. PAC1R primers were used to
measure changes in PAC1R mRNA expression relative to GAPDH.

Data analysis
Data are presented as means ± standard errors of the mean and were
analyzed statistically by analysis of variance (with repeated measures when
appropriate). Fisher LSD, and Tukey HSD analyses were used for post-hoc
group comparisons. Group sizes were designed to detect a 0.05 significance
level with a power of 0.8 assuming a standard deviation of 10% of the mean.
Statistical analyses were performed using SigmaPlot 11 (Systat Software, Inc,
San Jose, CA). P values less than 0.05 were considered statistically significant.
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Figure 3.1. PAC1R-shRNA transfection in
Neuro2A cells decreases PAC1R mRNA
expression. PAC1R-shRNA plasmid transfection
significantly reduced PAC1R mRNA levels
compared to non-silencing control (NSc-shRNA)
as measured by quantitative polymerase chain
reaction (qPCR)
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Results

shRNA-mediated PAC1R knockdown in Neuro2A cells
PAC1R-shRNA plasmid transfection of Neuro2A cells decreases PAC1R
mRNA expression in a concentration-dependent manner (Fig 3.1). PAC1Rplasmid concentrations at 0.5 µg and 1.0 µg induced significant decreases (85%
and 75%, respectively) in PAC1R mRNA expression when compared to the
control plasmid. However, a higher concentration of 1.5 µg PAC1R-shRNA
plasmid did not alter PAC1R mRNA levels from control treatment.

In vivo virus transduction (GFP only) in hypothalamic VMN tissue
Fluorescent and confocal microscopy image analyses show that 0.25 µl
injections of AAV serotypes 8, 9 and lentivirus particles produce successful
transduction of VMN cells as illustrated by GFP expression in rat VMN tissue.
Lentivirus-shRNA-mediated PAC1R knockdown in VMN tissue.
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Figure 3.2. AAV8, AAV9, and lentivirus transduce VMN cells. Sprague Dawley rats
were injected with a AAV8, AAV9 or lentivirus containing a green fluorescent protein
(GFP) expressing cassette in hypothalamic ventromedial nuclei (VMN). Left, middle,
right) Fluorescent photomicrographs of VMN cells transduced with AAV8, AAV9, or
lentivirus expressing GFP. 3V =third ventricle, Arc = arcuate nucleus.

Microscopy analysis validated rat brains injected with lentivirus particlescontaining PAC1R-shRNA plasmid transduce a large population of VMN cells
and suppressed PAC1R mRNA levels by 20% (Fig. 3.3) compared to nonsilencing control (Nsc)-shRNA.
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Figure 3.3. Left: Green
fluorescence expression in
hypothalamic cells
transduced with PAC1RshRNA containing lentivirus
particles. Right: Lentivirus
delivery of PAC1R-shRNA
reduced PAC1R mRNA
levels by 20% compared to
non-silencing control (NScshRNA) as measured by
quantitative polymerase
chain reaction (qPCR)
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Discussion

Dysregulation of energy homeostasis is complex as it involves multiple
signaling systems that regulate food intake, metabolism, and body weight. The
emergence of PACAP and its pleiotropic functions in regulating energy
homeostasis has drawn massive interest in the peptide and its receptors as a
potential solution for mitigating feeding related disorders and obesity (Marzagalli,
Scuderi, Drago, Waschek, & Castorina, 2015; Miles, May, & Hammack, 2019;
Rubio-Beltrán et al., 2018). Although we have gained tremendous insight into the
contributions of PACAP and its receptors in energy homeostasis regulations,
much of this effort has relied on global gene knockout and pharmacological
antagonist studies (Adams et al., 2008; Bozadjieva-Kramer et al., 2021; Filatov et
al., 2021; Gray, Cummings, Jirik, & Sherwood, 2001; Gray, Yamaguchi,
Vencová, & Sherwood, 2002; Vu et al., 2015). While gene knockout and
pharmacological manipulations are powerful and informative tools, interpretations
gained from use of these tools are limited. For example, gene knockouts and
pharmacological antagonist fail to account for the spatial and temporal
physiological conditions under which peptide signals function.
To address some of these limitations, we have developed and validated genetic
ablation tools for interrogating region-specific roles of endogenous PACAP and
PAC1R signaling in the control of food intake. Using Neuro2A cells, we
demonstrated that the Dharmacon PAC1R-targeting shRNA was sufficient to
significantly decrease PAC1R expression and that lentivirus-mediated delivery of

62
PAC1R shRNA to regionally suppress PAC1 receptor mRNA is a critical strategy
to target PAC1 receptors and make inferences about endogenous localized
PACAP signaling. To confirm the appropriate viral vehicle, we demonstrated that
lentivirus and adeno-associated virus (AAV) serotypes 8 and 9 transduce VMN
cells whereas, AAV serotype 5 did not. Our results confirm the successful use of
AAV serotypes to limit our interrogation of PAC1R function to the hypothalamus
and subsequently the VMN. Furthermore, we confirmed that our PAC1R shRNA
not only reduced PAC1 receptor mRNA in vitro, but also in vivo involving
hypothalamic VMN cells. Taken together, this tool will allow us to build on our
previous work on PACAP’s role in hypothalamic regulation of food intake and
energy expenditure (Hurley et al., 2020, 2016; Maunze et al., 2022; Resch et al.,
2011, 2013, 2014). Because of AAV8’s limited tropism in rat brain, we will used
this for the remainder of our studies.
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CHAPTER IV
HYPOTHALAMIC VENTROMEDIAL NUCLEI (VMN) PITUITARY ADENYLATE
CYCLASE-ACTIVATING POLYPEPTIDE RECEPTORS (PAC1RS) ARE
NECESSARY FOR FEEDING AND BODY WEIGHT REGULATION

Introduction
Obesity is a major public health concern affecting more than 1.5 billion
people worldwide (Beck, 2000; Boughton & Murphy, 2012; Rodrigues et al.,
2017). It is now apparent that obesity is a consequence of genetic, and
environmental factors leading to an imbalance of energy intake and energy
expenditure. Regulation of energy homeostasis involves a combination of
neurotransmitters and neuropeptide systems found in the peripheral and central
nervous system including the hypothalamus (Beck, 2000; Gastelum et al., 2021;
Wilding, 2002). Earlier studies by Hetherington and Ranson among others
established that the hypothalamus is an organized group of neuropeptidecontaining cells that regulates energy expenditure, and damage to the
hypothalamus and VMN leads to obesity (Hetherington & Ranson, 1942; King,
2006).
One fascinating hypothalamic peptide system that has emerged is pituitary
adenylate cyclase-activating polypeptide (PACAP) and its receptor PAC1R and
its role in feeding and metabolic regulation (Hurley et al., 2020; Resch et al.,
2011, 2013, 2014). PACAP and PAC1 receptors are highly expressed in the
hypothalamus, with the highest expression found in the VMN. PACAP stimulation
of PAC1 receptors decreases food intake, and body weight with concomitant
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increases in energy expenditure (Bozadjieva-Kramer et al., 2021; Hawke et al.,
2009; Resch et al., 2011, 2013). Although exogenous administration of PACAP in
the VMN generates discrete homeostatic responses suggesting an endogenous
role in these physiological and behavioral systems, we have still yet to delineate
specific anatomical circuitry to fully understand PACAP’s functional purpose.
In the current study, we tested the necessity for VMN PAC1R in normal
daily food intake and body weight regulation. We knocked down VMN PAC1
receptors using our adeno-associated virus (AAV) system to deliver PAC1Rtargeting shRNA in male Sprague-Dawley rats. Decreasing PAC1Rs in the VMN
increased meal sizes, reduced total number of meals, and induced body weight
gain. In addition, PAC1R knockdown decreased BDNF and SOCS3 mRNA
expression. To confirm the sufficiency of magnitude of our PAC1 receptor knockdown, we administered exogenous PACAP and observed no change in VMN
food intake and body weight regulation. As an added measure, we used slice
electrophysiology to confirm loss of PAC1R response to exogenous PACAP. We
found that knocking down PAC1Rs prevents PACAP-dependent increase in
action potential firing frequency. Our studies demonstrated that in the VMN
endogenous PACAP signaling significantly contributes to normal daily food intake
and body weight regulation, and this is mediated specifically through PAC1Rs.
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Materials & Methods

Animals
Male Sprague-Dawley rats (Envigo, Indianapolis, IN) weighing 225-300 g
were individually housed in either standard cages or BioDAQ feeding cages
(Research Diets, New Brunswick, NJ) in a climate-controlled room under a 12-hr
light/dark cycle (lights on at 0200h). Animals were weighed daily and provided ad
libitum access to standard chow (Teklad global 18% protein diet 2018
formulation, Envigo, Indianapolis, IN) and water. Food intake measurements
were collected using the BioDAQ Food Intake Monitor for 24-hours daily from the
onset of the experiments. For BioDAQ meal pattern analysis, meals were
defined as food intake of 0.2 g or more with less than 15 minutes elapsing
between feeding bouts (Dunn-Meynell et al., 2009; Farley et al., 2003; Resch et
al., 2011, 2013). All procedures using animals were approved by the Marquette
University Institutional Animal Care and Use Committee.

Surgery
Animals were anesthetized with 2% isoflurane using a SomnoSuite lowflow anesthesia system (Kent Scientific, Torrington, CT) and placed in a
stereotaxic apparatus (Stoelting, Wood Dale, IL). 26-gauge stainless steel
bilateral guide-cannulae (Plastics One, Roanoke, VA) were stereotaxically
implanted 3 mm dorsal to the hypothalamic ventromedial nuclei (VMN) in all
animals and secured to the surface of the skull with an acrylic resin. The
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stereotaxic coordinates for the VMN injection sites were: anterior/posterior, -2.5
mm from bregma; medial/lateral, ±0.6 mm from midline; dorsal/ventral, -9.2 mm
from surface of the skull based on The Rat Brain in Stereotaxic Coordinates, 6th
edition (Paxinos & Watson, 2007). Microinjectors extended 3 mm past the ventral
tip of the cannulae reaching an injection site of -9.2 mm ventral from the surface
of the skull. The upper incisor bar was positioned -3.3 mm below horizontal zero.
Animals were given 2 mg/kg ketoprofen once post-surgery and allowed to
recover from surgery for 1 week before they are included in experiments, during
which time the animals were handled daily to acclimate them to the necessary
physical manipulations during experiments. Correct cannulae placements were
confirmed at the conclusion of each experiment by microscopic examination of
fluorescent protein markers and Nissl-stained sections. Image capture was
conducted on a confocal microscope using 10X and 20X magnification (Nikonconfocal; Nyquist sampling) with Nikon NIS Elements software (Nikon, Melville,
NY, USA). On average, the included studies produced 85% accurate stereotaxic
placement. Only those with correct placement were included in the studies when
experimental design allowed.

Western Blot analysis
Bilateral dissections of the ventromedial hypothalamus (VMH; includes the
VMN and surrounding areas) were collected following rapid decapitation. VMH
tissue was homogenized by hand in ice-cold homogenization buffer (320 mM
sucrose, 10 mM Tris-HCl, pH 7.4, 10mM EDTA, 10mM EGTA) containing Halt
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protease and phosphatase inhibitor cocktail (#78447; Thermo Scientific;
Rockford, IL), followed by 3-4 seconds of sonication. Homogenates were
centrifuged at 1000 X g for 2 minutes at 4°C and the resulting supernatant was
further centrifuged at 10,000 X g for 30 minutes at 4°C to remove crude
membrane protein. The resulting supernatant containing crude cytoplasmic
protein was saved for further processing. Protein quantification of samples was
determined using a bicinchoninic (BCA) assay (#23252; Pierce). Protein (30 µg)
was run on an 8% gel by SDS-PAGE and transferred to a polyvinylidene fluoride
(PVDF) membrane (#LC2002; Thermo Fisher Scientific; Rockford, IL).
Membranes were blocked for 1 hour at room temperature with 5% bovine serum
albumin (BSA) or 5% non-fat milk in tris-buffered saline containing 0.1 % Tween20 (TBS-T). Blots were then probed with either rabbit anti-PAC1R antibody alone
(#AV-R003; 1:1000; Alomone labs; Jerusalem, Israel) or dually probed with bactin using a mouse anti-b-actin (#MA5-15452; 1:2000; Thermo Scientific;
Rockford, IL) overnight at 4°C, followed by washes with TBS-T and incubation
with an HRP-linked anti-rabbit secondary antibody (#7074P2; 1:3000; Cell
Signaling Technologies; Danvers, MA) and HRP conjugated anti-mouse
(#7076P2; 1:5000; Cell Signaling Technologies; Danvers, MA) at room
temperature for 2 hours. Band intensities were developed using SuperSignal
West Atto Chemiluminescent Substrate (#A38556; Thermo Scientific; Rockford,
IL) and visualized using the Odyssey Fc Dual Mode Imaging System (LI-COR;
Lincoln, NE). Band densities were measured and quantified using Odyssey Fc
Dual-Mode Imaging System software. PAC1R antibody specificity was validated
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by preincubating rabbit anti-PAC1R with PAC1R blocking peptide (#BLP-VR003;
Alomone labs; Jerusalem, Israel). Following visualization of PAC1R signal alone,
blots were stripped and re-probed in an identical fashion for b-actin using a
mouse anti-b-actin (#MA5-15452; 1:2000; Thermo Scientific; Rockford, IL) and
HRP conjugated anti-mouse (#7076P2; 1:5000; Cell Signaling Technologies;
Danvers, MA).

RNA extraction and quantitative reverse transcription
Total RNA was extracted from brain tissue by the Trizol extraction
(Invitrogen; Carlsbad, CA) method. Total RNA was treated with DNase (Life
Technologies, Carlsbad, CA) to remove contaminating genomic DNA.
Subsequently, 1µg total RNA was reverse transcribed into complementary DNA
(cDNA) using a mixture of random primers, oligodT primers and reverse
transcriptase (Reverse Transcription System, Promega; Madison, WI).
Quantitative PCR was performed using a StepOne Real-Time PCR System
(AppliedBiosystems; Carlsbad, CA), and PerfeCTa SYBR Green FastMix with
ROX (QuantaBiosciences; Gaithersberg, MD) according to the manufacturer’s
protocol. Quantification of PAC1R, BDNF, SOCS3 mRNA expression was done
using a relative standard curve and normalized to the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primers for each gene
were designed to span an exon-exon junction and had efficiencies of
approximately 95%. Melt curve analysis of experiments confirmed a single
product for each reaction.
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Slice electrophysiology
Coronal slices (250μm) containing the VMN of the hypothalamus were
obtained from adult male rats and prepared using a vibratome (Leica VT1000S).
Slices were prepared in ice-cold solution containing 229mM sucrose, 1.9mM KCl,
1.2mM NaH2PO4, 33mM NaHCO3, 10mM glucose, 0.4mM ascorbic acid, 6mM
MgCl2, and 0.5mM CaCl2 oxygenated using 95% O2 5% CO2. Slices were then
incubated at 31°C for ten minutes in a solution containing 119mM NaCl, 2.5mM
KCl, 1mM NaH2PO4, 26.2mM NaHCO3, 11mM glucose, 0.4mM ascorbic acid,
4mM MgCl2, and 1mM CaCl2 and further incubated a minimum of 35 minutes at
room temperature. Whole-cell recordings were performed in slices continuously
perfused with aerated aCSF (125mM NaCl, 2.5mM KCl, 25mM NaHCO3, 10mM
glucose, 0.4mM ascorbic acid, 1.3mM MgCl2, and 2mM CaCl2) at a temperature
of 29°- 33°C using a gravity-fed perfusion system with a flow rate of ~2 ml/min
oxygenated. Borosilicate (2.5–4.5MΩ) glass pipettes were filled with 140mM KGluconate, 5.0mM HEPES, 1.1mM EGTA, 2.0mM MgCl2, 2.0mM Na2-ATP,
0.3mM Na- GTP, and 5.0mM phosphocreatine (pH 7.3, 290mOsm). Action
potential (AP) firing was filtered at 1kHz, sampled at 5kHz, and measured using a
Sutter Integrated Patch Amplifier (IPA) with Igor Pro (Wave Metrics, Inc.) data
acquisition software.
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Experiments

Design and construction of shRNA
Hairpin RNA was designed to target specific regions of PAC1R mRNA
(CGGAATCCACTACACAGTATT) or a non-silencing control (NSc; scrambled
nucleotides) mRNA. The nucleotide sequences were individually inserted into an
AAV8 vector after the H1 promoter and a red fluorescent protein reporter
sequence (tdTomato) under the CMV enhancer. The resulting plasmids, AAV8H1-shPAC1R-CMV-tdTomato and AAV8-H1-shNSC-CMV-tdTomato were made
into an infectious virus with concentrations of 1.05x1013 vg/mL and 5.25x1012
vg/mL, respectively.

Virus Delivery
Approximately 1 week following cannulae surgery, rats (n=8/group) were
anesthetized and placed in a stereotaxic apparatus. 0.25 µl of AAV8-H1shPAC1R-CMV- tdTomato 1.05x1013 vg/mL or AAV8-H1-NSC-CMV-tdTomato
5.25x1013 vg/mL was microinjected through bilateral guide cannulae over 10
minutes. Following each injection an additional 20 minutes elapsed before
removing injectors to minimize backflow of delivered material. Animals were
allowed to recover from anesthesia and returned to their home-cage. Food intake
was measured using the BioDAQ Food Intake Monitor and body weights were
collected manually. Food intake and body weight measures were collected for 21
days following virus injections.
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AAV Transduction and shRNA-mediated PAC1R Knockdown
21 days following AAV injection, rats were either euthanized and brains
were collected for microscopic examination of fluorescent protein, quantitative
PCR, and western blot analyses or they received microinjections of vehicle or
pituitary adenylate cyclase activating polypeptide (#350-35; PACAP; 50
pmol/0.25µl/side; California Peptide Research; Napa, CA) followed by food intake
measurements for 24-hours and a final body weight measurement. To assess
fluorescent markers, rat brains were sectioned coronally at 14µm using a
cryostat, thaw-mounted onto electrostatically clean sides, and stored at -80°C
until postfixed. Prior to microscopic examination of fluorescent protein markers,
brain sections were postfixed in 4% paraformaldehyde, rinsed in 0.1 M PBS
(pH7.4), and cover-slipped with mounting medium (Vector Labs, Burlingame,
CA). Image capture was performed using a confocal microscope (Nikon Inc,
Tokyo, Japan).

PAC1R knockdown validation: Ex vivo slice-electrophysiology
14 days following AAV8 injections, control and PAC1 receptor knockdown
rats were euthanized for slice electrophysiology. Current-clamp recordings were
performed in spontaneously-firing neurons in the VMN with adequate whole-cell
access (Ra<20 MΩ) and capacitance verified at the beginning of the recording.
Picrotoxin (100μM) and NBQX (10μM) were added to the recording aCSF to
better isolate postsynaptic effects of PACAP. Following completion of a 2–5
minute baseline with <20% variation in spike firing, either PACAP (100nM), or
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PACAP6–38 (100nM) was added to the recording solution. For recordings
measuring PACAP-dependent spike firing after prior application of PACAP6–38,
a stable baseline was first acquired in the presence of PACAP6–38 (<20%
variation).

Data analysis
Data are presented as means ± standard errors of the mean and were
analyzed statistically by analysis of variance (with repeated measures when
appropriate). Fisher LSD, and Tukey HSD analyses were used for post-hoc
group comparisons. Group sizes were designed to detect a 0.05 significance
level with a power of 0.8 assuming a standard deviation of 10% of the mean.
Statistical analyses were performed using SigmaPlot 11 (Systat Software, Inc,
San Jose, CA). P values less than 0.05 were considered statistically significant.

Results

AAV transduction and shRNA-mediated PAC1R knockdown
Confocal fluorescent microscopy analysis (10x and 20x Nikon-confocal;
Nyquist sampling with Nikon NIS Elements software, Nikon, Melville, NY)
validated rat brains injected with AAV8-shPAC1R-tdTomato resulted in
transduction of a large population VMN cells (Fig. 4.1). Note that tdTomato
fluorescent images were converted to binary black and white images.
Microinjections of virus were contained within the borders of the VMN and shown
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to be expressed in a large percentage of VMN cells. Western blot analysis of
VMN homogenates (Fig. 4.1) confirmed that AAV8-shPAC1R-tdTomato
decreased VMN PAC1R expression by approximately 50-60% compared to the
scrambled shRNA non-silencing control (NSc; F(1,14)=11.276, p<0.01).

Figure 4.1. AAV8-mediated transduction of VMN cells with PAC1R shRNA decreases
PAC1R protein expression. A) 10X stitched confocal photomicrograph of VMN cells 21
days after transduction with AAV8 containing control or PAC1R-shRNA (scale bar = 100
µm). Inset is a 20X magnification of the injection area (scale bar = 50 µm). ARC =
arcuate nucleus, 3V = third ventricle. B) representative western blots and quantitation of
PAC1R protein expression in VMN tissue from Sprague Dawley rats injected with AAV8
non-silencing control (NSc) or PAC1R shRNA. Data are expressed as means ± SEM,
*=p<0.05 compared with control (n=8/group).
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Figure 4.2. Knocking down PAC1Rs in the VMN increases daily food intake and
cumulative body weight change. Knocking down VMN PAC1Rs increased daily food
intake by day 12 (Top left) and increased body weight by day 18 (Bottom right). Top
right) VMN anatomical schematic showing site of AAV delivery. Bottom left figure
shows a significant increase in dark phase food take but not light phase feeding
averaged over the 21-day period. Data are expressed as means ± SEM, *=p<0.05
compared with control (n=8/group).

PAC1R knockdown: food intake and body weight
RNA interference of PAC1 receptors by AAV8-shPAC1R-tdTomato
injections in the VMN increased both food intake and body weight compared to
the scrambled shRNA non-silencing control (Fig. 4.2). Specifically, decreasing
PAC1R expression in the VMN reduced the number of meals consumed while
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increasing overall meal size (Table 1). In addition, significant increased food
intake occurred only during the dark phase starting at day 4 and consistently
between days 13 to 21. The lower left graph in Fig 4.2, illustrates significantly
increased dark phase food intake averaged over the 21-day period but not light
phase feeding. Consistent and significant differences were detected in feeding by
day 13, whereas body weight changes were significant by day 18. Analysis of
variance (ANOVA) showed a significant main effect of treatment for food intake
F(1,25)=4.916, p<0.04, and body weight F(1,21)=3.534, p<0.001. Post-hoc all
pairwise multiple comparison procedures (Fisher LSD method) analysis showed
that rats injected with AAV8-shPAC1R-tdTomato significantly increased body
weight after day 18 (p<0.03) compared with non-silencing control shRNA (Fig.
42. Lower right)

Table 1. Meal pattern analysis following PAC1R knockdown
Average number of meals
Average Meal size (g)

Nsc-shRNA
8.381 ± 0.257
2.486 ± 0.08

PAC1R-shRNA
7.333 ± 0.268*
2.883 ± 0.08*

Data are means ± SEM. Meal patterns were analyzed for 21 days post-injection. Nsc, non-silencing control shRNA.
*P<0.05 vs Nsc-shRNA

To test the functional degree to which PACAP receptors in the VMN were
suppressed, exogenous PACAP was administered to stimulate hypophagia and
changes in body weight in both virus and non-silencing shRNA treated animals.
PAC1R-shRNA treatment prevented exogenous PACAP-induced hypophagia
and ameliorated the decrease in body weight (Fig. 4.3). Thus, a 50-60% PAC1R
knockdown was sufficient to disrupt PAC1R regulation of feeding and body
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weight in the VMN. Analysis of food intake data show a significant effect of
treatment (F(3,37)=6.499, p<0.001), time (F(11,33)=361.500, p<0.001), and
treatment x time interaction (F(33,460)=2.460, p<0.001; Figure 4.3, left), whereas
body weight changes showed a significant main effect of treatment F(3,37)=2.964,
p<0.05 when compared to the control group (Figure 4.3, right).

Figure 4.3. Knocking down VMN PAC1Rs blocks PACAP-dependent
hypophagia. Knocking down VMN PAC1Rs is sufficient to block PACAPinduced decreases in food intake (Left) and body weight (Right). Data are
expressed as means ± SEM, *=p<0.05 compared with control (n=8/group).

PAC1R-shRNA expression in VMN cells and PACAP-dependent action potential
firing frequency
Our lab in collaboration with the Hearing lab (Marquette University,
Wisconsin) and others have previously demonstrated that PACAP-dependent
increases in VMN cell action potential firing frequency is mediated through PAC1
receptors (Fig. 4.4). We used this prior knowledge to test if our knockdown of
PAC1R using shRNA was sufficient to prevent PACAP-induced increases in

77
action potential firing frequency. Bath application of PACAP (100nM) to ex vivo
VMN slices increased action potential firing frequency which can be blocked by
PACAP6-38, a PAC1 receptor-specific antagonist (Fig. 4.4). Similarly, PACAP
application to VMN cells expressing PAC1-shRNA does not show any change in
action potential firing frequency (Fig. 4.4).

midline
VMN

Figure 4.4. PAC1R-shRNA expression in the VMN prevents PACAP-dependent
action potential (AP) firing frequency. PACAP and PACAP 6-38 application in ex
vivo slice electrophysiology recording paradigm of transduced VMN cells (top left
and right panels). PAC1R-shRNA-containing AAV8 transduced VMN cells (bottom
left panel). (Bottom right panel) PACAP (100nM) application in slice increase AP
firing in VMN neurons. PACAP 6-38 application blocks PACAP PACAP-induced AP
firing frequency (bottom right).PAC1R-shRNA prevents PACAP-dependent
increases in AP firing. VMN cells do not respond to PACAP treatment (bottom left
panel). Change of firing frequency following PACAPPAC1Rs blocks exogenous
PACAP-induced increases in firing frequency.
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Figure 4.5. Knocking down PAC1Rs in the VMN downregulates BDNF and
SOCS3 mRNA. Top right) representative anatomy of VMN AAV8 delivery
in rat brain. Knocking down VMN PAC1Rs decreased BDNF (left, bottom)
and SOCS3 (right, bottom) transcripts after 21 days. Figures shows a
significant decrease in PAC1R, BDNF, and SOCS3 mRNA. Data are
expressed as means ± SEM, *=p<0.05 compared with control
(n=7/group).
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Discussion
In these experiments, we demonstrate that PACAP’s type I receptor
(PAC1R) signaling in the VMN is endogenously relevant for feeding and body
weight control. shRNA-mediated PAC1R knockdown in the VMN, resulting in a
50-60% reduction in PAC1R protein expression, functionally increased daily food
consumption and body weight gain. Specifically, diminishing PAC1R expression
to this magnitude significantly decreased the number of meals while increasing
the size of each meal (Table 1). This suggest that perhaps PACAP serves as a
satiety signal working to counterbalance hunger inducing factors. As such, rats
eat larger meals in the absence of endogenous PACAP signaling. This is
consistent with our data in which the largest impact of PACAP-induced anorexia
is observed almost exclusively in the dark phase when rats eat approximately
90% of their daily food intake. Moreover, the ability for exogenous PACAP
administration to potently induce hypophagia and body weight loss was blocked
following VMN PAC1R knockdown indicating that this magnitude of PAC1R
knockdown F(1,12)=35.752, p<0.001 was sufficient to disrupt endogenous VMN
PACAP signaling. The effectiveness of inhibition is further supported by our ex
vivo electrophysiology results showing that PACAP fails to increase action
potential firing frequency in VMN cells expressing PAC1-shRNA. Thus, there is a
clear role for endogenous PACAP signaling in the VMN for the control of feeding
behavior and body weight regulation.
The changes in food consumption and body weight gain following VMNspecific PAC1R knockdown is similar to that observed in postnatal steroidogenic
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factor-1 (SF1) knockout mice (Kim et al., 2011). In the CNS, not only is SF1
exclusively expressed in the VMN but VMN SF1 positive neurons co-express
both PACAP and PAC1Rs (Gonçalves et al., 2021; Hurley et al., 2020; Kim et al.,
2011). While VMN SF1 knockout animals exhibit dysregulated temperature
regulation and locomotion, we did not evaluate the metabolic consequences of
shRNA induced PAC1R knockdown. Although, we might predict that animals
lacking VMN PAC1Rs would exhibit decreased spontaneous locomotion and
core body temperature since the PAC1R antagonist in the VMN reverses
exogenous PACAP’s thermogenic and locomotor effects in addition to preventing
hypophagia (Hurley et al., 2020; Resch et al., 2013), it is also possible that we
would not detect any significant changes in core body temperature and locomotor
activity based on our previous work illustrating that PACAP6-38 alone did not
produce significant changes in these metabolic indices compared to control
(Resch et al., 2013). Overall, there are salient similarities between our findings
and those in mice with genetic mutations in PAC1R. Congenital PAC1R
mutations result in phenotypes that can be replicated by local genetic or
pharmacological PAC1R inhibition such as increased feeding suggesting that the
hypothalamic VMN could be a primary control site (H. Hashimoto et al., 2000).
In addition to the overt behavioral and physiological responses to VMN
PACAP manipulation, there are a cohort of PACAP regulated genes whose basal
expression is significantly decrease following PAC1R knockdown and whose
response to physiological challenge is altered in the absence of PAC1R
expression (Fig. 4.5). These genes include brain derived neurotrophic factor
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(BDNF) F(1,12)=35.033, p<0.001, and suppressor of cytokine signaling 3 (SOCS3)
F(1,12)=9.627, p=0.01 (Hammack et al., 2009; Hurley et al., 2020; Macdonald et
al., 2005; Resch et al., 2013; Yaka et al., 2003). BDNF and SOCS3 transcripts
normally increase in response to PACAP. Our laboratory (Resch et al., 2011) and
others (Macdonald et al., 2005; Yaka et al., 2003) have consistently shown that
PACAP promotes BDNF transcription in multiple brain regions, therefore, a
decrease in these genes following PAC1R knockdown suggest PACAP signaling
is required for their expression. Earlier reports in mice lacking PAC1 receptors
show reduced BDNF expression (Zink et al., 2004). The relationship between
PACAP and BDNF may be significant since BDNF has been shown to amplify
excitatory signaling as well as regulate energy balance (Crozier, Black, &
Plummer, 1999; Martin & Finsterwald, 2011). Global BDNF deficient mice or
regional deletion of BDNF in the VMN produces hyperphagia, weight gain, and
metabolic dysregulation (C. Gao & Wolf, 2007). Moreover, BDNF expression in
the VMN is the most abundant among hypothalamic cell groups (Xu et al., 2003).
Specifically, these studies show that PAC1R-deficiency decreases expression of
the exon-III and exon-IV transcripts (Zink et al., 2004). Interestingly, the promoter
sequence of exon III contains cAMP response elements, which suggests the
possibility of regulation by one of PACAP’s signaling arms, the Gs/cAMP/PKA
pathway (Yaka et al., 2003). To that end, PAC1R activation has been shown to
increase CREB phosphorylation with concomitant enhancement of BDNF
transcription (Solés-Tarrés, Cabezas-Llobet, Vaudry, & Xifró, 2020). Therefore,
BDNF transcription may be a mechanism by which PACAP signaling regulates
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energy homeostasis in the VMN. Alternatively, PACAP signaling could influence
BDNF transcripts indirectly via NMDA receptor (NMDAR) signaling. Previous
reports demonstrate that PACAP directly modulates NMDARs which, in turn,
increase BDNF transcript following activation, see Vaudry et al for a review
(Solés-Tarrés et al., 2020).
In addition to changes in BDNF mRNA expression, PACAP signaling in
the VMN also increases SOCS3 transcription with concomitant decreased food
intake and body weight (Hurley et al., 2020). Although we were not surprised that
SOCS3 mRNA transcript significantly decreased in the absence of PACAP
signaling F(1,12)=9.627, p=0.01 (Fig. 4.5), we were surprised that low SOCS3
mRNA was accompanied by increased in food intake and body weight. SOCS3
deficiency in the mediobasal hypothalamus has been shown to reduce food
intake and prevent weight gain (Matarazzo et al., 2012). Canonically, SOCS3
mRNA increases in response to leptin receptor activation as a mechanism to
negatively regulate leptin signaling (Buchanan, Mahesh, Zamorano, & Brann,
1998; Hawke et al., 2009; Ronghua Yang & Barouch, 2007a). We would expect
that endogenous leptin would chronically suppress feeding and weight gain when
SOCS3 transcription is low as seen following PAC1R knockdown. One
explanation could be that although PAC1 and leptin receptors have been shown
to co-localize in a majority of VMN cells, there may be PAC1 and leptin receptors
that do not reside in the same cell. Therefore, the SOCS3 mRNA transcript
decrease observed may be accounted for by VMN cells expressing PAC1
receptors alone, and that in this cell population SOCS3 mRNA transcript might
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not be necessary for leptin signaling and the comprehensive VMN-dependent
changes in food intake. In chapter VIII, we present data that demonstrate that
PAC1 and leptin receptors form an immunocomplex, therefore, it is possible that
PAC1R knockdown may structurally disrupt the leptin receptor and render it
unresponsive to their cognate ligand. In support of this idea, we administered
leptin in the VMN following PAC1R knockdown and found leptin to no longer
suppress food intake and decrease body weight. This could suggest that there
are transcriptional and physical effects of PAC1R deficiency on the physiological
function and behaviors of rats that may explain or reveal alternative mechanisms
of action and functions of neuropeptides in energy homeostasis regulation. The
results from these experiments showed two distinct and interesting outcomes: 1)
PAC1R knockdown decreases expression of genes that tend to suppress food
intake when their ligands are administered in the VMN, and 2) PACAPdependent SOCS3 mRNA expression might have multiple explanations including
independent cytokine receptor signaling in non-leptin receptor expressing cells or
that leptin receptors physically depend on PACAP receptors to maintain
functional integrity.
Collectively, the approximate 16% increase in feeding and 20% increase
in body weight following PAC1R knockdown demonstrate that PACAP signaling
in the VMN has a wide influence over energy balance. Additional studies will be
required to better understand the relationship between leptin, PACAP, and BDNF
in the VMN.
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CHAPTER V
PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE RECEPTOR
(PAC1R) ACTIVATION IN THE HYPOTHALAMIC VENTROMEDIAL NUCLEI
DIFFERENTIALLY REGULATES DIURNAL HYPOPHAGIA AND METABOLISM
BY RECRUITING PROTEIN KINASE A.

Introduction
Dysregulation of energy homeostasis causes obesity and health
complications such as cancer and diabetes resulting in shortened life expectancy
(reviewed in 11, 88). Understanding the mechanisms regulating energy
homeostasis is key to treating obesity-related diseases. The central nervous
system (CNS), and hypothalamic nuclei play indispensable roles in energy intake
and energy expenditure regulation through the reciprocal transfer of
neurotransmitter and neuropeptide signals to and from the peripheral milieu. The
neuropeptide pituitary adenylate-cyclase activating polypeptide (PACAP) has
emerged as an important and potent regulator of energy intake and expenditure
in the peripheral and central nervous systems (Filatov et al., 2021; Harmar et al.,
2012; Hurley et al., 2016; Maunze et al., 2022; Resch et al., 2013).
PACAP injections in hypothalamic ventromedial nuclei (VMN) decrease
food intake and body weight including increases in thermogenesis and
locomotion (Hawke et al., 2009; Resch et al., 2011, 2013). Although our
laboratory has previously shown that PACAP’s effects in the VMN are mediated
through the PAC1 receptors, the specific intracellular signaling mechanisms
responsible for PACAP’s pleiotropic effects remain to be fully explored.
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PAC1 receptors belong to the class B family of G-protein coupled
receptors (GPCRs) that can couple to Gs/cAMP/PKA-related signaling and has
been extensively reviewed (Denes, Geck, Mester, & Gabriel, 2019; Vaudry et al.,
2009). Cyclic adenosine monophosphate AMP (cAMP) is generated from
adenosine triphosphate (ATP) catalyzed by adenylyl cyclase (AC), which is
activated by Gs-coupled GPCRs such as PAC1R. Previous studies have
demonstrated that cyclic adenosine monophosphate (cAMP) and protein kinase
A (cAMP/PKA) signaling cascades act downstream of G-protein coupled
receptors to mediate neuropeptide regulation of feeding and metabolism
involving GPCRs in the hypothalamus and VMN (London, Bloyd, & Stratakis,
2020; London, Nesterova, & Stratakis, 2017; Sheriff et al., 2003; L. Yang, 2018).
For example, orexigenic peptides decrease cAMP/PKA whereas anorexigenic
peptides like PACAP increase cAMP/PKA activity (Sheriff et al., 2003). Earlier
studies demonstrate that hypothalamic cAMP/PKA activity and regulation of
scheduled feeding share an inverse relationship; cAMP/PKA activity levels are
low during the dark cycle, when rats normally eat, and peak during the light cycle,
when rats eat little (Murakami & Takahashi, 1983; Sheriff et al., 2003; Valases,
Wright, & Catravas, 1980). Moreover, administration of a membrane permeable
cAMP agonist (Sp-cAMP) in the perifornical hypothalamus results in a significant
increase in VMN PKA activity and suppression of food intake (Sheriff et al.,
2003). Taken together, hypothalamic circadian regulation of cAMP/PKA activity
appears to be correlated with the regulation of feeding. Although PAC1Rs are
known to couple with Gαs/cAMP/PKA signaling, no study has directly assessed
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the potential for PKA signaling to comprehensively mediate PACAP’s pleiotropic
effects on feeding and metabolism in the VMN. In the current study we examined
if PKA was necessary for PACAP’s pleiotropic functions in the VMN feeding and
metabolism regulation. To that end, we blocked VMN PKA prior to PACAP
injections and measured PACAP’s hypophagic, thermogenic and locomotion
effects during lights off and lights on.

Materials and Methods

Animals
Male Sprague-Dawley rats (Envigo, Indianapolis, IN) weighing 225-300 g
were individually housed in either standard cages or BioDAQ feeding cages
(Research Diets, New Brunswick, NJ) in a climate-controlled room under a 12-hr
light/dark cycle (lights on at 0200h). Animals were weighed daily and provided ad
libitum access to standard chow (Teklad global 18% protein diet 2018
formulation, Envigo, Indianapolis, IN) and water. On experiment days, animals
were weighed, and food intake measurements were collected using the BioDAQ
Food Intake Monitor for up to 24-hours after the onset of each experiment. For
BioDAQ meal pattern analysis the data were analyzed over the first 12 hours.
Meals were defined as food intake of 0.2 g or more with less than 15 minutes
elapsing between feeding bouts (Dunn-Meynell et al., 2009; Farley et al., 2003;
Resch et al., 2011, 2013). All procedures using animals were approved by the
Marquette University Institutional Animal Care and Use Committee.
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Surgery
Animals were anesthetized with 2% isoflurane using a SomnoSuite lowflow anesthesia system (Kent Scientific, Torrington, CT) and placed in a
stereotaxic apparatus (Stoelting, Wood Dale, IL). 26-gauge stainless steel
bilateral guide-cannulae (Plastics One, Roanoke, VA) were stereotaxically
implanted 3 mm dorsal to the hypothalamic ventromedial nuclei (VMN) in all
animals and secured to the surface of the skull with an acrylic resin. The
stereotaxic coordinates for the VMN injection sites were: anterior/posterior, -2.5
mm from bregma; medial/lateral, ±0.6 mm from midline; dorsal/ventral, -9.2 mm
from surface of the skull based on The Rat Brain in Stereotaxic Coordinates, 6th
edition (Paxinos & Watson, 2007). Microinjectors extended 3 mm past the ventral
tip of the cannulae reaching an injection site of -9.2 mm ventral from the surface
of the skull. The upper incisor bar was positioned -3.3 mm below horizontal zero.
Animals were given 2 mg/kg ketoprofen once post-surgery and allowed to
recover from surgery for 1 week before they are included in experiments, during
which time the animals were handled daily to acclimate them to the necessary
physical manipulations during experiments. Correct cannulae placements were
confirmed when possible at the conclusion of each experiment by microscopic
examination of fluorescent protein markers and Nissl-stained sections. Image
capture was conducted on a confocal microscope using 10X and 20X
magnification (Nikon-confocal; Nyquist sampling) with Nikon NIS Elements
software (Nikon, Melville, NY, USA). On average, the included studies produced
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85% accurate stereotaxic placement. Only those with correct placement were
included in the studies when experimental design allowed.

Microinjections
In all experiments, a microinjection pump was used to inject 0.25 µl/side of
vehicle or treatment through bilateral guide-cannulae in awake animals over a 2minute period. After injection delivery was complete, an additional minute
elapsed before removing injectors to minimize backflow. Control and treatment
groups were reversed after a two-day washout period and normal food intake
levels were confirmed. Microinjections were completed approximately 30 minutes
before lights off for experiments assessing nocturnal food intake. For
experiments assessing core body temperature and locomotor activity and
subsequent food intake, microinjections were initiated 2 hours after the onset of
the lights on and lasted approximately for 1 hour.

Experiments

PKA Inhibitor: Dark phase food intake
Thirty minutes before the onset of lights off, microinjections of vehicle, and
two doses of KT5720 (#1288/100U; protein kinase A inhibitor; 2.5nM/0.25µl/side
and 10nM/0.25µl/side; Bio-Techne Corporation, Minneapolis, MN) were
administered 15 minutes before rats (n=6/group) received a second bilateral
injection of either saline containing 1% DMSO or (PACAP; 50pmol/0.25µl/side).
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Approximately 5 minutes after injections, animals were returned to their homecage and food intake was measured for the next 24 hours followed by a final
measurement of body weight. KT5720 was prepared as DMSO stocks, diluted
and injected in animals. The final concentration of DMSO was <1%. PACAP was
prepared as a stock in 0.9% saline and diluted just before use.

PKA Inhibitor: Light phase food intake
Two hours after the onset of lights on, microinjections of vehicle, KT5720
(#1288/100U; protein kinase A inhibitor; 10nM/0.25µl/side; Bio-Techne
Corporation, Minneapolis, MN) were administered 15 minutes before rats
(n=6/group) received a second bilateral injection of either saline containing 1%
DMSO or PACAP (50pmol/0.25µl/side). Approximately 5 minutes after injections,
animals were returned to their home-cage. Food intake and body weight
measures were taken at the beginning of the experiment and again 24 hours
following pharmacological manipulations. KT5720 was prepared as DMSO
stocks, diluted and injected in animals. The final concentration of DMSO was
<1%. PACAP was prepared as a stock in 0.9% saline and diluted just before use.
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PKA Inhibitor: Thermogenesis and spontaneous locomotor activity

At the time of cannulation surgery, telemetry probes (Mini-Mitter, Sunriver,
OR) were implanted in the intraperitoneal cavity of rats to record core body
temperature and spontaneous locomotor activity. On the experiment day, 2 hours
after the onset of the light phase, rats (n=6/group) received bilateral injections of
KT5720 (10nM/0.25µl/side) 10-15 minutes prior to an injection of either saline or
PACAP (50pmol/0.25µl/side). Animals were returned to their home cage and
telemetric data for core body temperature and spontaneous locomotor activity
were collected remotely as previously described (Resch et al., 2011, 2013). In
brief, spontaneous locomotor activity was collected remotely every 5 minutes and
then summed to give cumulative activity every hour. Core body temperature data
were averaged by the hour, and spontaneous locomotor activity data were
summated to give cumulative activity over a specified amount of time.

Data analysis

Data are presented as means ± standard errors of the mean and were
analyzed statistically by analysis of variance (with repeated measures when
appropriate). Fisher LSD, and Tukey HSD analyses were used for post-hoc
group comparisons. Group sizes were designed to detect a 0.05 significance
level with a power of 0.8 assuming a standard deviation of 10% of the mean.
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Statistical analyses were performed using SigmaPlot 11 (Systat Software, Inc,
San Jose, CA). P values less than 0.05 were considered statistically significant.

Results

PKA inhibitor (KT5720): Dark phase PACAP and food intake
Bilateral VMN injections of KT5720 prior to PACAP dose-dependently
blocked PACAP-induced decrease in dark phase food intake (Fig. 5.1).
Specifically, KT5720 (2.5nM and 10nM) injections significantly attenuated
PACAP-induced hypophagia, p = 0.006 and p <0.001 respectively. KT5720
doses of 2.5nM and 10nM alone did not significantly influence food intake when
compared to saline controls (Fig. 5.1).

Figure 5.1. PKA Inhibitor, KT5720 injection in the VMN dose dependently
block PACAP-dependent decreases in food intake. Both 2.5nM/0.25µl/side
and 10nM KT5720/0.25µl/side significantly attenuate PACAP
50pmol//0.25µl/side suppression of cumulative food intake after 3 h and up to
8 h. Data are expressed as means ± SEM, *, **, ***=p<0.05 compared with
control (n=5/group).
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Bilateral VMN injections of KT5720 (10nM), a PKA-specific inhibitor just
prior to PACAP injections attenuates PACAP-induced decreases in dark phase
food intake for up to 8 hours and body weight at 24 hours compared to controls.
Food intake analyses show a significant interaction of treatment x time (F(33,264)
=9.820, p<0.001) and a significant main effect of treatment (F(3,24)=20.536,
p<0.001) when compared to saline controls (Fig. 5.2, Left). Significant inhibition
of PACAP-induced hypophagia by KT5720 is observed by 5h and up to 8h
p<0001(PACAP vs KT5720+PACAP), which was similar to feeding levels
observed in animals that received saline or KT5720 alone (Fig. 5.2, Left).
Analyses of body weight change (Fig. 5.2, Right) revealed that
pretreatment of KT5720 significantly attenuated but did not completely block
PACAP-induced decreases in body weight (saline controls vs PACAP;
F(3,18)=40.996, p<0.001) and (PACAP vs KT5720+PACAP; p=0.009).

Figure 5.2. Blocking PKA signaling with KT5750 blocks PACAP-dependent
decreases in food intake and attenuates PACAP-induced decrease in body weight.
Left) blocking PKA signaling with KT5720 (10nM) reverses PACAP-induced
suppression of food intake from 5 hours post-injection lasting up to 12 hours. Right)
KT5720 attenuated PACAP-induced reduction in body weight 24 hours following
injection. Data are expressed as means ± SEM, * (treatment vs control), # (PACAP
vs PACAP+KT5720) = p<0.05, (n=6/group)
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PKA inhibitor (KT5720): Light phase PACAP and hypophagia
Because it is still not clear whether endogenous PACAP exerts its action
on VMN regulation of feeding and energy expenditure during the dark and/or
light phases, we blocked PKA and measured PACAP-induced hypophagia
during lights on. We found that an acute dose of PACAP during lights on does
not influence food intake in ad lib fed animals over a 24 h period. This was not
surprising because our previous results show that PACAP’s hypophagic effects
only last up to 8 h following an acute dose of PACAP (Maunze et al., 2022;
Resch et al., 2011, 2013), and rats normally eat in the dark while consuming a
mere 10% of their daily food intake during the light phase. The 10% of light
phase food intake amount to approximately 2.5 g (data not shown). Interestingly,
blocking PKA prior to PACAP during lights on seems to influence 24 h food
intake (Fig. 5.3). One-way ANOVA of 24 h food intake data shows that blocking

Figure 5.3. PKA inhibition with KT5750 potentiates PACAP-dependent decreases in food
intake and body weight. Left) Blocking PKA signaling with KT5720 augments PACAPinduced suppression of food intake 24 hours post-injection. Right) KT5720 increased
PACAP-induced reduction in body weight 24 hours following injection. Data are
expressed as means ± SEM, * (treatment vs control), ** (PACAP vs PACAP+KT5720) =
p<0.05, (n=8/group)
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lights-on PKA activity significantly augmented PACAP-dependent decreases in
24 h feeding F(3,28) =18.88, p<0.001, and p <0.003 when compared to PACAP
treatment alone (Fig. 5.4). PACAP treatment alone trends toward suppressing
food intake although it was not significant. PACAP’s effects on feeding are
usually short-lived, lasting up to 8 hours (Maunze et al., 2022; Resch et al., 2011,
2013). Analysis of bodyweight change shows that blocking PKA during lights on
potentiates PACAP induced decrease in body weight when compared to PACAP
treatment alone (F(3,28) = 31.385, p<0.001).

PKA inhibitor (KT5720): Light phase PACAP and energy expenditure
Consequences of blocking PKA on PACAP-induced increases in core
body temperature and spontaneous locomotor activity were assessed at the
onset of the light phase when both are at their nadir. As previously shown (Resch
et al., 2013), PACAP infusions in the VMN increase both core body temperature

Figure 5.4. Effects of PKA inhibition on PACAP-dependent energy expenditure.
KT5720 potentiates PACAP’s thermogenic (Left) and locomotor effects (Right). Data
are expressed as means ± SEM, * (treatment vs control), # (PACAP vs
PACAP+KT5720) = p<0.05, (n=6/group)
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and locomotor activity. However, blocking PKA activity with KT5720 prior to
PACAP infusions did not suppress PACAP-induced increases in core body
temperature or locomotor activity. Interestingly, blocking PKA activity with
KT5720 appeared to potentiate PACAP-induced increases in both core body
temperature and locomotor activity (Fig. 5.4, Left, Right). ANOVA of core body
temperature and locomotor activity show a significant treatment x time interaction
(F(24,120)=13.527, p<0.001; F(24,127)=10.152, p<0.001), respectively when
compared to controls. Post-hoc analysis of treatment on core body temperature
and locomotor activity following a two-way repeated measures assessment
shows that blocking PKA prior to PACAP infusions potentiates both PACAPinduced increase in core body temperature and locomotor activity from 5h up to
8h p<0.01 (PACAP vs KT5720+PACAP; Figs. 5.4, Left, Right).

Discussion

It is now well established that PAC1Rs are GPCRs that couple to and
stimulate Gs/cAMP/PKA-related signaling that influence various physiological
systems (Blechman et al., 2013; Hardwick et al., 2017; Macdonald et al., 2005;
Zhou et al., 2001). However, it is yet to be determined whether PACAP signaling
through PKA might explain PACAP’s pleiotropic effects in the VMN as well as in
the hypothalamus since cAMP and PKA activity are implicated in neuronal
regulation of feeding and metabolism (Dorfman et al., 2017; London et al., 2017;
Ross et al., 2008; Sheriff et al., 2003; L. Yang & McKnight, 2015).
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In this study, we recapitulate previous observations that PACAP in the
VMN reduces specifically nocturnal food consumption and subsequent
decreases in body weight 24 hours following injection (Chang et al., 2021; Hawke
et al., 2009; Resch et al., 2011, 2013, 2014) in addition to increasing core body
temperature and spontaneous locomotor activity when administered in the VMN
during the light phase (Adams et al., 2008; Resch et al., 2011). Presently, we
demonstrate that directly inhibiting PKA had significant effects on PACAP
signaling in the VMN. PKA inhibition at the onset of the dark phase completely
blocked PACAP-induced hypophagia, whereas PKA inhibition during lights on
had no influence on PACAP’s actions on feeding. This is not surprising
considering that rats only consume 10% of their food during the light period. By
contrast, PACAP injections during the light phase seems able to influence
feeding occurring later in the dark phase following PKA inhibition (Fig 5.4).
It is worthwhile to note that, during the light phase, PACAP injections
alone in the VMN do not appear to significantly affect 24 h food consumption,
perhaps because feeding levels are at their lowest point and PACAP’s effects
have probably warn off. However, blocking PKA prior to PACAP during the light
phase seems to extend PACAP’s action into the dark phase and influence overall
nocturnal feeding levels. This is not surprising as studies show that cAMP and
PKA levels change throughout the day as energy demand changes potentially
impacting other orexigenic and anorexigenic peptide systems that utilize PKA in
the VMN. Interestingly, inhibiting PKA appears to facilitate PACAP-induced
thermogenesis and locomotor activity during lights on, suggesting that PACAP
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dependency on PKA signaling is behavior specific. Studies in other brain regions
show that leptin dependent signaling blocks PKA activity as a mechanisms to
prevent transcription of SOCS3, a negative regulator of leptin signaling (L. Yang
& McKnight, 2015). VMN cells express leptin receptors and respond to leptin by
inducing hyperthermia (Hawke et al., 2009; Hurley et al., 2020). Blocking PKA
alone had no effects on feeding or energy expenditure, however, there is a
possibility that PKA inhibition may be influencing other peptide systems that may
impact metabolism. Alternatively, we cannot rule out the fact that PACAP
signaling may still be occurring through the Gq/PLC/PKC arm of PAC1R. While
we can be more certain of the signaling mechanisms PACAP employs when we
can demonstrate they are discretely inhibited by our chemical interventions, we
are less confident when our treatment facilitates PACAP’s effects. Such is the
case with the enhanced hypophagic, thermogenic and locomotor activity
responses to the light phase administration of the PKA inhibitor and PACAP. In
this case, the observed effects on food consumption, core body temperature and
locomotor activity following inhibition of PKA signaling may or may not involve
PACAP. One possible alternative explanation is that adenosine monophosphateactivated protein kinase (AMPK) may be driving enhanced energy expenditure.
VMN AMPK inhibition suppresses appetite and enhances energy expenditure (J.
Wang et al., 2020). Interestingly, PKA regulates AMPK’s activity by decreasing
AMPK phosphorylation at threonine residue 172 (Thr172), a residue required for
its activation (Przygrodzka et al., 2021). This suggests that in the absence of
PKA, AMPK is inactive thereby enhancing energy expenditure.
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This combination of both positive and negative influences of PKA on
energy regulation creates a conundrum as to when PACAP might engage PKA.
PKA inhibition influences the directionality of PACAP’s hypophagic effects
depending on the time of day. In the hypothalamus, cAMP/PKA is a second
messenger target of several neuropeptides and hormones such as NPY and has
been shown to influence leptin signaling, both of which have been implicated in
the neuronal regulation of feeding and metabolism (Sheriff et al., 2003; L. Yang &
McKnight, 2015). Earlier reports find that cAMP and PKA activity increase in the
hypothalamus including the VMN when animals are fasting and asleep whereas,
cAMP and PKA levels diminish during nocturnal feeding when rats are active
(Murakami & Takahashi, 1983; Sheriff et al., 2003; Valases et al., 1980). In VMN
cells, genetic ablation of CREB binding protein, a downstream target of PKA
binding protein causes hyperphagia, and thermogenic dysregulation with
concomitant decreases in BDNF and POMC mRNA (L. Yang & McKnight, 2015).
The selectivity of PKA involvement suggests that other signaling
mechanisms may be primary for the metabolic features of PACAP signaling that
contribute to its overall effects on body weight. This raises important future
questions of how downstream PAC1R signaling differentially regulates indices of
homeostasis. In the hypothalamic arcuate nuclei for example, impaired PKA
signaling exaggerates leptin’s catabolic and molecular effects (L. Yang &
McKnight, 2015). In the absence of functional PKA, low leptin doses potently
decrease feeding with concomitant increases in energy expenditure suggesting
there exists a PKA-regulating signaling system that may dictate the magnitude of
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leptin’s influence on metabolism (L. Yang & McKnight, 2015). Considering that
accumulating evidence in the VMN is establishing a relationship between PAC1
and leptin receptor signaling, it is possible that VMN PKA may be involved in the
gating of leptin signaling although this remains to be tested (Hawke et al., 2009;
Hurley et al., 2020).
The failure of PKA inhibition to only attenuate nocturnal PACAP-induced
body weight loss may suggest that signaling mechanisms independent of PKA
inhibition continue to engage metabolic systems and reduce body weight
following PACAP administration. Taken together, these findings position PKA as
a key signaling cascade in the VMN regulation of energy balance. Further
experiments that combine mechanisms to inhibit PACAP signaling (PACAP6-38
or PAC1 shRNA) would need to be incorporated into similar studies to determine
whether our results are solely related to VMN PACAP signaling.
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CHAPTER VI
VENTROMEDIAL NUCLEI OF THE HYPOTHALAMUS UNIQUELY ENGAGE
PROTEIN KINASE C TO REGULATE FEEDING AND ENERGY EXPENDITURE

Introduction
The imbalance between energy intake and energy expenditure leads to
obesity and health complications such as diabetes and cancer (Nijhawan, Behl, &
Arora, 2020; Roh, Song, & Kim, 2016; Timper & Brüning, 2017). The pursuit and
discovery of therapeutic targets for treating energy homeostasis-related ailments
will alleviate a wide array of diseases while also improving the quality of life. A
prominent role is emerging for pituitary adenylate cyclase-activating polypeptide
(PACAP) in the regulation of energy homeostasis. PACAP and its receptors are
highly expressed in the peripheral and central nervous system where they
potently regulate food intake and energy expenditure (Gottschall et al., 1990;
Resch et al., 2011, 2013). This positions PACAP signaling to regulate multiple
aspects of energy homeostasis throughout the body.
In the hypothalamic ventromedial nuclei (VMN), PACAP suppresses food
intake and increases energy expenditure (Maunze et al., 2022; Resch et al.,
2011, 2013). PACAP’s hypophagic and thermogenic effects are mediated
through its PAC1 receptor, which belongs to the class B family of G-protein
coupled receptors (GPCRs). PAC1 receptors can dually couple to Gs/cAMP/PKA
and Gq/PLC/PKC to regulate a plethora of cell signaling mechanisms implicated
in energy homeostasis (Murakami & Takahashi, 1983; Planas, Cummings,
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Idzerda, & McKnight, 1999; Ross et al., 2008). As described earlier, the PAC1
receptor gene (ADCYAP1) transcript is highly spliced to generate PAC1
receptors isoforms, which adds an additional layer of complexity to PACAP
signaling (Blechman et al., 2013). These PAC1R isoforms display different
efficacies and potency to phospholipase C (PLC), an inducer of PKC. A link
between PKC signaling has now been recognized in peripheral and central
control of different aspects of energy homeostasis (Dewing, Christensen, Bondar,
& Micevych, 2008a; Z. Gao et al., 2007; Nijhawan et al., 2020; Raddatz et al.,
2011; Ross et al., 2008; Luoying Zhang et al., 2012). However, despite the
wealth of information on PKC mediated control of peripheral and central control
of energy homeostasis, the understanding of PKC’s contributions on PACAP’s
influence in feeding and energy expenditure remains limited. The pleiotropic
effects of peripheral and central PKC regulation of energy homeostasis make this
family of kinases a potential contributor to PACAP’s regulation of multiple
aspects of energy homeostasis.
Protein kinase C is a family of serine/threonine kinases that belong to the
cAMP-dependent, cGMP, and protein kinase C superfamily of protein kinases
involved in numerous signaling processes important for cell physiology (Farese,
Sajan, & Haley, 2010; Mehta, 2014). The PKC family is composed of different
lipid-dependent kinases that activate in response to diacylglycerol (DAG) and
calcium (Dewing, Christensen, Bondar, & Micevych, 2008b; Kolczynska, LozaValdes, Hawro, & Sumara, 2020). These include the classical conventional PKCs
(PKCa, PKCbII, PKCbII, and PKCg) and the novel PKCs (PKCd, PKCe, PKCq,
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and PKCh). Additionally, there is the atypical PKC (PKCz, and PKCi/l) whose
function are regulated by protein-protein interactions (Black & Black, 2012).
Despite limitations in our knowledge of specific PKC isozyme contributions
to PACAP’s role in energy homeostasis, we examined the broad role of PKCs in
PACAP’s role in the VMN. We used a broad PKC inhibitor, GF109203X to
examine PKC contributions to PACAP-induced hypophagia and energy
expenditure. We found that broad PKC inhibition in awake male Sprague Dawley
rats attenuates PACAP’s hypophagic and metabolism effects during the dark
phase whereas these effects are potentiated when PKC is inhibited during the
lights phase. Assessment of energy expenditure during lights on showed that
PKC inhibition potentiated only PACAP’s thermogenic and not spontaneous
locomotion effects.

Materials and methods

Animals
Male Sprague-Dawley rats (Envigo, Indianapolis, IN) weighing 225-300 g
were individually housed in either standard cages or BioDAQ feeding cages
(Research Diets, New Brunswick, NJ) in a climate-controlled room under a 12-hr
light/dark cycle (lights on at 0200h). Animals were weighed daily and provided ad
libitum access to standard chow (Teklad global 18% protein diet 2018
formulation, Envigo, Indianapolis, IN) and water. On experiment days, animals
were weighed, and food intake measurements were collected using the BioDAQ
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Food Intake Monitor before and up to 24-hours after the onset of the
experiments. For BioDAQ meal pattern analysis the data were analyzed over the
first 12 hours. Meals were defined as food intake of 0.2 g or more with less than
15 minutes elapsing between feeding bouts (Dunn-Meynell et al., 2009; Farley et
al., 2003; Resch et al., 2011, 2013). All procedures using animals were approved
by the Marquette University Institutional Animal Care and Use Committee.

Surgery
Animals were anesthetized with 2% isoflurane using a SomnoSuite lowflow anesthesia system (Kent Scientific, Torrington, CT) and placed in a
stereotaxic apparatus (Stoelting, Wood Dale, IL). 26-gauge stainless steel
bilateral guide-cannulae (Plastics One, Roanoke, VA) were stereotaxically
implanted 3 mm dorsal to the hypothalamic ventromedial nuclei (VMN) in all
animals and secured to the surface of the skull with an acrylic resin. The
stereotaxic coordinates for the VMN injection sites were: anterior/posterior, -2.5
mm from bregma; medial/lateral, ±0.6 mm from midline; dorsal/ventral, -9.2 mm
from surface of the skull based on The Rat Brain in Stereotaxic Coordinates, 6th
edition (Paxinos & Watson, 2007). Microinjectors extended 3 mm past the ventral
tip of the cannulae reaching an injection site of -9.2 mm ventral from the surface
of the skull. The upper incisor bar was positioned -3.3 mm below horizontal zero.
Animals were given 2 mg/kg ketoprofen once post-surgery and allowed to
recover from surgery for 1 week before they are included in experiments, during
which time the animals were handled daily to acclimate them to the necessary
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physical manipulations during experiments. Correct cannulae placements were
confirmed by microscopic examination of Nissl-stained sections.

Microinjections
In all experiments, a microinjection pump was used to inject 0.25 µl/side of
vehicle or treatment through bilateral guide-cannulae in awake animals over a 2minute period. After injection delivery was complete, an additional minute
elapsed before removing injectors to minimize backflow. Control and treatment
groups were reversed after a two-day washout period and normal food intake
levels were confirmed. Microinjections were completed approximately 30 minutes
before lights off for experiments assessing nocturnal food intake. For
experiments assessing core body temperature and locomotor activity and
subsequent food intake, microinjections were initiated 2 hours after the onset of
the lights on and lasted approximately for 1 hour.

Experiments

PKC Inhibitor: Dark phase food intake
Thirty minutes before the onset of lights off, microinjections of vehicle or
protein kinase C inhibitor (GF109203X; 0.1mM/0.25µl/side) were administered 15
minutes before rats (n=7/group) received a second bilateral injection of either
saline containing 1% DMSO or PACAP (50pmol/0.25µl/side). Approximately 5
minutes after injections, animals were returned to their home-cage and food

105
intake was measured for the next 24 hours followed by a final measurement of
body weight. GF109203X was prepared as DMSO stocks, diluted and injected in
animals. The final concentration of DMSO was <1%. PACAP was prepared as a
stock in 0.9% saline and diluted just before use.

PKC Inhibitor: Light phase food intake
Two hours after the onset of lights on, microinjections of vehicle,
GF109203X (#0741/1; protein kinase C inhibitor; 0.1mM/0.25µl/side; Bio-Techne
Corporation, Minneapolis, MN), were administered 15 minutes before rats
(n=7/group) received a second bilateral injection of either saline containing 1%
DMSO or PACAP (50pmol/0.25µl/side). Approximately 5 minutes after injections,
animals were returned to their home-cage. Food intake and body weight
measures were taken at the beginning of the experiment and again 24 hours
following pharmacological manipulations. GF109203X was prepared as DMSO
stocks, diluted and injected in animals. The final concentration of DMSO was
<1%. PACAP was prepared as a stock in 0.9% saline and diluted just before use.

PKC Inhibitor: Light phase PACAP, temperature and activity
At the time of cannulation surgery, telemetry probes (Mini-Mitter, Sunriver,
OR) were implanted in the intraperitoneal cavity of rats to record core body
temperature and spontaneous locomotor activity. On the experiment day, 2 hours
after the onset of the lights on cycle, rats (n=6/group) received bilateral injections
of GF109203X (0.1mM/0.25µl/side) 10-15 minutes prior to an injection of either
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saline or PACAP (50pmol/0.25µl/side). Animals were returned to their home cage
and telemetric data for core body temperature and spontaneous locomotor
activity were collected remotely as previously described (Resch et al., 2011,
2013). In brief, spontaneous locomotor activity was collected remotely every 5
minutes and then summed to give cumulative activity every hour. Core body
temperature data were averaged by the hour, and spontaneous locomotor
activity data were summated to give cumulative activity over a specified amount
of time.

Data analysis
Data are presented as means ± standard errors of the mean and were
analyzed statistically by analysis of variance (with repeated measures when
appropriate). Fisher LSD, and Tukey HSD analyses were used for post-hoc
group comparisons. Group sizes were designed to detect a 0.05 significance
level with a power of 0.8 assuming a standard deviation of 10% of the mean.
Statistical analyses were performed using SigmaPlot 11 (Systat Software, Inc,
San Jose, CA). P values less than 0.05 were considered statistically significant.
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Results

PKC inhibitor (GF109203X): Dark phase PACAP and food intake

Figure 6.1 Blocking PKC with GF109203X transiently reduces PACAP’s hypophagic
effects during the dark phase. Left) blocking PKC with GF109203X attenuates PACAPinduced decrease in food intake for 3 hours post injection. Right) GF109203X blocked
PACAP-induced decrease in body weight 24 hours following injection. Data are
expressed as means ± SEM, * (PACAP vs. Control), # (PACAP vs
PACAP+GF109203X) = p<0.05, (n=6/group)

Activation of PKC is a downstream response of PAC1R activation through
the Gαq /PLC pathway. Direct injections of GF109203X, a PKC-specific inhibitor
in the VMN, preceding PACAP injections significantly reversed PACAP’s
anorexigenic effects in rats during the first eight hours of the dark phase when
rats normally eat. Food intake data show a significant interaction between
treatment and time (F(33,231) = 2.242, p<0.001), whereas body weight data reveal
a significant main effect of treatment (F(3,21)=3.821, p<0.03; Figs. Left, Right).
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Post hoc analyses show that PACAP’s capacity to suppress food intake and
decrease body weight is dependent on time. PACAP significantly inhibits food
intake from 5h (p=0.028) up to 8h (p=0.016) and decreases body weight after
24h (p=0.019) respectively when compared to saline controls (Figs. 6.1, Left,
Right). PACAP’s hypophagic and anorexic effects are reversed by GF109203X at
5h (p<0.015), 8h (p<0.019) and 24h (p=0.023) respectively when compared to
PACAP alone (PACAP vs GF109203X+PACAP; Figs.6.1 Left, Right). However,
after five hours PACAP’s hypophagic actions persisted and food intake begins to
decrease although not significantly different from saline controls. This suggests
that PACAP-dependent regulation of feeding and body weight in the VMN likely
involves induction of PKC-related signaling.

PKC inhibitor (GF109203X): Light phase PACAP and food intake
Several organisms including rodents exhibit circadian rhythms in a myriad
of cellular, physiological and behavioral processes (Luoying Zhang et al., 2012).
PKC has been shown to influence food entrainment and overall activity in rodents
(Luoying Zhang et al., 2012). Because it is still not clear what time of day PACAP
exerts its action on VMN regulation of feeding and energy expenditure, we
blocked PKC and measured PACAP-induced hypophagia during the lights
phase. Light phase PKC inhibition facilitates PACAP-dependent decreases in
food intake occurring during the dark phase, and not during the light phase. Oneway ANOVA of food intake data shows that blocking PKC significantly intensified
PACAP-dependent decreases of food intake F(3,26) =4.36, p=0.020, when
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compared to PACAP treatment alone. PKC inhibition alone did not affect food
intake or body weight. Analysis of bodyweight change shows that GF109203X
injections also seem to extend PACAP induced decrease in body weight when
administered during the light phase. This is opposite to what we observed when
PKC inhibition during the dark phase reversed PACAP-dependent decreases in
body weight (3,26) = 16.89, p<0.001 when compared to PACAP treatment alone.
PACAP treatment alone during lights on did not significantly influence body
weight loss.

Figure 6.2. PKC inhibition with potentiates PACAP-dependent decreases in food
intake and body weight. Left) blocking PKC with GF109203X augments PACAPinduced decrease in food intake (Left) and body weight (Right) 24 hours post
injection. Data are expressed as means ± SEM, * (PACAP vs
PACAP+GF109203X) = p<0.05, (n=7/group)
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PKC inhibitor (GF109203X): Light phase PACAP and energy expenditure
During the light phase, however, when rodent core body temperature and
locomotor activity are at their nadir, GF109203X injections in the VMN prior to
PACAP injections were not sufficient to prevent PACAP-induced increases in
temperature and locomotor activity. In fact, GF109203X-mediated inhibition of
PKC enhanced PACAP-induced increase in core body temperature. Core body
temperature showed a significant interaction between treatment and time
(F(24,96)=3.405, p<0.001.) Post hoc pairwise comparisons show that PACAP
increased both core body temperature and locomotor activity from 3h lasting up
to 8h post injection p<0.03 when compared to saline controls. GF109203X
enhanced PACAP’s potentiation of core body temperature at 3h but not
locomotor activity p<0.25 when compared PACAP treatment alone (Figs.6.3 Left,
Right).

Figure 6.3. GF109203X attenuates PACAP’s effects on energy expenditure. Left)
GFX109203X potentiates PACAP-dependent increase in core body temperature
but not spontaneous locomotor activity (Right). Data are expressed as means
± SEM, * (PACAP vs. Control), # (PACAP vs PACAP+GF109203X) = p<0.05,
(n=6/group)
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Discussion

It is now well recognized that PAC1Rs couple to Gq/PLC/PKC second
messenger signaling, however, the direct consequences of this signaling on VMN
regulation of food intake and metabolism remains to be thoroughly investigated.
Our data suggest that PKC plays an important role in VMN PACAP-mediated
energy balance. We found that PKC is required for PACAP signaling in the VMN
since PKC inhibition abrogated nocturnal PACAP-induced hypophagia whereas,
it facilitated PACAP-stimulated hypophagia when injected during the light phase.
The effects of PKC inhibition on PACAP’s effect during the dark phase suggest
that the PAC1R arms that remain intact in the absence of PKC signaling are
insufficient to regulate feeding and body weight alone. What is interesting is that
the effects of PKC inhibition during the dark phase were short-lived suggesting
that either GF109203X had worn off, or other PAC1R signaling may have taken
over to suppress feeding. For example, we recently showed that PACAP
signaling through Gs/cAMP/PKA was also required for PACAP’s hypophagic
effects. This suggest that PACAP signaling may coordinate these two kinases
PKA and PKA to regulate VMN control of hypophagia. PKC activity also plays an
important role in PACAP’s role in energy expenditure. PKC inhibition potentiated
PACAP’s thermogenic effects and had no effect on PACAP-induced locomotor
activity. Previous studies have shown that VMN PKC is involved in regulating
other physiological and behavioral outcomes in rodents including sexual
behaviors and glucose metabolism (Dewing et al., 2008a; Irani et al., 2010; Ross
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et al., 2008; Thaler et al., 2009). It cannot be overlooked that PAC1R signaling
may also utilize PKC activity to regulate energy balance. One recent study
showed that isoforms of PKC are highly expressed in hypothalamic nuclei
including the VMN, where they have been shown to influence feeding and
metabolism in response to leptin and insulin (Thaler et al., 2009). Interestingly, a
recent study demonstrated that POMC-neuron-specific deletion of PKCl, a PKC
isoform disrupts leptin signaling and renders high fat diet fed mice susceptible to
obesity (Dorfman et al., 2017). VMN neurons also regulate glucose and lipid
metabolism and are significant targets of PACAP and leptin signaling (Flak et al.,
2020; Ross et al., 2008). In addition, emerging evidence suggest a dependent
relationship between PAC1 and leptin receptor signaling, positioning PKC as a
possible link. Taken together, however, these findings suggest a putative role for
VMN PACAP receptors to engage PKC-related signaling to regulate different
aspects of energy homeostasis. A complete understanding of PKC’s contribution
to PACAP signaling in VMN control of energy homeostasis will require examining
the specific contributions of individual PKC isozymes. Findings from this and
future studies may aid our understanding of the etiologies of energy imbalances
and design of nuanced therapies with minimal side effects.
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CHAPTER VII
PACAP’S HYPOHAGIC EFFECTS IN THE VMN ARE MEDIATED THROUGH
PAC1 RECEPTOR TRAFFICKING

Introduction

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a
multifunctional 38 amino-acid peptide that regulates a number of physiological
responses including energy intake and energy expenditure (Hurley et al., 2016;
Miyata et al., 1989; Resch et al., 2013) by binding to PAC1 receptors (PAC1R) in
the hypothalamic ventromedial nuclei (VMN) with high affinity (Hawke et al.,
2009; Resch et al., 2013). Identifying which specific PAC1R-mediated second
messenger signaling is activated or whether PACAP-induced PAC1R
endocytosis in the VMN affect feeding and metabolism are still unknown. The
PACAP-preferring PAC1 receptor is a G-protein coupled receptor transcribed
from the ADCYAP1R1 gene (Gottschall et al., 1990; H. Hashimoto et al., 1993;
Miyata et al., 1990). The transcribed PAC1R protein possesses amino acid
motifs within the C-terminal domain that determine the ability not only for Gprotein signal transduction, but also for receptor trafficking (Lyu et al., 2000).
G-protein coupled receptors (GPCRs) are cell surface transmembrane
proteins in eukaryotes that transduce and integrate a broad range of cell
signaling and physiological processes (Eichel & Von Zastrow, 2018). GPCRs
interact with multiple proteins, some that facilitate receptor coupling to
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heterotrimeric G-proteins while others attenuate receptor signaling. It has
emerged recently that in addition to plasma membrane signaling, PAC1
receptors are endocytosed and trafficked as part of several necessary processes
that are integral to neuronal action potential generation (May & Parsons, 2017).
Canonically, GPCRs are serine/threonine (Ser/Thr)-phosphorylated at specific
intracellular motifs by GPCR kinases following activation (Ferguson, 2007).
Subsequently, this phosphorylation facilitates the recruitment of endocytosis
machinery, and signaling molecules such as kinases, small GTPases, and barrestins (Hupfeld & Olefsky, 2007). b-arrestin 1 and b-arrestin 2 are some of the
key components in the mechanisms regulating G-protein coupled receptor
signaling termination and trafficking. In addition to GPCR desensitization and
endocytosis, b-arrestins’ recruitment to phosphorylated GPCRs promotes noncanonical signaling (Broca et al., 2009; DeWire et al., 2007). Recent findings
demonstrate that PACAP-stimulation of PAC1Rs induces PAC1R association
with b-arrestins 1 and 2 leading to differential b-arrestin 1 or b-arrestin 2
subcellular co-localization with PAC1R (Shintani et al., 2018). PAC1Rs
associated with b-arrestin 1 localize to the plasma membrane, whereas PAC1R
associated with b-arrestin 2 appear to be internalized into the cytosol (Shintani et
al., 2018). Earlier studies show that b-arrestins influence energy homeostasis
and prevent diet induced obesity suggesting a putative mechanism by which
PACAP signaling may influence energy homeostasis (Pydi et al., 2020; Rodgers
& Puigserver, 2009; Zhuang et al., 2011).
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In the current work, we examined PACAP-induced changes in PAC1R
association with b-arrestin, PAC1R subcellular localization, and the
consequences of blocking PACAP-induced PAC1R trafficking on VMN control of
food intake. Our data show that VMN PAC1 receptors co-immunoprecipitate with
b-arrestin 2, and PACAP injections in the VMN dose-dependently increase
PAC1R association with b-arrestin 2. To demonstrate functional trafficking of
PAC1 receptors, we tested whether VMN PACAP ligand binding leads to a
reduction in PAC1R expression in the plasma membrane while increasing
PAC1R expression in the cytosol, which can be blocked using endocytosis
inhibitors Pitstop 2 and Dyngo 4a. Furthermore, blocking endocytosis by
targeting clathrin and dynamin protein in the VMN prior to PACAP injection
prevented PACAP-induced decreases in food intake, whereas blocking b-arrestin
association with adaptor-protein 2 with Barbadin does not.
Materials and Methods

Animals
Male Sprague-Dawley rats (Envigo, Indianapolis, IN) weighing 225-300 g
were individually housed in either standard cages or BioDAQ feeding cages
(Research Diets, New Brunswick, NJ) in a climate-controlled room under a 12-hr
light/dark cycle (lights on at 0200h). Animals were weighed daily and provided ad
libitum access to standard chow (Teklad global 18% protein diet 2018
formulation, Envigo, Indianapolis, IN) and water. On experiment days, animals
were weighed, and food intake measurements were collected using the BioDAQ
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Food Intake Monitor before and up to 24-hours after the onset of the
experiments. All procedures using animals were approved by the Marquette
University Institutional Animal Care and Use Committee.

Surgery
Animals were anesthetized with 2% isoflurane using a SomnoSuite lowflow anesthesia system (Kent Scientific, Torrington, CT) and placed in a
stereotaxic apparatus (Stoelting, Wood Dale, IL). 26-gauge stainless steel
bilateral guide-cannulae (Plastics One, Roanoke, VA) were stereotaxically
implanted 3 mm dorsal to the hypothalamic ventromedial nuclei (VMN) in all
animals and secured to the surface of the skull with an acrylic resin. The
stereotaxic coordinates for the VMN injection sites were: anterior/posterior, -2.5
mm from bregma; medial/lateral, ±0.6 mm from midline; dorsal/ventral, -9.2 mm
from surface of the skull based on The Rat Brain in Stereotaxic Coordinates, 6th
edition (Paxinos & Watson, 2007). Microinjectors extended 3 mm past the ventral
tip of the cannulae reaching an injection site of -9.2 mm ventral from the surface
of the skull. The upper incisor bar was positioned -3.3 mm below horizontal zero.
Animals were given 2 mg/kg ketoprofen once post-surgery and allowed to
recover from surgery for 1 week before they are included in experiments, during
which time the animals were handled daily to acclimate them to the necessary
physical manipulations during experiments.
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Microinjections
In all experiments, a microinjection pump was used to inject 0.25 µl/side of
vehicle or treatment through bilateral guide-cannulae in awake animals over a 2minute period. After injection delivery was complete, an additional minute
elapsed before removing injectors to minimize backflow. Control and treatment
groups were reversed after a two-day washout period and normal food intake
levels were confirmed. Microinjections were completed approximately 30 minutes
before lights off for experiments assessing nocturnal food intake.

Western Blot analysis
Protein analysis using western blot was conducted once for each animal in
the study. Bilateral dissections of the ventromedial hypothalamus (VMH;
including the VMN and surrounding areas) were collected following rapid
decapitation. VMH tissue was homogenized by hand (10 strokes) in ice-cold
homogenization buffer (320 mM sucrose, 10 mM Tris-HCl, pH 7.4, 10mM EDTA,
10mM EGTA) containing Halt protease and phosphatase inhibitor cocktail
(#78447; Thermo Scientific; Rockford, IL), followed by 3-4 seconds of sonication.
Homogenates were centrifuged at 1000 X g for 2 minutes at 4°C and the
resulting supernatant was further centrifuged at 10,000 X g for 30 minutes at 4°C
to remove crude membrane protein. The resulting supernatant rich in crude
cytoplasmic protein was saved for further processing. Protein quantification of
samples was determined using a bicinchoninic (BCA) assay (#23252; Pierce).
Protein (30 µg) was run on an 8% gel by SDS-PAGE and transferred to a
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polyvinylidene fluoride (PVDF) membrane (#LC2002; Thermo Fisher Scientific;
Rockford, IL). Membranes were blocked for 1 hour at room temperature with 5%
bovine serum albumin (BSA) or 5% non-fat milk in tris-buffered saline containing
0.1 % Tween-20 (TBS-T). Blots were then probed with either rabbit anti-PAC1R
antibody alone (#AV-R003; 1:1000; Alomone labs; Jerusalem, Israel) or dually
probed with b-actin using a mouse anti-b-actin (#MA5-15452; 1:2000; Thermo
Scientific; Rockford, IL) overnight at 4°C, followed by washes with TBS-T and
incubation with an HRP-linked anti-rabbit secondary antibody (#7074P2; 1:3000;
Cell Signaling Technologies; Danvers, MA) and HRP conjugated anti-mouse
(#7076P2; 1:5000; Cell Signaling Technologies; Danvers, MA) at room
temperature for 2 hours. Band intensities were developed using SuperSignal
West Atto Chemiluminescent Substrate (#A38556; Thermo Scientific; Rockford,
IL) and visualized using the Odyssey Fc Dual Mode Imaging System (LI-COR;
Lincoln, NE). Band densities were measured and quantified using Odyssey Fc
Dual-Mode Imaging System software. PAC1R antibody specificity was validated
by preincubating rabbit anti-PAC1R with PAC1R blocking peptide (#BLP-VR003;
Alomone labs; Jerusalem, Israel). Following visualization of PAC1R signal alone,
blots were stripped and re-probed in an identical fashion for b-actin using a
mouse anti-b-actin (#MA5-15452; 1:2000; Thermo Scientific; Rockford, IL) and
HRP conjugated anti-mouse (#7076P2; 1:5000; Cell Signaling Technologies;
Danvers, MA).
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Crosslinking and immunoprecipitation
VMH tissue was homogenized by hand (10 strokes) in ice-cold
immunoprecipitation lysis buffer (50 mM Tris HCl, pH 7.5, 150 mM NaCl, 10 μM
CaCl2, 10 mM NaF, 20 mM sodium pyrophosphate, 1 mM Na3VO4, 2 mM
AEBSF, 1% Triton X-100) containing Halt protease and phosphatase inhibitor
cocktail (#78447; Thermo Scientific; Rockford, IL), followed by 3-4 seconds of
sonication. Homogenates were centrifuged at 1000 X g for 2 minutes at 4°C and
the resulting whole-cell lysate supernatant was saved for further processing.
Protein quantification of samples was determined using a bicinchoninic (BCA)
assay (#23252; Pierce). Chemical crosslinking and co-immunoprecipitation for
quantitating PACAP-induced association of PAC1 and β-arrestin1 or β-arrestin2,
covalent protein cross-linking with a chemical crosslinker, Dithiobis
succinimidylpropionate (DSP; Thermo Fisher Scientific). 100 mg/sample VMN
whole-cell lysate, crude membrane, and cytosolic fractions were incubated with
2.5 mM DSP for 30 mins at room temperature and the crosslinking reaction was
quenched with 0.1 ml of1 M Tris (pH 7.5). To prevent co-elution of IgG
fragments, the immobilized antibodies were covalently cross-linked to protein GSepharose beads. Antibody-coupled protein G-Sepharose beads were
resuspended in 5 mM BS3 (Thermo Fisher Scientific) and incubated for 30 min at
room temperature. Crosslinking was quenched by the addition of 0.1 ml of1 M
Tris (pH 7.5). VMN lysates were incubated with either PAC1R antibody (1:500),
b-arrestin1-, or b-arrestin2-coupled protein G-Sepharose beads for 2 h at 4˚C
while shaking. Following incubation, the beads were collected by magnet and
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washed three times with wash buffer (0.1M phosphate buffered saline). Proteins
bound to the beads were eluted and the crosslink was reversed with 2X Sample
buffer containing 3% (v/v) 2-mercaptoethanol and analyzed by performing
immunoblotting with specific antibodies as indicated.

Experiments

PACAP induces PAC1R co-immunoprecipitation with b-arrestin
Pituitary adenylate cyclase-activating polypeptide (PACAP
50pmol/0.25μl/side in the VMN; California Peptide Research; Napa, CA), or
saline were microinjected over a two-minute period in awake animals followed by
an additional minute to prevent backflow. Rats were returned to their home cages
and euthanized at 30, 60, or 90 minutes after PACAP and saline injections. VMN
tissue was harvested for immunoprecipitation and western blot analyses.

VMN PACAP Microinjections and PAC1R trafficking
Pituitary adenylate cyclase-activating polypeptide (PACAP
50pmol/0.25μl/side in the VMN; California Peptide Research; Napa, CA), or
saline were microinjected over a two-minute period in awake animals followed by
an additional minute to prevent backflow. Rats were returned to their home cages
and euthanized by rapid decapitation 30 minutes after PACAP and saline
injections. VMN tissue was collected, and crude subcellular fractionations were
collected for western blot analysis.
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Trafficking and Endocytosis Inhibitors
Microinjections of vehicle, endocytosis inhibitors Pitstop 2 (#ab120687;
clathrin inhibitor; 6mM/0.25µl/side; Abcam, Cambridge, MA), Hydroxy-Dynasore
(#HY-13863; dynamin inhibitor; Dyngo-4a; 0.38mM/0.25µl/side; MedChem
Express LLC; Monmouth Junction, NJ) and Barbadin (#AOB37364; b-arrestin/b2adaptin interaction inhibitor; 15µM/0.25ul/side; AOBIOUS INC; Gloucester, MA)
were administered 15 minutes before rats (n=6/group) received a second
bilateral injection of either saline containing 1% DMSO or (PACAP;
50pmol/0.25µl/side). Approximately 5 minutes after injections, animals were
returned to their home-cage and food intake was measured for the next 24 hours
followed by a final measurement of body weight. Barbadin, Pitstop 2 and Dyngo4a were prepared as DMSO stocks, diluted and injected in animals. In order to
avoid potential VMN cell toxicity, low concentrations of Pitstop 2 and Dyngo-4a
were combined and administered as an endocytosis inhibitor cocktail (Kuriyan et
al., 2017). The final concentration of DMSO was <1%. PACAP was prepared as
a stock in 0.9% saline and diluted just before use.
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Results

PAC1Rs undergo endocytosis following stimulation by their cognate
ligand, PACAP (Tompkins et al., 2018a). We measured changes in PAC1R
subcellular expression from rat VMN tissue injected with PACAP. Western blot
analysis of VMN tissue homogenates confirmed that exogenous PACAP
promotes PAC1R trafficking from the membrane to the cytosol. Crude subcellular
fractionation analyses show PACAP significantly increases cytosolic PAC1Rs

Figure 7.1. PACAP induces surface PAC1R endocytosis. Top and
middle) representative western blot analysis showing PAC1R
expression the membrane to the cytosol. Bottom) experimental
design for pharmacological treatments of PACAP and endocytosis
inhibitors, Dyngo-4a/Pitstop 2.
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and decreases membrane PAC1Rs F(3,12)=4.084, p=0.03, F(3,12)=4.619, p<0.03
respectively (Fig. 7.1, and 7.2) This PACAP-induced shift in PAC1R subcellular
localization was blocked using a cocktail of dynamin and clathrin inhibitors,
Dyngo-4a and Pitstop 2 p=0.025 (membrane), and p=0.023 (cytosolic) when
compared to PACAP treatment alone (Figs. 7.1, and 7.2).

Figure 7.2. Dyngo-4a/Pitstop 2 inhibit PAC1R
endocytosis. Western blot quantitation showing
PACAP promotes PAC1R trafficking from the
membrane to the cytosol, which can be blocked by
Dyngo-4a/Pitstop 2 and measured at 30 mins
following PACAP injection. Data are expressed as
means ± SEM, * (PACAP vs. Control), # (PACAP vs
PACAP+Dyngo-4a/Pitstop 2) = p<0.05, (n=8/group)
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Canonically, G-protein coupled receptors like PAC1R are known to
associate with endocytosis machinery and internalize following agonist exposure
(Merriam et al., 2013). To determine whether hypothalamic ventromedial nuclei
(VMN) cells express b-arrestins that may facilitate PAC1R trafficking, we used
western blot analysis of VMN homogenates to detect b-arrestin 1 and b-arrestin 2
expression. We found that VMN cells express b-arrestin 1 and b-arrestin 2 (Fig.
7.3). Next, we used co immunoprecipitation (coIP) to determine if PAC1Rs
associate with b-arrestins following stimulation. We found that PACAP promotes
PAC1R association with b-arrestin.

Figure 7.3. Hypothalamic ventromedial nuclei express b-arrestin 1 and
b-arrestin 2. Western blot showing b-arresting expression in
hypothalamic ventromedial whole cell homogenates. Ant-b-arrestin
antibodies correctly detected a 50 kDa band.
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Figure 7.4. PACAP promotes PAC1R association with b-arrestin 2. Data are
expressed as means ± SEM, * (PACAP vs. Control), # (PACAP vs PACAP+Barbadin)
= p<0.05, (n=4group)
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To determine if b-arrestin and PAC1R trafficking contributed to PACAP’s
hypophagic effects in the VMN, we used barbadin, a novel selective b-arrestinb2-adaptin association inhibitor that can prevent agonist-induced endocytosis of
GPCRs. We injected barbadin just prior to PACAP injection in the VMN and
measured changes in food intake and body weight and observed that barbadin
did not block PACAP’s hypophagic effects in the VMN. Repeated measures
analysis of variance shows that PACAP is able to significantly suppress food
consumption in the presents of barbadin (F(3,29)=677, p<0.003; Fig. 7.5, Left).
There is no difference in food consumption in rats that received PACAP alone or
combined barbadin and PACAP. Analysis of body weight change show that
blocking b-arrestin and adaptor proteins interaction may influence some

Figure 7.5. b-arrestin-Adaptin association is not required for PACAP-dependent
feeding. PACAP-induced decrease in body weight. Top, left and right) Western blot
analysis showing PACAP promotes PAC1R association with b-arrestin 2. Bottom left)
Barbadin, a b-arrestin and b2-adaptin binding inhibitor, does not block PACAPinduced suppression of food intake. Bottom, right) Barbadin potentiated PACAPinduced reduction in body weight after 24-hours. Data are expressed as means
± SEM, * (PACAP vs. Control), # (PACAP vs PACAP+Barbadin) = p<0.05,
(n=6/group)
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metabolic effect. One-way ANOVA showed that barbadin enhanced PACAP’s
effect on decreased body weight, however, a close assessment suggests that
barbadin alone may decrease body weight. The results indicate that blocking barrestin binding to adaptin is not sufficient to block PACAP’s suppression of
feeding, however, body weight results are unclear.

GPCRs use other nucleating proteins during endocytosis.
Because barbadin targets the association between b-arrestin with b2adaptin, we could not rule out other avenues for PAC1R trafficking. For example,
adaptin is able to interact directly with GPCRs through which it may facilitate
clathrin-mediated endocytosis independently of arresting (Chen, Paing, & Trejo,
2004; Diviani, Lattion, Abuin, Staub, & Cotecchia, 2003; Moo, Van Senten,
Bräuner-Osborne, & Møller, 2021). In addition our earlier results showed that
blocking clathrin and dynamin using Dyngo-4a and Pitstop 2 prevents PAC1R
endocytosis. To that end, we used a Dyngo-4a/pitstop 2 cocktail to determine
whether PACAP-induced PAC1R endocytosis was required for PACAP’s
anorexigenic effects in the VMN. In rats, combined Dyngo-4a and Pitstop 2
infusions in the VMN prior to PACAP administration briefly blocked PACAPinduced decreases in food intake (~ 3 hours) but did not block body weight
change (Fig. 7.6). Analyses of food intake data show that blocking endocytosis
transiently reversed PACAP induced hypophagia at 2h and 4 hours, p<0.03, and
p=0.023 respectively when compared to PACAP treatment (Fig. 7.6). There is a
significant interaction between treatment and time F(12,80)=2.320, p<0.02.

128
Comparably, blocking endocytosis prior to PACAP injection did not prevent
PACAP-induced decreases in body weight, it appears that PACAP continued to
suppress body weight at 24 hours following injections. There is a significant main
effect of treatment F(3,20)=7.267, p<0.003 (Fig. 7.6, Left).

Figure 7.6. Inhibiting surface PAC1R trafficking attenuates PACAP-induced
decrease in food intake and exaggerates PACAP-induced decrease in body
weight. Left) Dyngo-4a/Pitstop 2, dynamin and clathrin-dependent endocytosis
inhibitors, briefly attenuate PACAP-induced suppression of food intake for 5
hours post injection. Right) Dyngo-4a/Pitstop 2 does not prevent PACAP-induced
reduction in body weight at 24-hours. Data are expressed as means ± SEM, *
(PACAP vs. Control), # (PACAP vs PACAP+Dyngo-4a/Pitstop 2) = p<0.05,
(n=8/group)

Previously, our laboratory showed that PACAP increases VMN STAT3
phosphorylation, and STAT3 has been shown to influence food intake and
energy expenditure (Hurley et al., 2020). In this study, we also measured STAT3
phosphorylation to determine if PAC1R endocytosis may be a mechanism by
which PACAP regulates STAT3. Although we corroborated that PACAP
increases STAT3 phosphorylation (Fig. 7.7), we were not able to assess the
contributions of blocking PAC1R endocytosis on STAT3 phosphorylation
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because the same dose that blocked PACAP’s hypophagic effects, influenced
STAT3 phosphorylation alone (Figs. 7.7, 7.8). PACAP and endocytosis inhibitors
alone did not influence STAT3 endogenous expression (Figs. 7.7, 7.8).

~ 86 kDa

pSTAT3

~ 86 kDa

STAT3

~ 45 kDa

Actin

Figure 7.7. Inhibiting surface PAC1R trafficking promotes PACAPinduced STAT3 phosphorylation. Left) Western blot analysis
showing PACAP promotes STAT3 phosphorylation (86 kDa) which
is increased by Dyngo-4a/Pitstop 2 and measured at 30 mins
following PACAP injection. Right) Dyngo-4a/Pitstop 2, dynamin and
clathrin-dependent endocytosis inhibitors and PACAP affect
endogenous STAT3 expression. Sal = Saline, PAC =PACAP, DP
=Dyngo-4a/Pitstop 2, DP-PAC = Dyngo-4a/Pitstop 2 + PACAP.
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Figure 7.8. Blocking PAC1R trafficking increases STAT3
phosphorylation. Left) Western blot quantitation showing PACAP, and
endocytosis inhibitors promote STAT3 phosphorylation. Blocking
trafficking potentiates PACAP-dependent STAT3 phosphorylation.
Right) PACAP, Dyngo-4a/Pitstop 2, dynamin and clathrin-dependent
endocytosis inhibitors, does not influence STAT3 phosphorylation.

Discussion
We explored whether endocytosis of PAC1R was essential to PACAP’s
behavioral and physiological effects. Canonically, cell surface GPCRs are
endocytosed following stimulation, in part, as a desensitization mechanism.
However, more recent reports show that ligand-activated PAC1R endocytosis is
important for neuronal action potential firing for PAC1R in hippocampal and
cardiac neurons (Liao et al., 2021; Parsons & May, 2018; Tompkins et al.,
2018b). Considering that our lab recently reported that PACAP increases action
potential firing frequency in ex vivo VMN slices, it is possible that blocking VMN
PAC1R endocytosis would alter action potential generation and subsequently
food intake or metabolic indices such as thermogenesis and/or locomotor activity.
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In the VMN, PACAP promotes PAC1R endocytosis from the membrane to the
cytosol, which was subsequently blocked by the inhibitors of endocytosis, clathrin
and dynamin. Inhibition of PAC1R trafficking temporarily attenuated PACAPinduced hypophagia but did not prevent its anorexic effects after 5 hours. The
short-lived effects of endocytosis inhibitors are in line with data demonstrating
that endogenous endocytosis can be restored within approximately one hour
following washout (McCluskey et al., 2013). This experiment demonstrates that
PACAP’s hypophagic effects in the VMN could be mediated, in part, by PAC1R
endocytosis. Conversely, temporal blockade of PAC1R trafficking and food intake
produced a more pronounced body weight loss suggesting that transient
inhibition of trafficking is not sufficient to attenuate PACAP’s decrease in body
weight. The fact that we observe partial potentiation of PACAP’s effects on body
weight may indicate a delayed effect of PAC1R endocytosis on other metabolic
factors that may contribute to body weight change, however this is only
speculation at this point. Interestingly, targeting the b-arrestin dependent
endocytosis mechanisms did not influence PACAP’s effects on food intake in the
VMN. Suggesting that GPCR trafficking is a complicated process which requires
the coordination of multiple proteins. In our case, PAC1R association with barrestin seems dispensable in PACAP’s hypophagic effects. However, we show
that barbadin is sufficient to influence PACAP’s effects on body weight,
suggesting that barbadin may be influencing aspects of energy homeostasis in
addition to PACAP. Alternatively, It has been demonstrated that GPCRs can
internalize independent of b-arrestin by directly binding adaptin and recruiting
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clathrins, suggesting that PAC1Rs may have internalized and induced
hypohagia. b-arrestin is also know to engage other signaling cascades in
addition to GPCR trafficking (DeWire et al., 2007). For example, b-arresting
induce extracellular regulated kinase (Erk) (Rahmouni, Sigmund, Haynes, &
Mark, 2009)which has directly been implicated in decreasing feeding in the brain.
Other studies show that b-arrestin are involved in energy regulation. An
extensive review (Pydi et al., 2021, 2020) on b-arrestins and their role in
metabolism highlight the fact that b-arresin 1 and b-arrestin knock out in the
peripheral or central nervous system of mice cause severe metabolic disorders.
Future studies will need to assess whether blocking PAC1R trafficking delays the
onset of thermogenesis and increase in locomotor activity as well as the need to
determine the consequences of blocking PAC1R endocytosis on PACAP-induced
increase in firing frequency.
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CHAPTER VIII
VMN CELLS INTEGRATE MULTIPLE COMPLEX SIGNALS TO REGULATE
FEEDING AND ENERGY HOMEOSTASIS: PACAP AND LEPTIN SIGNALING

Introduction
The balance between energy intake and energy expenditure is tightly
regulated by several brain structures including the hypothalamic ventromedial
nuclei (VMN) (Andermann & Lowell, 2017; Timper & Brüning, 2017). Factors that
cause extreme swings in energy balance result in health complications including
obesity and anorexia (Andermann & Lowell, 2017; Gastelum et al., 2021;
Wilding, 2002). The VMN is thought to regulate food intake by stimulating satiety
and energy expenditure by integrating short-term and long-term feedback from
the gut and adipose tissue (Andermann & Lowell, 2017; Hawke et al., 2009; Roh
et al., 2016) via several anorexigenic and orexigenic neuropeptides including
pituitary adenylate cyclase-activating polypeptide (PACAP), leptin, and their
cognate receptors, PAC1 and leptin receptor (Bozadjieva-Kramer et al., 2021;
King, 2006).
Decades of research have now identified and implicated leptin signaling
malfunction as one of the leading causes of obesity (Boughton & Murphy, 2012;
Wada et al., 2014; Ronghua Yang & Barouch, 2007c). Despite the breadth of
knowledge on leptin signaling, several attempts to target this signaling system as
a therapeutic approach have fallen short of treating obesity (Boughton & Murphy,
2012). Recent findings in our lab and others have identified a novel signaling
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partner, PACAP, that may contribute to understanding and treating obesity
stemming from leptin signaling malfunction (Hawke et al., 2009; Hurley et al.,
2020).
Leptin is an adipose tissue-derived peripheral hormone encoded by the
LEP gene and it plays an important role in several central nervous system
structures including the VMN that regulate food intake and energy expenditure
(Buchanan et al., 1998; Hawke et al., 2009; Wada et al., 2014). PACAP is a
neuronally derived peptide whose actions in the VMN mirror that of leptin wherein
both ligands induce hypophagia and increase energy expenditure (Hawke et al.,
2009; Hurley et al., 2020; Resch et al., 2011, 2013). PACAP and leptin share
other striking similarities in their expression and signaling mechanisms. For
example, in situ hybridization analysis shows that leptin and PACAP receptor
transcripts co-localize within the same VMN cells (Hawke et al., 2009; Hurley et
al., 2020). Leptin and PACAP both stimulate their cognate receptors to induce
signal transducer and activator of transcription 3 (STAT3) phosphorylation
(pSTAT3), and subsequently silencer of cytokine signaling 3 (SOCS3)
transcription (Hawke et al., 2009; Hurley et al., 2020). More importantly, blocking
PAC1 receptors prevents leptin’s ability to engage its downstream signaling and
influence feeding and energy expenditure (Hawke et al., 2009; Hurley et al.,
2020). Collectively, these findings suggest that elucidating the signaling
mechanisms underlying the cross talk between PACAP and leptin signaling may
help us understand the etiologies of obesity, while providing potential therapeutic
avenues to treat obesity.
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In this study, we not only corroborated that rat VMN PAC1 and leptin
receptors are expressed in the same cell, we also demonstrated that leptin and
PAC1Rs co-immunoprecipitated, suggesting they are in close proximity and may
share a physical connection. Using a newly developed immortalized rat
hypothalamic in vitro model, rHypoE-19 (Belsham et al., 2009; Gingerich et al.,
2009; Nazarians-Armavil, Menchella, & Belsham, 2013), we found that PACAP
induces Janus kinase 2 phosphorylation and that blocking protein kinase C, a
downstream effector of PACAP signaling, attenuates leptin induced STAT3
phosphorylation.
Materials & Methods

Animals
Male Sprague-Dawley rats (Envigo, Indianapolis, IN) weighing 225-300 g
were individually housed in either standard cages or BioDAQ feeding cages
(Research Diets, New Brunswick, NJ) in a climate-controlled room under a 12-hr
light/dark cycle (lights on at 0200h). Animals were weighed daily and provided ad
libitum access to standard chow (Teklad global 18% protein diet 2018
formulation, Envigo, Indianapolis, IN) and water. All procedures using animals
were approved by the Marquette University Institutional Animal Care and Use
Committee.
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In situ Hybridization
Rat brains were sectioned coronally at 12 μm and then postfixed in 4%
paraformaldehyde, rinsed in 0.1 M PBS (pH 7.4), equilibrated in 0.1 M
triethanolamine (pH 8.0) and acetylated in triethanolamine containing 0.25%
acetic anhydride. Standard in vitro transcription methods were used to generate
both sense and antisense riboprobes recognizing PAC1R, and long-form leptin
receptor (LepRb) transcripts (Choi, Milwaukee, WI), which were subsequently
diluted in hybridization cocktail (Amresco, Solon, OH) with tRNA. Sections were
hybridized overnight at 60°C with either digoxigenin (DIG) or fluorescein (FITC)labeled riboprobes. After hybridization, slides were treated with RNase A and
stringently washed in 0.3X SSC at 65°C (PAC1R) for 30 min. Slides were
incubated with an antibody against DIG or FITC conjugated to horseradish
peroxidase (HRP; Roche) overnight at 4°C. Riboprobe signal was amplified using
the TSA-Plus fluorophore system with either fluorescein or Cy3 (PerkinElmer;
Waltham, MA). Image capture was performed using fluorescent microscopy
(Axioskop-2; Zeiss, Thornwood, NY) and Axiovision image analysis software
(Zeiss, Thornwood, NY).

Cell culture and reagents
rHypoE-19 neurons (Cedarlane CELLutions Biosystems; Burlington, NC),
generated as described previously were cultured in monolayer in Dulbecco’s
modified Eagle’s medium (Thermo Fisher Scientific; Rockford, IL) supplemented
with 8% fetal bovine serum (# 26140; GIBCO), and grown in 5% CO2 at 37°C.
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Mouse recombinant leptin (Bio-Techne Corporation, Minneapolis, MN), PACAP
(25nM; California Peptide Research, Napa, CA), PACAP6-38 (100nM; Anaspec,
Fremont, CA) were reconstituted in saline. KT5720 (#1288/100U; protein kinase
A inhibitor; 10µM; Bio-Techne Corporation, Minneapolis, MN), and GF109203X
(#0741/1; protein kinase C inhibitor; 10µM; Bio-Techne Corporation, Minneapolis,
MN) were diluted in dimethyl sulfoxide (DMSO; #116070; Thermo Fisher
Scientific; Rockford, IL). Anti-STAT3, phospho-specific STAT3 (Tyr705), antiJAK2, phospho-specific JAK2 (Tyr1007/1008), anti-Src, phospho-specific
antibodies were obtained from (Cell Signaling Technologies; Danvers, MA).

Immunohistochemistry
Immortalized rat hypothalamic embryonic day 19 neurons (rHypoE-19)
were grown and fixed in 12-well plates. Prior to immunohistochemical staining,
cells were fixed in 4% PFA for 10 minutes on ice and rinsed in 0.1 M PBS (pH
7.4). Cells were incubated in blocking buffer (0.05M KPBS, 3% normal donkey
serum, 0.1% Triton X-100) for 1h at room temperature followed by an overnight
incubation at 4°C in blocking buffer containing either primary antibody against
PAC1R (rabbit anti-PAC1R, (#AV-R003; Alomone; Israel), leptin receptor (mouse
anti-LepR; Santa Cruz Biotechnology), or rabbit anti-phospho-specific STAT3
(Tyr705) (Cell Signaling Technologies; Danvers, MA). After several rinses in
0.05M KPBS, sections were incubated in blocking buffer containing donkey antirabbit Alexafluor 594 or Alexafluor 488 conjugated secondary antibody (1:250;
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Life Technologies; Grand Island, NY). Upon completion of fluorescent staining,
cells labelled with PAC1R and lepRb were imaged.

Measurement of forskolin-induced cAMP release.
cAMP release was determined using mouse/rat cAMP assay kit (catalog
no. KGE012B) from R&D Systems (Minneapolis, MN). rHypoE19 cells were
cultured in a monolayer in DMEM. Cell lysates were prepared using the lysis
buffer provided in the kit. A representative sample was taken from each condition
and subject to the competitive immunoassay. After addition of stop solution,
optical density readings were performed using a microplate reader system that
was set to 450 nm and 540 nm wavelengths. Wavelength correction was made
by subtracting 450-nm readings from 540-nm readings. A cAMP standard was
prepared as per the manufacturer’s protocol. The mean absorbance of the
samples was normalized to the standard, then multiplied by the dilution factor.
Western Blot analysis
VMH tissue or rHypoE-19 cells were homogenized in ice-cold
homogenization buffer (320 mM sucrose, 10 mM Tris-HCl, pH 7.4, 10mM EDTA,
10mM EGTA) or RIPPA buffer containing Halt protease and phosphatase
inhibitor cocktail (#78447; Thermo Scientific; Rockford, IL), followed by 3-4
seconds of sonication. Homogenates were centrifuged at 1000 X g for 2 minutes
at 4°C and the resulting supernatant was saved for further processing. Protein
quantification of samples was determined using a bicinchoninic (BCA) assay
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(#23252; Pierce). Protein (30 µg) was run on an 8% gel by SDS-PAGE and
transferred to a polyvinylidene fluoride (PVDF) membrane (#LC2002; Thermo
Fisher Scientific; Rockford, IL). Membranes were blocked for 1 hour at room
temperature with 5% bovine serum albumin (BSA) or 5% non-fat milk in trisbuffered saline containing 0.1 % Tween-20 (TBS-T). Blots were then probed with
rabbit anti-PAC1R antibody alone (#AV-R003; 1:1000; Alomone labs; Jerusalem,
Israel) or dually probed with b-actin using a mouse anti-b-actin (#MA5-15452;
1:2000; Thermo Scientific; Rockford, IL) overnight at 4°C, followed by washes
with TBS-T and incubation with an HRP-linked anti-rabbit secondary antibody
(#7074P2; 1:3000; Cell Signaling Technologies; Danvers, MA) and HRP
conjugated anti-mouse (#7076P2; 1:5000; Cell Signaling Technologies; Danvers,
MA) at room temperature for 2 hours. Band intensities were developed using
SuperSignal West Atto Chemiluminescent Substrate (#A38556; Thermo
Scientific; Rockford, IL) and visualized using the Odyssey Fc Dual Mode Imaging
System (LI-COR; Lincoln, NE). Band densities were measured and quantified
using Odyssey Fc Dual-Mode Imaging System software. PAC1R antibody
specificity was validated by preincubating rabbit anti-PAC1R with PAC1R
blocking peptide (#BLP-VR003; Alomone labs; Jerusalem, Israel). Following
visualization of PAC1R signal alone, blots were stripped and re-probed in an
identical fashion for b-actin using a mouse anti-b-actin (#MA5-15452; 1:2000;
Thermo Scientific; Rockford, IL) and HRP conjugated anti-mouse (#7076P2;
1:5000; Cell Signaling Technologies; Danvers, MA).
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Crosslinking and immunoprecipitation
VMH tissue was homogenized by hand (10 strokes) in ice-cold
immunoprecipitation lysis buffer (50 mM Tris HCl, pH 7.5, 150 mM NaCl, 10 μM
CaCl2, 10 mM NaF, 20 mM sodium pyrophosphate, 1 mM Na3VO4, 2 mM
AEBSF, 1% Triton X-100) containing Halt protease and phosphatase inhibitor
cocktail (#78447; Thermo Scientific; Rockford, IL), followed by 3-4 seconds of
sonication. Homogenates were centrifuged at 1000 X g for 2 minutes at 4°C and
the resulting whole-cell lysate supernatant was saved for further processing.
Protein quantification of samples was determined using a bicinchoninic (BCA)
assay (#23252; Pierce). Chemical crosslinking and co-immunoprecipitation for
detecting association of PAC1-leptin receptors, covalent protein cross-linking
with a chemical crosslinker, dithiobis(succinimidyl) propionate (DPS; Thermo
Fisher Scientific). 100 mg/sample VMN whole-cell lysates were incubated with
2.5 mM DSP for 30 mins at room temperature and the crosslinking reaction was
quenched with 0.1 ml of 1 M Tris (pH 7.5). To prevent co-elution of IgG
fragments, the immobilized antibodies were covalently cross-linked to protein GSepharose beads. Antibody-coupled protein G-Sepharose beads were
resuspended in 5 mM BS3 (Thermo Fisher Scientific) and incubated for 30 min at
room temperature. Crosslinking was quenched by the addition of 0.1 ml of 1 M
Tris (pH 7.5). VMN lysates were incubated with either PAC1R antibody (1:500),
or leptin receptor antibody-coupled protein G-Sepharose beads for 2 h at 4˚C
while shaking. Following incubation, the beads were collected by magnet and
washed three times with wash buffer (0.1M phosphate buffered saline). Proteins
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bound to the beads were eluted and the crosslink was reversed with 2x sample
buffer containing 3 % (v/v) 2-mercaptoethanol and analyzed by performing
immunoblotting with specific antibodies as indicated.

RNA extraction and quantitative reverse transcription
Total RNA was extracted from brain tissue by the Trizol extraction
(Invitrogen; Carlsbad, CA) method. Total RNA was treated with DNase (Life
Technologies, Carlsbad, CA) to remove contaminating genomic DNA.
Subsequently, 1µg total RNA was reverse transcribed into complementary DNA
(cDNA) using a mixture of random primers, oligodT primers and reverse
transcriptase (Reverse Transcription System, Promega; Madison, WI).
Quantitative PCR was performed using a StepOne Real-Time PCR System
(AppliedBiosystems; Carlsbad, CA), and PerfeCTa SYBR Green FastMix with
ROX (QuantaBiosciences; Gaithersberg, MD) according to the manufacturer’s
protocol. Quantification of PAC1R isoforms, BDNF, SOCS3, xCT, and lepRb
mRNA expression was done using a relative standard curve and normalized to
the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Primers for each gene were designed to span an exon-exon junction and had
efficiencies of approximately 95%. Melt curve analysis of experiments confirmed
a single product for each reaction.
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Data analysis

Data are presented as means ± standard errors of the mean and were
analyzed statistically by analysis of variance (with repeated measures when
appropriate). Fisher LSD, and Tukey HSD analyses were used for post-hoc
group comparisons. Group sizes were designed to detect a 0.05 significance
level with a power of 0.8 assuming a standard deviation of 10% of the mean.

Results
PAC1 and the long-form leptin receptor form an immunocomplex.
Given that our lab and others previously demonstrated that VMN PAC1
and leptin receptors exist in the same cell, we investigated whether the
overlapping expression pattern of PAC1R and lepRb might allow for potential
binding interactions. To that end, we used immunoprecipitation with antibodies
specific for the long-form leptin receptor and PAC1R. We found that when the
PAC1R antibody was used to isolate PAC1 receptors from VMN tissue
homogenates, we were able to detect leptin receptor expression in the
immunocomplex, and the opposite was true (Fig. 8.1). When we used the leptin
receptor antibody to isolate the leptin receptor from VMN tissue homogenates,
PAC1R protein was present in complex with the leptin receptor (Fig. 8.1). As a
control measure, we pre-absorbed PAC1R or leptin receptor antibodies and
subsequently failed to detect their cognate receptors. This finding suggests that
the PAC1R and leptin receptor immunocomplex is not coincidental and PAC1
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and leptin receptors could potentially interact physically or are in very close
proximity.

Wash

VMN
lysate

aPAC1R

aLepRb

LebRb

PAC1R

PAC1R

Figure 8.1. VMN PAC1 and leptin receptors form an immunocomplex.
Representative western blot showing PAC1R (50 kDa, 100 kDa) and
LepRb (140 kDa) bands. aPAC1R = anti-PAC1R pull down, aLepRb =
anti-LepRb pull down.

144
VMN and rHypoE19 cells express PAC1 and long-form leptin receptors
Accumulating evidence suggests PAC1R, a G-protein coupled receptor
may be involved in regulating a cytokine receptor in leptin, which becomes more
likely considering emerging evidence of crosstalk between the two receptor
families (Moody et al., 2020; Swift et al., 2011; W. Wang et al., 2018). Here, we
sought to evaluate the overlapping PACAP signaling mechanisms that may
influence leptin receptor function. To closely examine shared PAC1 and leptin
receptor signaling, we employed a newly developed immortalized rat
hypothalamic neuronal cell line, rHypoE-19 (Belsham et al., 2009; Gingerich et
al., 2009; Nazarians-Armavil et al., 2013). First, we confirmed the presence of
both PAC1R and leptin receptors within rHypoE-19 neurons, using
immunohistochemical (IHC) staining for both the PAC1 and leptin receptor
proteins (Fig 8.2; bottom row). PAC1 receptor immunoreactivity localized
perinuclear and extensively to the periphery whereas leptin receptor
immunoreactivity was seen throughout the cell. An image overlay of PAC1 and
leptin receptor immunoreactivity show similar co-localization of PAC1 and leptin
receptors to that seen in the VMN (Fig 8.2; top row).
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Figure 8.2. in situ hybridization and immunofluorescence labeling of PAC1 and
leptin receptors in VMN and rHypoE-19 neurons. Top row, hypothalamic VMN:
(left) PAC1R mRNA (red). (center) LepRb mRNA (green), (right) PAC1R and leptin
mRNA double labeling overlay (Hurley et al. 2020.) Bottom row, rHypoE-19 cells:
(left) PAC1 receptor staining was revealed by mouse anti-PAC1R and Alexa Fluor594 conjugated anti mouse antibodies (red staining), (center) leptin receptor
staining was detected by rabbit anti-LepRb and Alexa Fluor-488 conjugated antirabbit antibodies (green staining), and (right) PAC1 and leptin receptor staining
composite.

rHypoE-19 neurons express functional PAC1 and Leptin receptors
In rat hypothalamic ventromedial nuclei (VMN), PAC1R activation
stimulates cAMP accumulation with concomitant induction of BDNF, SOCS3, and
xCT transcription. We begin by investigating the effects of PACAP treatment on
rHypoE-19 cells on cAMP accumulation and gene transcription. PACAP
treatment in rhypoE-19 cells caused an increase in cAMP accumulation (Fig. 8.3,
Right), which was confirmed using forskolin, a well-known direct stimulator of
cAMP generation, as a positive control (Fig. 8.3). rHypoE-19 exposure to PACAP
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treatment increases BDNF and SOCS3 mRNA expression as well as the PAC1
receptors isoforms PAC1null, and PAC1hop, as previously identified in the VMN.
PACAP’s hypophagic effects in the VMN have been shown to be mediated by
Src kinase phosphorylation (pSrc), which can be reversed using protein
phosphatase 1 (PP1) (Resch et al., 2014). Similarly, PACAP responses in
rHypoE19 cells also revealed that PACAP significantly induces pSrc
F(3,30)=13.121, p<0.001 when compared to control, which was blocked using PP1
pretreatment (Fig. 8.4, Right).

Figure 8.3. rHypoE-19 neurons PAC1 receptors are biologically functional. Left &
right) cAMP immunoassay standard curve and ligand-induced cAMP
accumulation. Bottom left) quantitative PCR for PACAP-induced BDNF, SOCS3,
LepRb, and xCT gene expression. Bottom, right) PACAP induces pSrc which is
blocked by PP1, a Src phosphorylation inhibitor. Data are expressed as means
± SEM, * = p<0.05.
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Figure 8.4. rHypoE-19 neurons PAC1 receptors are biologically functional. Left)
quantitative PCR for PACAP-induced BDNF, SOCS3, LepRb, and xCT gene expression.
Right) PACAP induces pSrc which is blocked by PP1, a Src phosphorylation inhibitor. Data
are expressed as means ± SEM, * = p<0.05.

Canonically, leptin binding to its receptor leads to induction of pSTAT3 in
the VMN and other brain regions (Hurley et al., 2020; Wada et al., 2014). As
such, pSTAT3 induction has been used as the hallmark of leptin signaling.
Hurley, et al (Hurley et al., 2020) recently showed that acute leptin injections in
the VMN induce pSTAT3. In this study, we found that leptin treatment in rHyoE19 cells induced pSTAT3 in a dose-dependent manner (Fig 8.5). This is
consistent with a study by Belsham et al (Nazarians-Armavil et al., 2013)
showing leptin treatment in rHypoE-19 cells leads to pSTAT3. With the
confidence that rHypoE19 cells express functional PAC1 and leptin receptors,
next we investigated if PACAP signaling influences leptin signaling. We blocked
PAC1R signaling using PACAP 6-38 and asked whether leptin can induce
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pSTAT3. We found that, blocking PAC1Rs prevents leptin induced pSTAT3
inductions.

Figure 8.5. Leptin dose-dependently induces pSTAT3 in rHypoE19 cells. Western
blot showing antisera detection of phosphorylated STAT3 at approximately 86 kDa
(Top) and normalized to endogenous STAT3 (Top, bottom). Bottom) Leptin-induced
pSTAT3 quantitation. Data are expressed as means ± SEM, * = p<0.05.
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Figure 8.6. PACAP6-38 blocks leptin induced pSTAT3 in rHypoE19 cells. pSTAT3
western blot showing revealed by rabbit-anti pSTAT3 (top, left) and mouse antiSTAT3 (left, bottom) following leptin and PACAP 6-38 treatments. Right)
pSTAT3/STAT3 ratio quantitation. Data are expressed as means ± SEM, * = p<0.05,
n=5/group.

In an effort to understand how blocking PACAP signaling might influence
leptin signaling, we first assessed if PAC1 receptor stimulation is capable of
activating the Janus kinase/signal transducers and activators of transcription
(JAK/STAT) in rHypoE-19 neurons. Although STAT3 phosphorylation is highly
associated with canonical cytokine signaling, studies have now demonstrated
that GPCRs signaling pathways can also lead to STAT3 phosphorylation (Ram &
Iyengar, 2001). Previous work in our lab showed PACAP injections in the VMN
lead to STAT3 phosphorylation which can be blocked by PACAP6-38 (Hurley et
al., 2020). Similarly, PACAP treatment in rHypoE19 cells significantly induced
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STAT3 phosphorylation which could be attenuated by prior treatment with
PACAP6-38 (Fig 8.7), p<0.023, when compared to control. However, saline or
PACAP6-38 treatment alone did not influence STAT3 phosphorylation.
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Figure 8.7. PACAP application in rHypoE-19 neurons induces
pSTAT3. PAC1 receptors are functional. Top) Immunoblots
showing pSTAT3 and STAT3 following combined inhibitors and
PACAP. Bottom) pSTAT3/STAT3 quantitation. Data are
expressed as means ± SEM, * (PACAP vs Saline), # PACAP vs
PACAP 6-39 + PACAP)= p<0.05.

151
To determine whether PACAP stimulated the phosphorylation of STAT3 in
a direct manner or at the antecedent step with the phosphorylation of the JAK
kinase, PACAP-induced phosphorylation of JAK 2 (pJAK2) was measured in
rhypoE19 cells. PACAP treatment increased pJAK2 significantly p<0.038, when
compared to saline control (Fig 8.8) suggesting that PACAP and leptin receptor
activation share similar pathways to pJAK2 and possibly pSTAT3.
Saline

PACAP

125 kDa

125 kDa

Figure 8.8. PACAP induces JAK2 phosphorylation in rHypoE-19 cells. Left top) rabbit antipJAK2 revealed by anti-rabbit-HRP. Left bottom) rabbit anti-JAK2 detected by anti-rabbit-HRP.
Right) PACAP-induced pJAK quantitation. Data are expressed as means ± SEM, * = p<0.05,
n=8/group.

The phosphorylation state and activities of enzymes that are regulated by
tyrosine phosphorylation are controlled by the combined actions of protein
tyrosine kinases and protein tyrosine phosphatases. To investigate potential
mechanisms by which PACAP signaling may influence leptin receptor function
we examined known downstream effectors of PACAP signaling. Recently, we
demonstrated that PACAP’s action in the VMN control of feeding are mediated
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through PKA and PKC activity (Maunze et al., 2022). To determine whether PKA
or PKC activity was required for leptin-induced pSTAT3, we blocked PKA and
PKC activity and measured leptin-dependent pSTAT3. We found that blocking
PKC prevented leptin-induced pSTAT3 in rHypoE-19 cell whereas blocking PKA
did not (Fig. 8.9). Blocking PKC activity significantly reduced leptin-dependent
pSTAT3, p<0.043 when compared to control. This result suggests the possibility
that PACAP 6-38 inhibition of PACAP signaling could be perturbing endogenous
protein kinase activity downstream of PACAP to provide net inhibition of leptin
receptor signaling. The effects of blocking PKA on leptin-induced pSTAT3 agree
with studies showing that leptin potently increases pSTAT3 in the absence of
functional PKA (L. Yang & McKnight, 2015).

Discussion
Dysregulation of energy homeostasis and obesity can be caused by leptin
signaling malfunction (Ronghua Yang & Barouch, 2007c). Attempts to restore
normal leptin signaling have fallen short of treating obesity suggesting that our
understanding of leptin signaling malfunction and consequent obesity is still
lacking (Beck, 2000; Boughton & Murphy, 2012). Recent studies have suggested
that PACAP signaling may be a key regulator of leptin signaling in rodents
(Hawke et al., 2009; Hurley et al., 2020). The present studies extend these
earlier findings by suggesting a potential physical interaction between PAC1 and
leptin receptors in VMN cells. PAC1 and leptin receptors are widely distributed in
hypothalamic nuclei including the VMN where they both influence feeding and
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metabolism (Dhillon et al., 2006; Hawke et al., 2009; Hurley et al., 2020; Resch
et al., 2011). In this study, we demonstrated that PAC1 and leptin receptors not
only co-express within the same cell but isolate within the same immunocomplex,
suggesting that PAC1 and leptin receptors have the capacity to
influence or facilitate the other’s signaling as evidenced by studies showing that
lepRb and PAC1R
expression overlaps in
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Figure 8.9. Blocking PKA and PKC kinase activity in rHypoE19 neurons influences leptin induced pSTAT3. PAC1
receptors are functions. Top) Immunoblots showing pSTAT3
and STAT3 following combined inhibitors and leptin. Bottom)
pSTAT3/STAT3 quantitation. Data are expressed as means
± SEM, * = p<0.05, n=4/group.
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The extent to which PAC1 and leptin receptors co-localize raises the
possibility that these receptors either share a physical interaction, or they exist in
a shared complex that allows for very close proximity. Although the capacity for
PAC1 and leptin receptors to form PAC1R-LepRb heterodimers has not yet been
reported, and the two receptors are entirely dissimilar, recent advances in
molecular biology suggest potential mechanisms for crosstalk. Reciprocal
GPCRs and cytokine receptor regulation has been proposed to occur indirectly
through transactivation review in (W. Wang et al., 2018). For example, PAC1R
has been show to regulate transactivation of the receptor tyrosine kinases for the
epidermal growth factor (EGFR), HER2, and HER3) by modulating receptor
phosphorylation (Moody et al., 2020). Such a PAC1 and leptin receptor
collaboration could provide a potential mechanism by which energy homeostasis
regulation combines GPCR-related signaling with cytokine signaling. For
example, one receptor can be differentially coupled to two transduction pathways
depending on a specific naturally distinct ligand. Alternatively, this receptor could
collaborate or interact with another receptor to modify the pharmacology of a
ligand binding site and/or the molecular interactions within the receptor binding
site to influence coupling. Thus, dysregulation in PAC1 or LepRb signaling could
impact the intrinsic function of PACAP and leptin signaling necessary for normal
energy homeostasis regulation.
While the mechanism by which PACAP blocks leptin function remains
speculative, we have in this study explored possible aspects of PACAP receptor
activation that may intersect with leptin signaling. For example, we found that
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PACAP induces pJAK2, suggesting that the JAK/STAT3 signaling cascade is a
potential link between leptin receptor cell surface activation and nuclear
transcriptional events leading to changes in physiology or behavior. While
JAK/STAT3 is considered a canonical cytokine signaling sequence, recent
studies have revealed that JAK/STAT3 can also be activated by GPCRs
(Marrero, Venema, Ju, Eaton, & Venema, 1998). GPCRs principally coupled to
Gaq have been shown to associate and couple to JAK2 (Ferrand et al., 2005).
PAC1 receptors are known to couple to Gas, and Gaq-related signaling in
several brain regions and recently, the VMN (H. Hashimoto et al., 1993; Maunze
et al., 2022). To that end we explored whether blocking Gas/cAMP/PKA or
Gaq/PLC/PKC-related signaling influenced leptin’s ability to induce pSTAT3. We
found that blocking PKC, a Gaq signaling mechanisms prevents leptin induced
pSTAT3. However, blocking PKA prior to leptin, potentiated leptin stimulated
pSTAT3. This finding is not shocking considering earlier reports demonstrating
that leptin potently stimulates pSTAT3 in the absence of functional PKA in part by
preventing PKA-dependent transcription of SOCS3, a negative regulator of leptin
signaling (L. Yang & McKnight, 2015). Although Gq/PKC signaling has not been
directly implicated in pSTAT3 induction, Gq/PKC signaling has been shown to
regulate JAK2, a known upstream regulator of pSTAT3 (Ferrand et al., 2005).
In summary, the PAC1R and leptin receptor immunocomplex suggests a
functional or overlapping dependence in PACAP and leptin receptor signaling
that involves JAK2 and PKC.
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CHAPTER IX
GENERAL DISCUSSION
The hypothalamic ventromedial nuclei (VMN) integrate information about
the body’s energy state and responds accordingly to maintain energy balance
(Flak et al., 2020; Hawke et al., 2009; Hetherington & Ranson, 1942; King, 2006).
Previously, our lab and others demonstrated that pituitary adenylate cyclaseactivating polypeptide (PACAP) and the Type 1 PACAP receptor (PAC1R) are
abundantly expressed in the VMN, and exogenous activation of those receptors
cause hypophagia and increased metabolism (Hawke et al., 2009; Resch et al.,
2011, 2013). However, the endogenous role of PACAP in the VMN remain
unclear.
The findings described in this dissertation demonstrate that endogenous
PACAP signaling has a role in normal VMN regulation of energy balance since
knocking down VMN PAC1 receptors increased overall food intake and body
weight, which is consistent with global PACAP and PAC1R knockout models
(Gray et al., 2001, 2002; H. Hashimoto et al., 2000). The increase in food intake
was characterized by an increase in meal size along with a decrease in meal
number suggesting that endogenous PACAP may exert short-term changes in
energy requirements by serving to signal satiety or meal duration. In our case,
the absence of PAC1 receptors and the subsequent reduction in the satiety
signal could leave a hunger drive unopposed. Previously reported in mice,
PACAP signaling correlates with energy status and increases immediately
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following a meal. Starved mice show decreased VMN PACAP and PAC1R
mRNA expression, which is reversed following food presentation (Delgado et al.,
2019; Hawke et al., 2009; Resch et al., 2011). This emergence of PACAP’s
influence on food intake and meal microstructure is not unusual, Resch et al
showed that PACAP in the paraventricular nuclei (PVN) increases latency to
engage in meals and overall food intake (Resch et al., 2013), which is not
surprising considering that both VMN and PVN express PACAP and project and
receive input from each other, as shown in retrograde tracing experiments
(Resch et al., 2013). Such a feature can be found in other orexigenic and
anorexigenic neuropeptides such as neuropeptide Y (NPY), histamine, serotonin
(Leibowitz & Alexander, 1998) and dopamine that act in the hypothalamus to
regulate meal structure and overall feeding, see review (King, 2006). The VMN is
well positioned to regulate meal-related satiety information since it receives
inputs from the nucleus tractus solitarius (NTS) (Lindberg, Chen, & Li, 2013),
likely conveying gastrointestinal tract information regarding gastric distension and
glucose levels (Travers, Travers, & Norgren, 1987). Future studies will have to
determine if NTS neurons that project to the VMN contain PACAP.
Following PAC1R knock-down, the increase in food intake and weight gain
could be explained mostly in part, by the subsequent decrease in brain derived
neurotrophic factor (BDNF) transcripts. Previous studies show that in mice,
BDNF deficiency in the VMN cause overeating and weight gain (Mou et al.,
2015). Moreover, it does not come as a surprise that BDNF expression
decreases following PAC1R knockdown since we and others have consistently
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demonstrated that PACAP signaling stimulates BDNF transcription in
hypothalamic brain regions (Macdonald et al., 2005; Resch et al., 2011; Yaka et
al., 2003). Thus, PACAP-induced hypophagia may be facilitated, in part, by
BDNF transcription and release either in the VMN or VMN projections.
In addition to neuropeptides, hypothalamic cell groups express numerous
receptors for both intrinsic and extrinsic signaling molecules to regulate both
feeding behavior and metabolism. One in particular that has been given
considerable attention is the leptin receptor, which binds the adipose secreted
leptin. Mutations in the obese (ob) gene encoding leptin or the diabetes (db)
gene encoding the leptin receptor leads to positive energy states with increased
feeding behavior, hypometabolism, hyperinsulinemia, and obesity. The
hypothalamus abundantly expresses the receptors for leptin, which require active
transport across the blood-brain barrier. Leptin administration into the VMN
mimics the behavioral and metabolic responses that are produced by exogenous
PACAP administration such as hyperphagia, elevated core body temperature,
and weight gain. While the similar functional outcomes could suggest parallel but
distinct pathways to coordinate energy balance, it could also suggest that these
two receptors have a shared circuitry.
Rats lacking VMN PAC1 receptor expression gain a considerable amount
of weight and allow for the speculation that PAC1R knockdown may dysregulate
energy sensing mechanisms such as insulin or leptin signaling systems in the
hypothalamus. In support of this idea, previous work in our lab demonstrated that
pharmacologically inhibiting PACAP receptors in the VMN with a PAC1 receptor
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antagonist prevented the canonical responses to VMN leptin. In the current
studies, we injected leptin in rats following VMN PAC1R knockdown produced by
RNA interference and found that exogenous leptin failed to induce canonical
cytokine signaling, suppress feeding and decrease body weight, and not only did
it not produce a significant increase in SOCS3 mRNA, there was a significant
decrease in SOCS3 mRNA levels. With the growing evidence that PACAP and
leptin signaling could be intertwined in the VMN, it becomes necessary to have a
better understanding of PAC1 receptor signaling mechanisms that could interact
with the leptin receptor signaling cascade. Conversely, future studies examining
PACAP actions on energy balance will need to factor in body weight and tonic
circulating levels of leptin since the receptors may be functionally connected.
Since circulating leptin levels are typically proportional to body weight adipose
tissue (Buchanan et al., 1998; Sims et al., 2020), future considerations will have
to take into account basal circulating levels of leptin. Additionally, leptin signaling
malfunction is typically characterized by leptin insensitivity (Farley et al., 2003;
Morris & Rui, 2009), which has been implicated in the majority of all human
obesity.
Genetically knocking down PAC1R or using a pharmacological inhibitor for
the receptor decreases suppressor of cytokine signaling 3 (SOCS3) mRNA,
which would be expected since PACAP signaling is known to increase SOCS3
transcription. However, we find it perplexing considering that rats still manage to
increase food consumption and gain weight despite the fact that SOCS3
functions as a negative feedback inhibitor on the leptin receptor. Diminishing
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SOSC3 concentrations should alleviate negative actions on the leptin receptor
and increase the sensitivity of the receptor to leptin and subsequently decrease
feeding. This is contrary to results from recent studies showing that mediobasal
SOCS3 deficiency is protective of overeating and weight gain and SOCS3
deficiency improves leptin signaling and sensitivity (Matarazzo et al., 2012). In
studies in which PAC1R knock down increased feeding behavior, an acute leptin
injection in the VMN did not induce hypophagia suggesting that PACAP signaling
through PAC1R in the VMN may have an independent or alternate path to parts
of the leptin receptor cascade. In support of this possibility is the fact that
PACAP can phosphorylate Janus Kinase 2 (pJAK2), which is known to
phosphorylate signal transducer and activator of transcription 3 (STAT3), that in
turn drives SOCS3 transcription. Moreover, this is consistent with reports that
other class B G-protein coupled receptors (GPCRs) also induce pJAK2 (Marrero
et al., 1998), suggesting a putative explanation for the decreased SOCS3 in the
absence of PAC1R.
While it was previously unclear how PACAP induces pleiotropic effects on
VMN regulation of feeding and energy expenditure, the current studies may
begin to add some clarity. PAC1 receptors are class B G-protein coupled
receptors that can dually couple to Gs/cAMP/PKA, and Gq/PLC, PKC (Blechman
et al., 2013). In addition, the PAC1R gene (ADCYAP1R1) is highly spliced to
generate several isoforms including PAC1 receptors isoforms PAC1null and
PAC1hop (Braas et al., 1998; Holighaus et al., 2011; Lyu et al., 2000;
Rongquiang Yang, Winters, & Moore, 2020). The experiments in chapter (II)
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identified the presence of PAC1null and PAC1hop receptor isoforms in the VMN,
and that PAC1hop isoform transcript increased, whereas PAC1null decreased in
response to changes in energy state and stress. This finding suggests that
PACAP signaling could be much more complex in the VMN control of feeding
and energy expenditure than previously described. Such a dichotomy in PAC1R
isoform response to physiological changes is not uncommon in the rat brain. For
example, PAC1 signaling is required for physiological stress responses since
PACAP activates CRH transcription in vivo (Amir-Zilberstein et al., 2012) and that
PAC1R isoforms and their relative expression ratio may be involved in
homeostasis in response to stress (Amir-Zilberstein et al., 2012; Blechman et al.,
2013). Moreover, the activation and termination of CRH transcription, in response
to stress, is dually regulated by PAC1null and PAC1hop in that PAC1hop
terminates transcription and PAC1null activates transcription (Blechman et al.,
2013). Similarly, PACAP’s effects in the VMN may be a consequence of a
collective contribution of individual PAC1R isoforms. This is exemplified in our
experiment showing that injecting PACAP-conjugated saporin should ablate all
VMN PAC1R isoforms.
As mentioned previously, fasted mice exhibited decreases in PAC1R
mRNA expression in the VMN with a reversal following refeeding (Delgado et al.,
2019; Hawke et al., 2009; Resch et al., 2011). However, in our early studies we
failed to detect any changes in rat PAC1R mRNA (without consideration of
isoforms) regardless of an animal’s energy state (data not shown). By contrast,
when we probed for specific PAC1R isoforms we found that PAC1null mRNA
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decreases whereas PAC1hop increases after a meal. Therefore, comprehensive
PACAP signaling in the current studies most likely entails contributions from
PAC1 receptor isoforms PAC1null and PAC1hop. In addition, the ability to parse
PACAP signaling in this manner may be key to explaining the pleiotropic
molecular and physiological consequences of PACAP signaling. Recent work in
cardiac, and dentate neurons of the hippocampus demonstrate that PAC1
receptor endocytosis following stimulation is necessary for action potential
generation and physiology, and is dependent on PKC (May et al., 2014).
Interestingly, the PAC1hop isoform contains a consensus sequence for PKC
phosphorylation possibly contributing to fine-tuned regulation of receptor function
(May et al., 2014) and would also be in line with studies showing that PACAP
signaling potentiates glutamatergic signaling by modulating AMPA and NMDA
receptors (Macdonald et al., 2005; Resch et al., 2014; Yaka et al., 2003).
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Figure 9.1. Schematic of PAC1 receptor signaling at the plasma membrane and endocytosis.
PACAP/PAC1R activation can engage multiple signaling from the plasma membrane to the
cytosol following internalization. PACAP/PAC1R activation can stimulate adenylyl cyclase
(AC), cAMP/protein kinase A (PKA), or phospholipase c (PLC)/ diacyl glycerol (DAG) protein
kinase C (PKC), and endocytosis. Created with BioRender.com

To begin to describe which PACAP signaling mechanisms may explain
PACAP’s effects in VMN-dependent hypophagia and hyperthermia, we examined
known downstream effectors of PAC1R signaling. As previously mentioned
above, PAC1 receptors are GPCRs that can dually couple to Gs/cAMP/PKA and
Gq/PLC/PKC PKA, which have directly been implicated in regulating
hypothalamic energy balance (Nakajima et al., 2016; L. Yang & McKnight, 2015).
Blocking PKA or PKC activity prior to PACAP injections at the onset of the dark
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phase attenuated PACAP-induced hypophagia, suggesting that PACAP utilizes
both signaling mechanisms to regulate feeding. However, PKA or PKC inhibition
during the light phase did not block but enhanced PACAP’s hyperthermia,
whereas only PKA inhibition enhanced spontaneous locomotor activity. One
possible explanation is that blocking PKA or PKC might disinhibit other
mechanisms in the VMN that positively drive energy expenditure such as leptin.
A recent study in hypothalamic arcuate neurons showed that PKA deficiency
impairs hypothalamic SOCS3 expression and prevents feedback inhibition of
leptin signaling (L. Yang & McKnight, 2015). Adding to the possibility that
blocking VMN PKA might facilitate leptin signaling to potentiate energy
expenditure, which would need to be confirmed in future studies.
An alternative explanation for how PKA and PKC may influence VMN
regulation of feeding and metabolism involves glutamatergic signaling. PKA and
PKC have both been implicated in glutamate signaling by modulating AMPA and
NMDA receptors (Ciranna & Costa, 2019; Fukuchi et al., 2015; Macdonald et al.,
2005; Yaka et al., 2003) to augment glutamate signaling. Earlier studies in our
lab have previously demonstrated that PACAP’s hypophagic effects in the VMN
are mediated by glutamatergic signaling (Resch et al., 2014). Therefore, the
inhibition of PKA or PKC could prevent modulation of glutamate signaling that is
important for PACAP-mediated hypophagia.
PKC is also utilized in VMN neurons and studies have demonstrated that
manipulations of PKC in the VMN regulate glucose metabolism thus, connecting
VMN PKC activity with regulating energy homeostasis. Administration of a PKC
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agonist, OAG, suppresses glucose production (Ross et al., 2008), suggesting
that PACAP signaling through PKC could facilitate glucose homeostasis. This is
in line with the finding by Resch et al that PVN and VMN PACAP injections
increase plasma glucose (Resch et al., 2013). Moreover, direct Gq activation in
VMN PACAP-containing neurons increases glucose in a glucose tolerance test.
In this study, CNO was used to activate Gq DREADS and expressed in VMN
cells by virus transduction (Khodai et al., 2018; Ross et al., 2008). Taken
together, aspects of PACAP signaling may engage PKC signaling to regulate
glucose homeostasis and influence food intake.
New and emerging model of GPCR signaling adds another possible
explanation for PACAP’s numerous effects on energy balance. The generation of
second messengers by GPCRs like PAC1R and its termination is currently
thought to occur exclusively at the plasma membrane. However, this paradigm is
not consistent with recent observations that PAC1R stimulation continues to
suppress food intake and increase metabolism long after the peptide has likely
been cleared from the synapse and membrane signaling has been terminated.
The transcribed PAC1 receptor protein possesses amino acid motifs within the
C-terminal domain that determine G-protein coupling and receptor trafficking (Lyu
et al., 2000). In addition to G-protein dependent signaling at the plasma
membrane, the internalization and trafficking of GPCRs are recognized to
represent fundamental processes targeting complex signaling networks to
different cellular compartments (May & Parsons, 2017). We found that PACAP
induces PAC1R trafficking from the plasma membrane and into the cytosol,
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which could be blocked using Dyngo-4a and Pitstop 2, dynamin and clathrin
inhibitors. This finding suggesting that PAC1R behaves similarly to other class B
GPCRs that internalize following activation. However, a recent study
demonstrated that PAC1Rs are rapidly phosphorylated and internalized
immediately (Lyu et al., 2000) and approximately 50% are internalized within 3
minutes after application of radiolabeled PACAP and reaching a plateau after 60
minutes (Lyu et al., 2000). While it is still unclear whether internalized receptors
are degraded or recycled back to the plasma membrane, the internalization of
the receptor may play a role in the enduring behavioral and physiological effects
of PACAP receptor activation.
Canonically, GPCR kinases (GRKs) phosphorylate the C-terminal tail of
GPCRs to attenuate G-protein signaling and allow for the binding and activation
of b-arrestins which mediate receptor desensitization and internalization.
However, recent work has shown that some GPCRs engage in sustained Gprotein signaling from within internalized cellular compartments rather than
desensitizing the complex. b-arrestins, which are classically considered signaling
terminating proteins, are critical signal transducers at GPCRs in the membrane
as well as downstream of numerous GPCRs through their ability to nucleate
signaling complexes containing members of the MAPK and Src kinases (Broca et
al., 2009; DeWire et al., 2007; Eichel & Von Zastrow, 2018; Shintani et al., 2018;
Thomsen et al., 2018). Activated cardiac and dentate neurons show PAC1R
forms a complex with b-arrestins and becomes critically necessary for receptor
trafficking, neuronal excitability and consequent biological outcomes (Johnson et
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al., 2020; May et al., 2021; May & Parsons, 2017; Parsons & May, 2018). With
data directly implicating b-arrestins in mediating this phenomenon, we
hypothesize that PAC1R signaling is potentially mediated by endocytosis. While
it has already been demonstrated that PAC1Rs associate and internalize with barrestins in vitro, this mechanism remains to be elucidated in VMN control of food
intake and metabolism.
Our data indicate that PACAP promotes PAC1R trafficking from the
membrane to the cytosol as well as PACAP-induced PAC1R and b-arrestin
association in a dose-dependent manner. Specifically, we demonstrated the
VMN PAC1 receptors form a complex with b-arrestin 2 following PACAP
stimulation. Others have demonstrated that PACAP stimulation induces PAC1R
association with b-arrestins leading to differential b-arrestin 1 or b-arrestin 2
subcellular co-localization with PAC1R (Shintani et al., 2018). In this case,
PAC1Rs associated with b-arrestin 1 localize to the plasma membrane, whereas
PAC1Rs associated with b-arrestin 2 appear to be internalized into the cytosol
(Shintani et al., 2018). Moreover, its been shown that b-arrestins influence
energy homeostasis and prevent diet induced obesity suggesting a putative
mechanism by which PACAP signaling may influence energy homeostasis (Pydi
et al., 2020; Rodgers & Puigserver, 2009; Zhuang et al., 2011). In the current
work, we examined whether PAC1 receptor endocytosis was required for VMN
regulation of energy balance by inhibiting PAC1R endocytosis. We found that
blocking b-arrestin dependent endocytosis, with barbadin was not sufficient to
block PACAP induced hypophagia although, blocking clathrin and dynamin
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proteins using a Dyngo-4a and Pistop 2 cocktail did prevent PACAP-induced
hypophagia.
PACAP and leptin receptors are both potent regulators of food intake and
metabolism in the VMN via their intracellular signaling cascades that involve Gprotein and cytokine signaling, respectively (Dhillon et al., 2006; Hawke et al.,
2009; Hurley et al., 2020; Resch et al., 2011). We and others have also
demonstrated that PACAP and leptin induce the phosphorylation of STAT3 and
transduction of SOCS3 and BDNF mRNA expression. More recently, we showed
that blocking PACAP signaling (Hurley et al., 2020) or knocking down PAC1Rs
using RNA interference prevents leptin receptor function in the VMN. Collectively,
these findings suggest a crosstalk between PACAP and leptin signaling. To
explore the means of this crosstalk, we used co-immunoprecipitation to
demonstrate that PAC1R and leptin receptors form an immunocomplex,
suggesting these two receptors either share a physical interaction or are in close
proximity and form a signaling complex. Interestingly, we found that PACAP
treatment in PAC1R expressing rHypoE-19 cells induced pJAK2, which is in line
with reports that other GPCRs have the ability to phosphorylate Janus Kinase
(Ferrand et al., 2005). The characteristics demonstrated here for PAC1 and leptin
receptors are similar to findings that suggest the two receptors may signal
through GPCR transactivation mechanisms, extensively reviewed by Wang et al
(W. Wang et al., 2018). Several studies indicate that GPCRs transactivate
cytokine or receptor tyrosine kinases (McCole, Truong, Bunz, & Barrett, 2007;
Shi, Jin, & Andres, 2010) and, in turn, cytokine receptors can reciprocally
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transactivate GPCRs. (W. Wang et al., 2018) propose that there are two possible
modes of transactivation between a GPCR and a receptor tyrosine kinase: the
ligand dependent and the ligand independent pathway (W. Wang et al., 2018).
The ligand-dependent pathway is mediated by an active GPCR induced ligand
whereas, in the ligand-independent pathway GPCRs activate Src kinases. This
latter method is intriguing since PACAP not only induces Src kinase
phosphorylation but Src kinase appears to be required for PACAP’s hypophagic
effects (Resch et al., 2014). Interestingly, Src has been shown to induce pSTAT3
which could account for the observed PACAP-induced phosphorylation of STAT3
through a pathway that is potentially independent of leptin. Even more
convincing is a recent report (Shi et al., 2010) demonstrating that PAC1Rs
transactivate tyrosine kinase receptors such as EGFR, HER2, and HER3 (Moody
et al., 2020), and insulin like growth factor 1 (IGF1) (Delcourt et al., 2007). A
recurring theme and common denominator in PACAP-dependent transactivation
of RTKs and cytokine receptors is Src kinase.
Taken together we have accumulated evidence for a potential model
signaling mechanism that may explain how signaling from a single peptide is
amplified to regulate several aspects of cell signaling and physiology through
close proximity and a shared PAC1 and leptin receptor signaling. Findings from
this work revealed that endogenous PACAP signaling in the VMN has a potent
regulatory influence over both energy intake in the form of feeding and energy
output via thermogenesis and locomotor activity. Moreover, PACAP actions in
the VMN share a nearly identical molecular and physiological consequences to
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leptin administration in the same brain region suggesting that these two
neuropeptides could functionally intersect. These experiments begin to explore
the VMN PAC1Rs dependence on PKA, PKC, and receptor trafficking to mediate
PACAP’s pleiotropic effects on feeding and metabolism as well as potential
intersecting points with leptin receptor signaling. By understanding the complex
cell signaling complex involving PACAP and leptin we might find more complex
receptor configurations such as transactivated receptors, which may open new
doors to understanding the neurochemistry of behaviors and physiological
regulation as well as provide better insight to disease states like obesity and their

Figure 9.2. Schematic of proposed hypothalamic ventromedial (VMN) PAC1 and leptin
receptor signaling milieu. PAC1R and LepRb exist in a complex with shared downstream
effectors that combine to influence transcription and consequent energy balance in rats.
Created with BioRender.com
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therapeutic treatment. Receptor transactivation has emerged as an important
aspect of the GPCR repertoire that allows GPCRs access to a broader array of
highly interconnected signaling mechanisms that influence numerous
physiological and pathological conditions (Fig. 9.2). Therefore, nuanced
approaches to characterizing PAC1R signaling will be necessary for the
development of novel drugs to treat disease states like overweight and obesity.

PERSPECTIVES ON THE RELEVANCE AND NECESSITY FOR NUANCED
UNDERSTANDING OF CELL SIGNALING TRANSDUCTION
GOVERNING ENERGY BALANCE.
The role of biochemical signaling transduction networks is to reliably
transmit specific information about the extracellular environment to downstream
effectors, allowing the cell to adjust its physiological state to changing conditions
(Brennan et al., 2012; Selimkhanov et al., 2014). Understanding the complex
network of information relays in the form of signal transduction is critical as
evidence of aberrant signaling is emerging in diseases such as obesity
(Abdelsalam et al., 2019; Dorfman et al., 2017; Z. Gao et al., 2007; Sutton et al.,
2004; Zheng et al., 2013).
The stochasticity of molecular interactions that underlies various forms of
competing signal transduction perturbations (noise) in biological systems can
interfere and influence the directionality of biochemical signal transduction while
also degrading the transmitted information (Brennan et al., 2012; Purvis & Lahav,
2013; Selimkhanov et al., 2014).
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The work in this thesis has revealed an endogenous role of VMN PACAP
while also shedding some light on the nature of exogenous PACAP-dependent
downstream signaling on feeding and metabolism that may be perceived as
stochastic at first glance. What has become apparent is that even with a
knowledge of the downstream effectors of PACAP signaling, the comprehensive
state of the system (VMN) cannot be precisely predicted. This includes the
observations of the negative and positive influences of PKA, PKC or endocytosis
inhibition on light phase or dark phase PACAP-dependent effects on feeding and
metabolism, which raises the question, how do biochemical signaling
transduction networks perform their core functions in the presence of a
cacophony of crosstalk?
Protein kinases and subcellular cytoskeletal structures are key
transducers in signaling transduction networks that determine the collective
spatial resolution and dynamic properties of signaling that influences physiology
(Rosse et al., 2010). Current ligand-receptor models of signaling are based on
scalar measurements performed at a single time point and assume
comprehensive whole cell signaling (Selimkhanov et al., 2014). However, the
information on activating ligands like PACAP is likely encoded using dynamic
signaling represented by a multivariate vector such as combined PACAP-induced
PKA, PKC, and PAC1R trafficking and other molecular events that are contained
as a single cell’s response at multiple timepoints. The effect of signal location can
be as important as signal strength in determining net cell response. The
localization of signaling molecules to appropriate subcellular milieu that possess
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appropriate downstream targets is critical and may determine the output of a
particular signaling cascade.
The relevance of kinases, PKA and PKC has long been recognized in cell
biology, and subcellular location of kinase activity has important physiological
importance (Gervasi et al., 2007; Igumenova, 2015; Rosse et al., 2010). For
example, PKA at the membrane can modulate receptor and ion channels to
influence neuronal excitability, whereas in the cytosol and nucleus, PKA affects
cytoskeletal proteins, metabolic enzymes, and gene transcription (Gervasi et al.,
2007). The functional compartmentalization of kinase activity has been
demonstrated in cardiomyocytes and neurons that process spatially restricted
signaling microdomains (Koschinski & Zaccolo, 2017; Rosse et al., 2010; Sposini
et al., 2017).
Our findings in this dissertation isolated (static) VMN experiments
involving PKA, PKC, and endocytosis inhibition and their influence on PACAP
signaling during the circadian light and dark phases suggest the likelihood that
VMN PACAP-dependent dynamic responses contain more information than static
responses where PACAP influences feeding and metabolism. This relevant
functional information may be encoded in the structural components of the cells
and will require empirical measurements in sufficient detail. Despite the
recognition of the importance of localized signaling, our ability to locally interfere
with signals to prove evidence of necessity and sufficiency has been limited by a
lack of appropriate experimental methodologies. However, albeit mostly
descriptive, encouraging new advances is microscopy resolution and
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developments in genetically engineered tools that can track and localize
signaling events allowing us to nuance our interpretations. Such promising tools
can be leveraged to develop future strategies that allow manipulation of
spatiotemporal and dynamic physiological contexts. These strategies may
employ unique cell compartmentalization markers that deliver and limit cell
perturbations to subcellular compartments. Nonetheless, there is immense value
that can be derived from scalar biological measures, although there is
understanding that aspects of biological function cannot be discovered by simply
looking at static structures.
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